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Summary
Short-chain dehydrogenase/reductase (SDR) enzymes play a key role in the metabolism of 
steroids, fatty acids, prostaglandins and xenobiotic chemicals. This thesis investigated the role of 
ȕ-K\GUR[\VWHURLG GHK\GURJHQDVH W\SH  ȕ-HSD1) in the metabolism of xenobiotics. It 
further addressed species-specific differences of the inhibition of ȕ-HSD1 and some related 
microsomal SDRs by xenobiotics. ȕ-HSD1 catalyzes the conversion of the inactive 
glucocorticoids cortisone and 11-dehydrocorticosterone to the active cortisol and corticosterone,
respectively. Recently, studies using microsomes and the unspecific inhibitor glycyrrhetinic acid 
(GA) suggested that ȕ-HSD1 metabolizes the antidepressant drug bupropion to 
erythrohydrobupropion (EHB) and threohydrobupropion (THB), and the fungicide triadimefon to 
triadimenol. In the present work, tKH UROHRIKXPDQȕ-HSD1 in the reduction of triadimefon 
and bupropion was studied in vitro using the recombinant ȕ-HSD1 enzyme, DVHOHFWLYHȕ-
HSD1 inhibitor and microsomes from liver-VSHFLILFȕ-HSD1 knock-out mice. Activities were 
determined using microsomes from human, rat and mouse liver to assess species-specific 
differences. The results suggest WKDWȕ-HSD1 is the major enzyme responsible for triadimenol 
IRUPDWLRQ6XUSULVLQJO\ȕ-HSD1 exclusively formed THB but not EHB from bupropion. Due 
to lower activities of rat and mouse ȕ-HSD1 towards these xenobiotics, they are models of 
limited value WR VWXG\ ȕ-HSD1-dependent metabolism of bupropion and triadimefon. A 
comparison of IC50 values suggests that exposure to these compounds is unlikely to impair the 
ȕ-HSD1-dependent activation of glucocorticoids. In contrast, elevated glucocorticoids during 
stress or upon pharmacological administration are likely to LQKLELW ȕ-HSD1-dependent 
metabolism of these xenobiotics. 
ȕ-hydroxysteroid dehydrogenase type 2 ȕ-HSD2) catalyzes the conversion of the active
glucocorticoid cortisol to the inactive cortisone. It has been reported that some organotins and
dithiocarbamates are potent inhibitors of human 11ȕ-HSD2. We found that the zebrafish enzyme 
is not inhibited by these organotins. Furthermore, the dithiocarbamate thiram showed a reduced 
inhibitory eIIHFW RQ ]HEUDILVK ȕ-HSD2 compared with the human enzyme. Sequence 
comparison revealed the presence of an alanine at position 253 on zebrafish 11ȕ-HSD2, 
corresponding to cysteine-264 in the substrate binding pocket of the human enzyme. Substitution 

of alanine-253 by cysteine resulted in a more than 10-fold increased sensitivity of zebrafish 11ȕ-
HSD2 to thiram. These findings are important, as the zebrafish is a widely used model in 
ecotoxicology, and ȕ-HSD2 is catalyzing the conversion of 11ȕ-hydroxytestosterone to 11-
ketotestosterone, the main androgen in fish. 
The gene enFRGLQJ ȕ-HSD1 in zebrafish is absent. Therefore, the mechanism how the ratio 
between active and inactive glucocorticoids is controlled in fish is unclear. It was suggested by a 
phyloJHQHWLF DQDO\VLV WKDW RQH RI WKH WZR DQFHVWRUV RI ȕ-HSD1 might reduce cortisone to 
FRUWLVRO7KHVHDQFHVWRUVDUHȕ-+6'DDQGȕ-HSD3b. We cloned both zebrafish cDNAs and 
tested them for 11-oxosteroid reductase activity. Furthermore, we examined the metabolism of 
cortisone in zebrafish microsomes. Our results indicate that the 11-oxosteroid reductase activity 
is completely absent in zebrafish.
17ȕ-hydroxysteroid dehydrogenase type 3 (17ȕ-HSD3) catalyzes the conversion of ǻ4-
androstenedione to testosterone. We reported earlier that some UV filters inhibit the human 
enzyme. We tested whether these UV filters also inhibit the zebrafish enzyme. We found 
interesting species-specific differences of the inhibitory potential of UV filters on human and 
zebrafish ȕ-HSD3. Furthermore, we were able to show additive inhibitory effects of UV filter 
mixtures and bioaccumulation of UV filters in vitro.
In conclusion, the results presented in this thesis significantly extend the knowledge of the role of 
ȕ-HSD1 in the metabolism of xenobiotics. The thesis further emphasizes the importance of 
considering species-specific differences when trying to extrapolate effects of xenobiotics 
observed in animal models to humans.  

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Chapter 1: YFP-Project: The quest for ER luminal enzymes

Introduction 
The aim of the Yellow Fluorescent Protein (YFP) project was to identify enzymes that interact 
with hexose-6-phosphate dehydrogenase (H6PDH) in the endoplasmic reticulum (ER) and which
might play a role in the metabolism of xenobiotics. 
H6PDH is a microsomal enzyme. It has been shown that it interacts directly with ȕ-
hydroxysteroid dehydrogenase type 1 (ȕ-HSD1) [1, 2]. H6PDH converts glucose-6-phosphate 
(G6P) to 6-phosphogluconate and thereby converts NADP+ to NADPH, the cofactor for ȕ-
HSD1 [3]. Currentlyȕ-HSD1 is the only enzyme described which is localized in the lumen of 
the ER and utilizes NADPH to reduce its substrates. The ER has been described as an oxidative 
environment compared with the cytosol. We believe that there are additional reductive enzymes 
inside the ER that need NADPH as a cofactor and we hypothesize that some of these also interact 
with H6PDH.
In the YFP project we aimed to identify new interacting partners of H6PDH with the use of the 
protein fragment complementation assay (PCA). We started with the plasmids obtained from the
study published by Nyfeler et al. [4]. The authors were able to detect protein-protein interactions 
in the secretory pathway of living cells with the use of the PCA. In the literature the PCA is 
described as relatively simple assay to perform with the advantage of providing a simple 
fluorescent readout. The DNA sequence coding for the YFP is split into two parts, one coding for 
the N-terminal fragment of YFP (YFP1), the other coding for the C-terminal fragment (YFP2). If 
these fragments are simultaneously expressed in cells and brought into close proximity, the YFP 
fragments can reconstitute and, upon proper folding, form a complete YFP that serves as a 
reporter. YFP can be excited at 514 nm and an emission peak of 527 nm can be recorded. The 
fluorescence can be detected with a fluorescence microscope, or any other fluorescence 
measuring device. Subcloning of these fragments into two separate vectors each containing an
interacting partner, should bring the YFP fragments in close proximity to each other and allow 
complementation and detection of a fluorescence signal. The YFP fragments are directly linked 
to the enzymes, either N or C-terminally, with the help of a linker on each of the interacting 
proteins. 

We planned to use H6PDH linked via the C-terminal to the YFP2 fragment with a (GGGGS)2
linker as bait and to construct a cDNA library linked via the C-terminal to the YFP1 with a 
(GGGGS)2 linker as prey, in order to find new interacting proteins as described by Nyfeler et al. 
[4]. 
Results & Discussion
Before constructing the cDNA library, we generated a positive and negative control. Therefore,
the H6PDH was linked C-terminally to YFP2 with a (GGGGS)2 lLQNHUDQGȕ-HSD1 was linked 
C-terminally to YFP1 with a (GGGGS)2 linker as a positive control. In this project the enzymes 
were tagged C-terminally as performed by Atanasov et al. [1], using C-terminally tagged H6PDH 
DQGȕ-HSD1 for Förster resonance energy transfer (FRET). For the negative control, a chimeric 
construct of ȕ-HSD2 was used. It has previously EHHQ VKRZQ WKDW ȕ-HSD1 interacts with 
H6PDH [2]ZKLOHȕ-HSD2 does not, because it is utilizing NAD+ and therefore no interaction 
should occur. These constructs have been transfected into HEK-293 and COS-1 cells using the 
calcium phosphate transfection method and Fugene HD, respectively. Protein expression was 
verified by western blotting. Although all protein constructs were sequence verified and the 
expression was controlled, the interaction of H6PDH with ȕ-HSD1 could not be monitored 
with the protein fragmentation assay, since we were not able to detect any fluorescence signal 
with the positive control. However, the full-length YFP control did show a fluorescence signal 
under the fluorescence microscope. Unfortunately, taking into account the positive control did 
not work we decided to stop the YFP project.
In theory the protein fragment complementation assay seems to be a straightforward approach to 
visualize direct protein interactions in living cells and enables the determination of the subcellular 
sites of protein interactions. Unfortunately, in our setting we could not confirm a known protein 
interaction. The specific reasons are unclear. In my opinion, carrying out PCA, the following 
points need to be considered: 
x Steric hindrance, 

x N-terminally or C-terminally linkage of YFP fragments,
x Length of the linker, 
x Accurate folding of the proteins. 
In order to successfully apply the PCA, the two YFP fragments must be close enough for
complementation. It could be possible that the two interacting proteins connected to the 
fragments prevent proper complementation of the two YFP fragments by so called steric 
hindrance. This problem might be solved with the use of a wide set of linkers of different length.
Further, it is important to know the localization of the N- and C-terminal position of the protein. 
ER membrane-bound proteins can have the N-terminus and C-terminus cytosolic or ER luminal. 
Soluble proteins might have the termini inside the protein and therefore the YFP fragments are 
not accessible for complementation, depending on the protein tertiary structure. Therefore two
plasmids should be constructed, one N-terminally tagged and one C-terminally tagged, in case the 
structure is not known. A further pitfall is the accurate folding of the protein if the primary 
structure of the protein is modified, as it is the case in the PCA, whereby the sequence is 
prolonged N- or C-terminally, this might ultimately affect the complete folding of the proteins. 
Incorrectly folded proteins might not be able to interact with each other anymore.
Taking these points into consideration, we realized that the identification of new interacting 
proteins with H6PDH by this approach was very ambitious. In a cDNA screening approach, the 
YFP fragment would have been constructed twice (N- and C-terminally), with different length 
linkers. Another idea would be to create double tagged enzymes, with the same fragments N- and 
C-terminally tagged. These modifications would lead to a highly time-consuming screening 
approach, which is still very risky, especially if the H6PDH-YFP2 does not fold properly. For 
these reasons, we decided to stop the YFP project. 

Chapter 2: 11ȕ-HSD1-dependent xenobiotica metabolism

Introduction 
The pivotal role of ȕ-HSD1 has been extensively studied, with its main function in the 
conversion of the inactive glucocorticoid cortisone to the active cortisol (Fig. 1) and by activating 
pharmacological applied prednisone to prednisolone. Cortisol and prednisolone are able to 
activate the glucocorticoid receptor (GR) and therefore are responsible for the expression of GR-
dependent genes in metabolically relevant tissues such as the liver, adipose and skeletal muscle
[5]. Currently, research is focusing on the developmHQWRIȕ-HSD1 inhibitors. Several studies 
suggest that the LQKLELWLRQRIȕ-HSD1 might be beneficial in the treatment of obesity, type 2 
diabetes mellitus and metabolic syndrome [6-8]. 
Figure 1: The conversion of inactive cortisone (left) and active cortisol (right) E\ȕ-hydroxysteroid 
dehydrogenase type 1 DQGW\SHȕ-+6'ȕ-HSD2)
We UHSRUWHGHDUOLHUWKDWȕ-HSD1 has a broad substrate spectrum and plays an important role in 
the metabolism of 7-ketodehydroepiandrosterone [9], 7-ketocholesterol [10] and the secondary 
bile acid 7-oxolithocholic acid [11]. In addition, several xenobiotics have been identified as 
substrates of ȕ-HSD1 like oracin [12], metyrapone [13] and ketoprofen [14]. 
Lately, by the use of rat liver microsomes and the XQVSHFLILFȕ-HSD inhibitor glycyrrhetinic 
acid (GA), it has been suggested that the triazole fungicide triadimefon is reduced to its 
PHWDEROLWHWULDGLPHQROE\ȕ-HSD1 (Fig. 2) [15, 16]. Barton et al. showed the involvement of 
cytochrome P450 in the metabolism of triadimefon in human and rat liver microsomal
preparations [17]. Triadimefon and the active metabolite triadimenol are extensively used as 
broad-spectrum fungicides in agriculture and landscaping [16]. The wide use of triadimefon and
the long degradation half-life of around 23 days under controlled laboratory conditions [18] 
ȕ-HSD1
ȕ-HSD2

demonstrates the need to not only study the effects on mammalian models, but also to investigate 
the metabolism of this fungicide in humans. 
Figure 2: Suggested carbonyl reduction of triadimefon (left) to triadimenol (right) E\ȕ-HSD1
Another interesting compound is climbazole, which is used in anti-dandruff shampoos. It is 
structurally similar to triadimefon, with the exception of belonging to the imidazoles and having 
therefore only two nitrogens in the ring system instead of three (Fig. 3). Due to the structural 
similarity of climbazole and triadimefon, it can be assumed that climbazole is metabolized by 
ȕ-+6'8QIRUWXQDWHO\ WKH WKHRUHWLFDOO\ UHGXFHGPHWDEROLWH RI FOLPED]ROH E\ ȕ-HSD1 is 
not commercially available. Therefore, a quantitation of the product is inaccurate and further 
testing was put on hold.  
Figure 3: Structure of climbazole
It has been suggested that bupropion (Wellbutrin®) LV PHWDEROL]HG E\ ȕ-HSD1 [19-21].
Bupropion is used as a racemic mixture of R- and S-bupropion (Fig. 4). Bupropion is used for 
more than 20 years for the treatment of depression by approximately 40 million people [22, 23]. 
Cytochrome P450 2B6 has been identified to be responsible for hydroxybupropion formation [24,
25]. Lately, it was thought that the antidepressant bupropion might be metabolized by one of the 

ȕ-HSDs to erythrohydrobupropion (EHB) and threohydrobupropion (THB) by human 
placental microsomes [20], baboon hepatic and placental microsomes [19] and human liver 
microsomes [21]. This hypothesis was based on observations from experiments with human 
microsomes of liver and placenta with bupropion DQG WKH XQVSHFLILF ȕ-HSD inhibitor GA. 
Incubations with GA yielded lower amounts of THB and EHB. These studies suggested the 
LQYROYHPHQWRIȕ-HSD in the carbonyl reduction of bupropion. 
Cl
O
NH
Cl
O
NH
Figure 4: Structure of R-bupropion (left) and S-bupropion (right)
:HSHUIRUPHGVHYHUDOH[SHULPHQWVLQRUGHUWRHOXFLGDWHWKHȕ-HSD1-dependent metabolism of 
these three xenobiotics. This is interesting for three reasons: First, the metabolism of these 
xenobiotics PLJKWEHLPSDLUHGE\WKHIXWXUHWKHUDSHXWLFXVHRIȕ-HSD1 inhibitors. Second, as it 
LVVXJJHVWHGWKDWVXEVWDQFHVPHWDEROL]HGE\ȕ-HSD1 in the ER could undergo direct phase II 
metabolism in the ER, i.e. glucuronidation. Third, if under circumstances of glucocorticoid 
treatment the metabolism of these xenobiotica might be impaired or vice versa. The results of 
triadimefon and bupropion are included in the paper and the paper draft at the end of this chapter.
We obtained livers from liver-VSHFLILFȕ-HSD1 knockout mice from Prof. Lavery (University 
of Birmingham, UK) to investigate the relative FRQWULEXWLRQRIȕ-HSD1 to the metabolism of 
xenobiotics by microsomal incubations. First, I optimized the protocol for the preparation of 
microsomes from liver tissue. Important in the preparation of microsomes is the intactness of the 
microsomal vesicles, which allows afterwards in the microsomal incubations to distinguish 
between luminal enzymes and microsomal enzymes facing the cytoplasm. If the microsomal 
vesicles are intact, ȕ-HSD1 activity can be measured upon incubation with G6P, as G6P is 
transported by glucose-6-phosphate translocase (G6PT) into the lumen of the ER, where it is used 
by H6PDH, which then produces NADPH. Whereas upon addition of NADPH, NADPH will be

exclusively utilized by enzymes facing the cytoplasm, since the ER membrane is a barrier for 
NADPH (Fig 5).  
Figure 5: Schematic picture of microsomal incubations. Glucose-6-phosphate (G6P) is transported by glucose-
6-phosphate translocase (G6PT) into the lumen of the ER, where it is used by hexose-6-phosphate 
dehydrogenase (H6PDH), which then produces NADPH. Addition of NADPH will only stimulate enzymes 
facing the cytosol, i.e. cytochrome P450 reductase leading to cytochrome P450 (CYP) mediated metabolism. 
Figure was produced using Servier Medical Art (www.servier.com). 
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Results & Discussion
The protocol to prepare microsomes was optimized, the final protocol can be found in the 
appendix. By following the optimized protocol, tKHODWHQF\RIȕ-HSD1 activity in microsomes 
was about 90%, whereas the latency of commercially available human liver microsomes (Celsis 
In Vitro Inc (Baltimore, MD)) was around 75%. In order to generate intact microsomal vesicles 
from frozen liver tissue, the pieces should be homogenized with a Potter-Elvehjem PTFE pestle 
and glass tube, and ultrasonification should be avoided. No more than 12 strokes should be 
applied. The buffer should be of physiological ionic strength. If these points are taken into 
consideration, a high degree of intactness of the microsomal vesicles can be achieved. 
Microsomal incubations with climbazole have been performed as for triadimefon and bupropion. 
We were able to monitor the disappearance of the climbazole peak by liquid chromatography-
tandem mass spectrometry (LC-MS/MS), but since no authentic standard of the product is 
commercially available, the hydroxyclimbazole peak cannot be verified and no quantitation of the 
peak is possible. Nevertheless, our results indicate that climbazole is metabolized by ȕ-HSD1.
Ultimately, this has to be tested with an authentic standard. This finding is interesting from a 
mechanistic point of view, although I would assume that it is biologically less relevant, because 
anti-dandruff shampoos contain only concentrations up to 2% climbazole, and the human 
exposure to climbazole is expected to be very low. 

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Abstract  1 
2 
11ȕ-hydroxysteroid dehydrogenase  ȕ-HSD1) catalyzes the conversion of inactive 11-oxo 3 
glucocorticoids (endogenous cortisone, 11-dehydrocorticosterone and synthetic prednisone) to 4 
WKHLUSRWHQWȕ-hydroxyl forms (cortisol, corticosterone and prednisolone). %HVLGHVȕ-HSD1 5 
accepts several other substrates. Using rodent liver microsomes and the unspecific inhibitor 6 
glycyrrhetinic acid, it has been proposed earlier WKDW ȕ-HSD1 catalyzes the reversible 7 
conversion of the fungicide triadimefon to triadimenol. In the present study, recombinant human, 8 
UDW DQG PRXVH HQ]\PHV WRJHWKHU ZLWK D KLJKO\ VHOHFWLYH ȕ-HSD1 inhibitor were applied to 9 
DVVHVV WKH UROH RI ȕ-HSD1 in the reduction of triadimefon and to uncover species-specific 10 
differences. To further demonstUDWH WKH UROH RI ȕ-HSD1 in the carbonyl reduction of 11 
triadimefon, microsomes from liver-VSHFLILF ȕ-HSD1-deficient mice were employed. 12 
Molecular docking was applied to investigate substrate binding. The results revealed important 13 
species differences and demonstrated the irreversible ȕ-HSD1-dependent reduction of 14 
triadimefon. Human liver microsomes showed 4 and 8 times higher activity than rat and mouse 15 
liver microsomes. The apparent Vmax/Km of recombinant human ȕ-HSD1 was 5 and 15 times 16 
higher than tKDWRIPRXVHDQGUDWȕ-HSD1, respectively, indicating isoform-specific differences 17 
and different expression levels for the three species. Experiments using inhibitors and 18 
PLFURVRPHV IURP ȕ-HSD1-deficient mice indicated WKDW ȕ-HSD1 is the major if not only 19 
enzyme responsible for triadimenol formation. The IC50 values of triadimefon and triadimenol for 20 
cortisone reduction suggested WKDWH[SRVXUHWRWKHVH[HQRELRWLFDXQOLNHO\LPSDLUVWKHȕ-HSD1-21 
dependent glucocorticoid activation. However, elevated glucocorticoids during stress or upon 22 
pharmacological administration likely LQKLELWȕ-HSD1-dependent metabolism of triadimefon in 23 
humans. 24 

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1. Introduction1 
2 
Triadimefon and to a lesser extent the active metabolite triadimenol are used as broad-spectrum 3 
fungicides in agriculture and landscaping, with annual application rates of about 135,000 and 4 
24,000 lbs/year, respectively [1]. Humans can be exposed through consumption of foods 5 
containing triadimefon or triadimenol residues [2]. More critical is occupational exposure 6 
through dermal contact and inhalation of sprays by field workers applying these fungicides [3].7 
The wide use of triadimefon and its long half-life of around 23 days under controlled laboratory 8 
conditions [4] emphasizes the need to investigate both the environmental fate and the potentially 9 
hazardous effects on animals and humans.  10 
Toxicological studies revealed neurotoxic effects of triadimefon and triadimenol in rats, mice and 11 
rabbits [1]. Teratogenic effects were observed at very low concentrations in experiments using rat 12 
embryos [5]. Furthermore, triadimefon and triadimenol were shown to cause thyroid and liver 13 
tumors in rats, and they are considered as potential human carcinogens [1]. They act by inhibiting 14 
the activity of fungal lanosterol-Į-demethylase, a cytochrome P450 enzyme (CYP51), thereby 15 
blocking ergosterol biosynthesis which is essential for fungal cell wall integrity [6]. Like other 16 
azole fungicides, triadimefon and triadimenol can inhibit some of the mammalian cytochrome 17 
P450 enzymes involved in steroidogenesis, which may lead to endocrine disturbances [7].  18 
According to conclusions by the US Environmental Protection Agency (EPA), the mechanisms 19 
of toxicity of triadimefon and triadimenol differ from those of other azole fungicides [1]. 20 
Kenneke et al. proposed that differences in the metabolism of triadimefon compared with other 21 
azole fungicides may be involved [8]. Experiments by Barton et al. with liver microsomes 22 
revealed that triadimefon can be metabolized by CYPs, whereby CYP2B6, CYP2C19 and 23 
CYP3A4 were the most active enzymes in human liver [9]. The authors mentioned very low24 
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formation of triadimenol; however, they used assay conditions that do not allow to measure 1 
luminal carbonyl reductase activity. Kenneke et al., using rat liver microsomes and the 2 
unselective inhibitor glycyrrhetinic acid, then provided evidence that triadimefon is mainly 3 
metabolized to triadimenol and that this reaction is catalyzed by 11ȕ-hydroxysteroid 4 
dehydrogenase 1 (ȕ-HSD1, SDR26C1) [8, 10, 11]. Interestingly, in a follow-on study they 5 
reported the conversion of triadimefon to triadimenol by rainbow trout microsomes [12],6 
although it is known WKDW WKH JHQH HQFRGLQJ ȕ-HSD1 is absent in teleost species [13], thus 7 
suggesting the involvement of another enzyme.  8 
ȕ-HSD1 plays a pivotal role in the regulation of energy metabolism through the activation of 9 
endogenous glucocorticoids in tissues such as liver, adipose and skeletal muscle [14]. Moreover, 10 
it essentially regulates the balance of mineralocorticoid receptor (MR)- and glucocorticoid 11 
receptor (GR)-mediated modulation of inflammatory parameters in macrophage-derived cells 12 
[15-17]. ȕ-HSD1 is required for the pharmacological effect of cortisone and prednisone, which 13 
GRQRWELQGWRFRUWLFRVWHURLGUHFHSWRUV6LQFHȕ-HSD1 is considered as a promising target for 14 
the treatment of metabolic disorders, there is great interest in the deveORSPHQW RI ȕ-HSD1 15 
inhibitors [14, 18]. Besides its role in glucocorticoid activation, ȕ-HSD1 catalyzes the carbonyl 16 
reduction of several endogenous oxidized sterols such as 7-ketocholesterol [19, 20], 7-17 
ketodehydroepiandrosterone [21] and the secondary bile acid 7-oxolithocholic acid [22], as well 18 
as that of several xenobiotics including oracin [23], metyrapone [24], ketoprofen [25], 4-19 
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) [26], and as mentioned above, triadimefon 20 
[8, 10, 11].  21 
Since the evidence for a rolHRIȕ-HSD1 in the metabolism of triadimefon was based on rat 22 
microsomal activities and inhibition by the unselective inhibitor glycyrrhetinic acid (GA), we 23 
aimed in the present study to 1) optimize the assay conditions to distinguish between luminal 24 
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enzymes and microsomal enzymes facing the cytoplasm, 2) compare carbonyl reduction activity 1 
LQKXPDQUDWDQGPRXVHOLYHUPLFURVRPHVLQWKHSUHVHQFHDQGDEVHQFHRIDVHOHFWLYHȕ-HSD1 2 
inhibitor, 3) assess whether other enzymes contribute to the carbonyl reduction of triadimefon in 3 
human, rat and mouse liver microsomes, 4) assess activities of the corresponding recombinant 4 
ȕ-HSD1 enzymes, DQG LQYHVWLJDWH WKH ELQGLQJ RI WULDGLPHIRQ WR ȕ-HSD1 by molecular 5 
modeling.   6 
7 
2. Materials and Methods8 
9 
2.1. Chemicals and reagents 10 
11 
Human liver microsomes were purchased from Celsis In Vitro Inc (Baltimore, MD) and were 12 
obtained from a 77 year old male Caucasian. Human embryonic kidney (HEK-293) cells from 13 
ATCC (No CRL-1573) were obtained through LGC Standards S.a.r.l., Molsheim Cedex, France. 14 
Cell culture medium was from Invitrogen (Carlsbad, CA) and 5H-1,2,4-triazolo(4,3-15 
a)azepine,6,7,8,9-tetrahydro-3-tricyclo(3·3·1·13·7)dec-1-yl (T0504) from Enamine (Kiev, 16 
Ukraine). BNW16 was kindly provided by Dr. Thomas Wilckens, BioNetWorks GmbH, Munich, 17 
Germany. Steroids were purchased from Steraloids (Newport, RI). Triadimefon, triadimenol,18 
glycyrrhetinic acid (GA) and all other chemicals were from Sigma-Aldrich Chemie GmbH 19 
(Buchs, Switzerland). The solvents were of analytical and high performance liquid 20 
chromatography grade and the reagents of the highest grade available.  21 
22 
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2.2. Cell culture, transfection and enzyme expression1 
2 
HEK-293 cells were cultivated in Dulbecco's modified Eagle medium (DMEM) containing 4.5 3 
g/L glucose, 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/mL streptomycin, 1 × MEM 4 
non-essential amino acids and 10 mM HEPES buffer, pH 7.4. Cells were incubated at 37°C in a 5 
humidified 5% CO2 atmosphere. Cells were transiently transfected by the calcium phosphate6 
transfection method with plasmids for C-terminally FLAG-tagged human, rat or mouse 11ȕ-7 
HSD1 [27], or human 11ȕ-HSD2 [28]. Briefly, HEK-293 cells at 70% confluence on a 10 cm28 
dish with 10 mL of culture medium were transfected with 10 μg plasmid. The plasmid was 9 
diluted in 430 μL sterile water, followed by drop wise addition of 62.5 μL of 2 M CaCl2. This 10 
mixture was then added drop wise to 500 μL BEST buffer (500 mL H2O containing 8.0 g NaCl,11 
0.198 g Na2HPO4-heptahydrate, 5.3 g BES (N, N-bis [2-hydroxyethyl] -2 amino ethane sulfonic 12 
acid), pH 7.0). After incubation for 10 min at room temperature, this mixture was added to the 13 
cells. Medium was changed at 6 h post-transfection. The transfection efficiency was 14 
approximately 20%. Cells were trypsinized 48 h post-transfection, followed by centrifugation at 15 
900 × g for 4 min. Cell pellets (4 pellets per 10 cm2 dish) were immediately shock frozen on dry 16 
ice and stored at -80°C. Upon determination of the protein concentration using the Pierce BCA 17 
protein assay kit (Thermo Fisher Scientific Inc., Rockford, IL, USA), 20 μg of total protein were 18 
loaded onto SDS-PAGE and expression of FLAG-tagged enzymes was semi-quantitatively 19 
analyzed by Western blotting and immune-detection using mouse monoclonal M2 anti-FLAG 20 
antibody (Sigma-Aldrich Chemie GmbH) and horseradish peroxidase-conjugated secondary 21 
antibodies as described previously [29]. ȕ-actin was used as a loading control and was detected 22 
using rabbit anti-actin IgG from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 23 
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2.3. Preparation of liver microsomes  1 
2 
Sprague Dawley rats were obtained from Charles River, Paris, France, and housed in the breeding 3 
facility of the Biocenter, University of Basel, in groups of four in a 12:12-h light-dark cycle with 4 
standard laboratory chow and tap water ad libitum. Mice on a mixed C57BL/6J/129vJ 5 
background and liver-specific knock-out mice (LKO) generated by crossing albumin-Cre 6 
transgenic mice on a C57BL/6J background with floxed homozygous HSD11B1 mice on a mixed 7 
C57BL/6J/129SvJ background were bred at the breeding facility of the University of 8 
Birmingham, UK, as described earlier [30]. Pooled microsomes were prepared from the livers of 9 
three adult male Sprague Dawley rats or three C57BL/6J/129vJ parental mice or LKO mice. 10 
Liver pieces were homogenized in solution A (0.3 M sucrose, 10 mM imidazole, pH 7.0; 2 mL 11 
per 100 mg tissue) with a Potter-Elvehjem PTFE pestle with 10 – 12 strokes and at 220 rpm. 12 
Debris and nuclei were removed by two centrifugation steps for 10 min at 1,000 × g. The 13 
supernatant was centrifuged twice for 10 min at 12,000 × g to remove mitochondria, followed by 14 
ultracentrifugation for 1 h at 100,000 × g to obtain microsomes. The pellet was resuspended in 15 
solution B (0.6 M potassium chloride, 0.3 M sucrose, 20 mM tris-maleate, pH 7.0; 500 μL per 16 
100 mg tissue) and the ultracentrifugation step was repeated. The final pellet was resuspended in 17 
solution C (0.15 M potassium chloride, 0.25 M sucrose, 10 mM tris-maleate, pH 7.0; 200 μL per 18 
100 mg tissue). The microsomes were then aliquoted, shock frozen on dry ice and stored at -80°C 19 
until further use. The microsomal protein concentration was measured using the Pierce BCA 20 
protein assay kit. The quality of the microsomal preparations was analyzed using the cytochrome 21 
C reductase assay kit (Sigma-Aldrich Chemie GmbH) and by assessing the latent activity of the 22 
ȕ-HSD1-dependent oxoreduction of cortisone in the presence of glucose-6-phosphate (G6P).  23 
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2.4. Determination of enzyme activities using microsomal preparations1 
2 
In order to measure the oxoreduction of cortisone, microsomes of human liver (final 3 
concentration (f.c.) 0.5 mg/mL), rat liver (f.c. 0.25 mg/mL), mouse liver (f.c. 0.5 mg/mL) and 4 
LKO mouse liver (f.c. 0.5 mg/mL) were incubated in a final reaction volume of 22 μL of TS2 5 
buffer (100 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM MgCl2, 250 mM sucrose, 20 mM 6 
Tris–HCl, pH 7.4), supplemented with 1 μM cortisone and either 1 mM G6P or 1 mM NADPH in 7 
the presence or absence of 20 μ0RIWKHVHOHFWLYHȕ-HSD1 inhibitor T0504 for 15 min at 37°C.8 
For measuring the metabolism of triadimefon, 1 μM triadimefon and rat liver microsomes (f.c. 19 
mg/mL), mouse liver microsomes (f.c. 1 mg/mL) or human liver microsomes (f.c. 0.2 mg/mL)10 
were incubated for 1 h at 37°C. Reactions were stopped by the addition of 200 μL 0.3 M zinc 11 
sulfate in a 1:1 (v/v) mixture of water and methanol. The internal standard (atrazine for 12 
triadimefon and deuterized d4-cortisol for cortisone) was added at a final concentration of 50 nM, 13 
followed by vortexing for 10 sec and centrifugation for 10 min at 12,000 × g on a table top 14 
centrifuge. Supernatants (180 μL) were transferred onto solid phase extraction columns (Oasis 15 
HBL 1cc (30 mg) Waters WAT094225, Waters, Milford, MA, USA) pre-conditioned with 1 mL 16 
of methanol and 1 mL of distilled water. After washing with 1 mL water, compounds were eluted 17 
with 1 mL methanol. The eluate was evaporated to dryness, reconstituted in 100 μL methanol and 18 
stored at -20°C until analysis by liquid chromatography–tandem mass spectrometry (LC–19 
MS/MS) (section 2.6).  20 
21 
22 
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2.5. Determination of enzyme activities using lysates of transfected HEK-293 cells  1 
2 
Frozen pellets of HEK-293 cells transiently WUDQVIHFWHG ZLWK KXPDQ UDW RU PRXVH ȕ-HSD1 3 
were resuspended in TS2 buffer and immediately sonicated at 4°C using a Branson sonicator (5 4 
pulses, output 2, and duty cycles 20). Lysates were incubated for 1 h at 37°C in the presence of 1 5 
mM NADPH and different concentrations of triadimefon (8 μM, 4 μM, 2 μM, 1 μM, 500 nM, 6 
250 nM and 125 nM) in a final volume of 22 μL to estimate apparent KM and apparent Vmax7 
values for the three species. Substrate conversion in all experiments was kept below 25%. 8 
Reactions were stopped and processed as described in section 2.4. 9 
Alternatively, the oxidation of triadimenol was assessed by incubating lysates of cells, transiently 10 
tUDQVIHFWHGZLWKKXPDQȕ-+6'RUȕ-HSD2 (SDR9C3), with 1 μM triadimenol and 1 mM 11 
NADP+ WRPHDVXUH WKHR[LGDWLRQFDSDFLW\RIȕ-HSD1, or with 1 μM triadimenol and 1 mM 12 
NAD+ WRPHDVXUHȕ-HSD2 activity. The conversion of cortisol (at a concentration of 1 μM) 13 
was determined as a positive control.  14 
For determination of the reductase activity of KXPDQȕ-HSD1, cell lysates were incubated in 15 
the presence of 1 μM cortisone or 1 μM triadimefon as substrate and various concentrations of 16 
either triadimefon and triadimenol or cortisone as the respective inhibitor. IC50 values were 17 
calculated by non-linear regression using four parametric logistic curve fitting (GraphPad Prism18 
software). 19 
20 
21 
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2.6. Liquid chromatography-tandem mass spectrometry measurements1 
2 
All chromatographic separations (HPLC) were performed using an Atlantis T3 column (3 μm, 3 
2.1 × 150 mm, Waters) and an Agilent 1200 Infinity Series chromatograph (Agilent 4 
Technologies, Basel, Switzerland). The mobile phase consisted of solvent A (water:acetonitrile,5 
95:5 (v/v), containing 0.1% formic acid) and solvent B (water:acetonitrile, 5:95 (v/v), containing 6 
0.1% formic acid), at a total flow rate of 0.4 mL/min. Triadimefon and triadimenol were 7 
separated using 25% solvent B for 1 min, followed by a linear gradient from 1 to 20 min to reach 8 
70% solvent B, and then 100% solvent B for 3min. The column was then re-equilibrated with 9 
25% solvent B. Cortisone and cortisol were resolved using 30% solvent B from 0 to 4 min, 10 
followed by a linear gradient from 30% solvent B to 40% solvent B from 4 to 7 min, solvent B 11 
was then increased to 100% from 7 to 7.5 min and then continued for another 2.5 min, followed 12 
by re-equilibration with 30% solvent B for 3 min. 13 
The LC was interfaced to an Agilent 6490 triple quadropole tandem mass spectrometer (MS/MS).14 
The entire LC-MS/MS system was controlled by Mass Hunter workstation software (version 15 
B.01.05). The injection volume of each sample was 10 μL. The mass spectrometer was operated 16 
in electrospray ionization (ESI) positive ionization mode, with the source temperature of 350°C, 17 
with nebulizer pressure of 20 psi. The capillary voltage was set at 4000 V. The compounds were 18 
analyzed using multiple-reaction monitoring (MRM) and identified by comparing their retention 19 
time and mass to charge ratio (m/z) with those of authentic standards. The transitions, collision 20 
energy and retention time were m/z 294.8/197, 12 V, 13 min for triadimefon; m/z 296.8/70, 12 V, 21 
11.0 and 11.5 min (R/S enantiomer) for triadimenol; m/z 216/174, 16 V, 5 min for atrazine; m/z22 
361/163, 25 V, 4.6 min for cortisone; m/z 363/121, 26 V, 4.3 min for cortisol; and m/z23 
367.2/121.1, 36 V, 4.3 min for the internal standard d4-cortisol.24 
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The LC-MS/MS method was validated for accuracy, precision, sensitivity, stability, recovery, 1 
and calibration range. Acceptable inter-day assay precision (DQGDFFXUDF\– 103.9 2 
%) were achieved over a linear range of 50 to 5000 nM for both triadimefon and triadimenol.3 
Recovery of triadimefon was close to 100% and that of triadimenol >60% in all solid phase 4 
extractions. For each experiment a new calibration curve was determined.5 
6 
2.7. Molecular modeling7 
8 
Triadimefon and triadimenol were docked to the X-UD\ FU\VWDO VWUXFWXUH RI ȕ-HSD1 using 9 
AutoDock4 [31]. The 3D-structures of the ligands were downloaded from PubChem [32] (CID-10 
codes: 39385 for triadimefon and 41368 for triadimenol, respectively), and the structure of the 11 
protein was obtained from Protein Data Bank (PDB, www.pdb.org [33], entry: 2BEL [34]). The 12 
selected protein structure contains the tetrameric form of the protein; however, the docking 13 
studies were performed only with chain A. The protein was prepared for docking by removing 14 
the cocrystallized ligand carbenoxolone and water molecules from the protein structure as well as 15 
by adding hydrogens. The atom types of the protein and the ligands were automatically created 16 
by the program. During the docking, the ligand conformations were set flexible (with five 17 
rotatable bonds for triadimefon and six for triadimenol, respectively) and the protein was handled 18 
as rigid. The binding site was defined as a 3D-grid, centered at the binding site point X=8.858, 19 
Y= 22.143, and Z=15.547, with 30, 40, and 30 points in the respective dimensions. The grid 20 
spacing was set to 0.375 Å. The genetic algorithm was selected as search method with default 21 
settings, except for the maximum number of evaluations, which was set to short (250,000). The 22 
default settings for docking run were kept, with one exception: the RMS cluster tolerance was set 23 
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to 1.0 Å. Using these settings, the docking program was able to reproduce the binding orientation 1 
of the cocrystallized ligand, carbenoxolone, which validated the docking settings. 2 
 3 
3. Results4 
5 
3.1. Optimization of assay conditions and measurement of cortisone reduction in liver 6 
microsomes7 
8 
In a first step, the assay conditions were optimized in order to distinguish between NADPH-9 
dependent activities of microsomal enzymes facing the cytoplasm and enzymes facing the ER-10 
lumen. The preparation employed in the present study yielded microsomes with approximately 11 
90% inside-out orientation, bDVHGRQWKHODWHQF\RIȕ-HSD1-dependent reduction of cortisone 12 
as well as the latent activity of hexose-6-phosphate dehydrogenase (H6PDH) [35]. Thus, the 13 
luminal compartment is protected by the microsomal membrane, and enzymes with a cytoplasmic 14 
orientation such as CYPs DQGȕ-+6'RUȕ-HSD3 can be readily measured upon addition of 15 
NADPH to the reaction mixture [36]. A NADPH regenerating system using bacterial G6PDH and 16 
G6P, widely used for measurements of CYP activities, further stimulates microsomal enzymes 17 
with cytoplasmic orientation when high substrate concentrations (> 10 μM) are applied. In 18 
FRQWUDVWFDUERQ\OUHGXFWDVHVVXFKDVȕ-HSD1 that protrude into the ER-lumen are dependent 19 
on the NADPH pool present in the microsomal vesicle [37-39]. The high endogenous expression 20 
of H6PDH in the liver represents an endogenous NADPH regenerating system, and we found that 21 
WKH DGGLWLRQ RI *3 WR WKH DVVD\ PL[WXUH ZDV UHTXLUHG DQG VXIILFLHQW WR VWLPXODWH ȕ-HSD1 22 
reductase activity. Due to the relatively small vesicle volume, the capacity of this endogenous 23 
regenerating system is limited, however, and substrate concentrations have to be kept below 5-10 24 
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μM. Therefore, a substrate concentration of 1 μM was chosen for the experiments with liver 1 
microsomes.  2 
A comparison of the cortisone reduction in human, rat and mouse liver microsomes yielded 3 
comparable activities of human and mouse liver microsomes and approximately two-fold higher 4 
activity of rat microsomes (p < 0.001) (Fig. 1)7KHODWHQF\RIȕ-HSD1 activity was about 90% 5 
for rat and mouse microsomes and about 75% for the commercially available human liver 6 
microsomes (data not shown). To compare the activity of liver microsomes from wild-type and 7 
ȕ-HSD1-deficient mice, cytochrome C reductase activity was determined. Comparable 8 
activities were obtained for microsomes of wild-type and knock-out mice with 3.35 U/mL and 9 
3.13 U/mL, respectively. ,PSRUWDQWO\PLFURVRPHVRIȕ-HSD1-deficient mice were devoid of 10 
cortisone reductase activity as expected, and cortisone reductase activity in hepatic microsomes 11 
from wild-type mice ZDV FRPSOHWHO\ EORFNHG XSRQ FRLQFXEDWLRQZLWK WKH VHOHFWLYH ȕ-HSD1 12 
inhibitor T0504.  13 
14 
3.2. Reduction of triadimefon in liver microsomes15 
16 
In the presence of G6P triadimefon was efficiently converted to triadimenol by mouse liver 17 
microsomes (Fig. 2). In contrast, much lower activity was detected when microsomes were 18 
incubated with NADPH (p < 0.001), an activity corresponding to the low percentage of right-side 19 
out vesicles. Importantly, the conversion of triadimefon to triadimenol could be completely 20 
blocked with the specific ȕ-HSD1 inhibitors T0504 (Fig. 2) and BNW16 (not shown) as well 21 
as with the unspecific inhibitor glycyrrhetinic acid (GA). Further excluding the possibility that 22 
other enzymes might be involved in the observed carbonyl reduction of triadimefon, microsomes23 
of liver-VSHFLILFȕ-HSD1 knock-out mice showed no conversion of triadimefon to triadimenol.  24 
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A species comparison revealed about 4-fold higher triadimefon carbonyl reductase activity of 1 
human liver microsomes compared with rat liver microsomes (p < 0.001) and 8-fold higher 2 
activity than mouse liver microsomes (p < 0.001) (Fig. 3). The fact that the selective inhibitor 3 
T0504 completely abolished triadimefon reductase activity indicated that ȕ-HSD1 is the major 4 
if not only microsomal enzyme catalyzing this reaction.  5 
6 
3.3. Reduction of triadimefon by recombinant 11ȕ-HSD1 measured in cell lysates 7 
8 
The different microsomal activities can potentially be due to differences in 11ȕ-HSD1 expression 9 
levels, differences in the expression of H6PDH and/or its interaction with 11ȕ-HSD1, or species-10 
specific differences in the kinetic properties of 11ȕ-HSD1. Significant species-specific 11 
differences in the substrate and inhibitor specificity of 11ȕ-HSD1 have been reported [27, 40].12 
Therefore, in a next step, the carbonyl reduction of triadimefon by recombinant human, rat and 13 
mouse 11ȕ-HSD1 was measured in lysates of transiently transfected HEK-293 cells. HEK-293 14 
cells were chosen because they do not express endogenous steroid-metabolizing enzymes and to 15 
be able to compare the enzymes of the three species in the same cellular background. Because 16 
HEK-293 cells express no or very low H6PDH levels [37], lysates were prepared by sonication, 17 
which leads to microsomal vesicles with mixed orientation and allows measuring 11ȕ-HSD1 18 
activity in the presence of NADPH. Lysates of untransfected HEK-293 cells did not metabolize 19 
triadimefon. A comparison of the triadimefon reduction revealed a 3-4 fold higher affinity of 20 
human compared with rat and mouse 11ȕ-HSD1 (Table 1). The expression levels of 11ȕ-HSD1 21 
in transiently transfected cells were semi-quantitatively analyzed by Western blotting and 22 
densitometry and did not vary significantly between species (data not shown). Human 11ȕ-HSD1 23 
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was most active with 2-fold and 4-fold higher Vmax and 5-fold and 15-fold higher Vmax/Km values 1 
than mouse and rat 11ȕ-HSD1, respectively (Table 1). 2 
3 
3.4. Inhibition of 11ȕ-HSD1-dependent cortisone reduction by triadimefon and vice versa4 
5 
In order to estimate the potential of triadimefon and triadimenol to interfere with glucocorticoid 6 
activation, inhibition of human 11ȕ-HSD1-dependent cortisone reduction by the azole fungicides 7 
was measured. IC50 values of 15.3 ± 7.0 μM and 56 ± 14 μM were obtained for triadimefon and 8 
triadimenol, respectively (Fig. 4). The 11ȕ-HSD1-dependent reduction of triadimefon was 9 
inhibited by cortisone with an IC50 of 289 ± 54 nM (Fig. 5).  10 
11 
3.5. 11ȕ-HSD1 and 11ȕ-HSD2 do not catalyze the oxidation of triadimenol 12 
13 
11ȕ-HSD1 is a reversible enzyme in vitro and catalyzes the interconversion of cortisone/cortisol, 14 
11-GHK\GURFRUWLFRVWHURQHFRUWLFRVWHURQH SUHGQLVRQHSUHGQLVRORQH ȕ-hydroxycholesterol/7-15 
oxocholesterol, and Į- DQG ȕ-hydroxydehydroepiandrosterone/7-oxodehydroepiandrosterone 16 
[41]. However, we reported recently that 11ȕ-HSD1 irreversibly catalyzes the reduction of the 17 
secondary bile acid 7-oxolithocholic acid to chenodeoxycholic acid [22]. Therefore, the potential 18 
oxidation of triadimenol by 11ȕ-HSD1 was tested in the presence of the cofactor NADP+.19 
Triadimenol was not oxidized by 11ȕ-HSD1 (Fig. 6). As a control to verify enzyme activity, the 20 
reduction of triadimefon was measured, resulting in efficient formation of triadimenol, with 70% 21 
substrate conversion. Furthermore, incubation of triadimenol with lysates of cells expressing 11ȕ-22 
HSD2 in the presence of NAD+ did not result in the formation of any triadimefon. Under similar 23 
conditions, cortisol was converted by 90% to cortisone (not shown).  24 
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3.6. Analysis of the binding of triadimefon and triadimenol to 11ȕ-HSD1 by molecular 1 
modeling2 
3 
Using molecular docking, the binding orientations were predicted for triadimefon and 4 
triadimenol. The binding orientation of triadimefon is comparable to that reported by Mazur et al.5 
[10], while triadimenol is observed in the binding pocket in a flipped way compared with6 
triadimefon (Fig. 7). Triadimefon is located in the binding pocket with the carbonyl-oxygen 7 
facing towards the catalytic amino acids Tyr183 and Ser170, and forming hydrogen bonds with 8 
them (Fig. 8A and B). In contrast, triadimenol is located in the same area with the alcohol group 9 
pointing away from Tyr183 and Ser170 (Fig. 8A, C and D). Instead, the alcohol group forms a 10 
hydrogen bond with the cofactor molecule.  11 
12 
4. Discussion13 
14 
Almost all studies on the assessment of NADPH-dependent enzyme activities reported in the 15 
literature so far used either NADPH or an NADPH-regenerating system (NRS), consisting of 16 
NADP+, G6P and purified bacterial G6PDH. Mazur et al. compared different conditions to 17 
PHDVXUH ȕ-HSD1 reductase activity and observed highest activity upon incubation of 18 
microsomes with an NRS in the presence of the pore forming agent alamethicin [10]. However, 19 
in this setting NADPH is produced in the extra-vesicular space and can be readily utilized by 20 
cytochrome P450 enzymes.  21 
In the present study, optimized assay conditions have been applied to distinguish between 22 
activities of NADPH-dependent microsomal enzymes facing the cytoplasm and enzymes 23 
protruding into the ER luminal compartment. Intact liver microsomes contain an endogenous 24 
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NRS, consisting of the luminal pyrimidine nucleotide pool, the glucose-6-phosphate translocase 1 
(G6PT) and H6PDH. Because of the neglectible permeability of the ER membrane for pyridine 2 
nucleotides, the NADPH generated by H6PDH upon addition of G6P into the assay buffer is3 
exclusively available for ER luminal enzymes. The intactness of microsomal vesicles and the 4 
percentage of inside-out vesicles (approximately 90% in the protocol used) can be tested by 5 
FRPSDULQJȕ-HSD1-dependent cortisone reduction in the presence of either NADPH or G6P. 6 
The quality of microsomal preparations can be further assessed by measuring cytochrome C 7 
reductase activity. This approach should be valuable for the characterization of enzymatic 8 
conditions of other luminal carbonyl reductases.  9 
In mouse liver microsomes the NADPH-dependent conversion of triadimefon to metabolites 10 
other than triadimenol was almost two times higher than the G6P-dependent formation of 11 
triadimenol. This ratio was significantly different in rat and human liver microsomes, where the 12 
carbonyl reduction of triadimefon was 2- and 8-fold higher than in mice. The cytochrome P450-13 
mediated metabolism of triadimefon has been described earlier [9, 42]. Barton et al. reported a 14 
role for cytochrome P450 subfamilies 2C and 3A in the hydroxylation of triadimefon by rat liver 15 
microsomes [9]. Iyer et al. identified the two metabolites 1-(4-chlorophenoxy)-4-hydroxy-3,3-16 
dimethyl-1-(1H-1,2,4-triazol-1-yl)-2-butanone (kwg1323) and ȕ-(4-chlorophenoxy)-Į-(1,1-17 
dimethylethyl)-1H-1,2,4-triazole-1-ethanol (desmethyl kwg1342) in experiments using cultured 18 
rat hepatocytes. 19 
The use of selective ȕ-HSD1 inhibitors demonstrates that the carbonyl reduction of triadimefon 20 
is catalyzHG H[FOXVLYHO\ E\ ȕ-HSD1. This is further substantiated by the fact that no 21 
WULDGLPHQROIRUPDWLRQFRXOGEHREVHUYHGLQPLFURVRPHVIURPOLYHUVRIȕ-HSD1-deficient mice. 22 
7KH DQDO\VLV RI WKH NLQHWLF SURSHUWLHV RI UHFRPELQDQW ȕ-HSD1 revealed clearly higher 23 
triadimefon reductase activity of the human isoform compared with the rodent isoforms.24 

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Although it must be taken into consideration that the rat and mouse enzymes were expressed in a 1 
human cell line, and that it cannot be fully excluded that the lower activities might emerge from 2 
protein folding disturbances, or the lack of some mouse- or rat-specific factors in human cells,3 
comparable cortisone reductase activities for the three enzymes have been observed in this cell 4 
system in previous experiments [27]. The present study revealed similar affinities for triadimefon 5 
of rDWDQGPRXVHȕ-HSD1. The fact that the recombinant mouse enzyme had three-fold higher 6 
catalytic efficiency (Vmax/Km) than the rat enzyme but rat microsomes were twice as active as 7 
mouse microsomes (in line with a previous study by Crowell et al. [11]) suggests a higher 8 
H[SUHVVLRQ RI ȕ-HSD1 in rats. Indeed, approximately two times higher cortisone reductase 9 
activity was obtained in rat liver microsomes compared with mouse liver microsomes. A reliable 10 
FRPSDULVRQRIȕ-HSD1 protein expression levels in human, rat and mouse is difficult due to 11 
significant species specificity of available antibodies. The present study suggests that rats and 12 
mice are of limited use to study the possible consequences of impaired carbonyl reduction of 13 
triadimefon for humans; however, ȕ-HSD1-deficient mice turned out to be very useful for 14 
solving mechanistic questions.  15 
Crowell et al. recently developed a physiologically based pharmacokinetic model for triadimefon 16 
and triadimenol in rats and humans [43]. The model showed good results for peak blood and 17 
tissue levels, but the clearance of both compounds was over estimated. Better results were 18 
REWDLQHG E\ D UHYHUVH PHWDEROLVP PRGHO EDVHG RQ WKH DVVXPSWLRQ WKDW ȕ-HSD1, or 19 
DOWHUQDWLYHO\ ȕ-HSD2, might catalyze the oxidation of triadimenol. However, our results 20 
UHYHDOHG WKDWQHLWKHUȕ-+6'QRUȕ-HSD2 catalyze the oxidation of triadimenol. Previous 21 
studies GHPRQVWUDWHGWKDWȕ-HSD1 is a reversible enzyme that catalyzes the interconversion of 22 
endogenous glucocorticoids as well as 7-oxigenated cholesterol and 7-oxigenated DHEA in vitro, 23 
and molecular modelling revealed the close proximity of the carbonyl and the respective 24 

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hydroxyl on C7 and C11 of the steroid backbone to the catalytic Tyr183 [21, 44, 45]. However, a 1 
recent study reported the irreversible reduction of 7-oxolithocholic acid by ȕ-HSD1, whereby 2 
molecular modelling suggested that only 7-oxolithocholic acid has optimal binding of substrate 3 
and cofactor to Tyr183 and Lys187, thus allowing electron transfer with the cofactor [22].4 
Similarly, the docking studies of the present study support our experimental findings that 5 
triadimenol is not oxidized by ȕ-HSD1 (Fig. 7, 8) 7ULDGLPHIRQ ELQGV WR ȕ-HSD1 in an 6 
orientation, where the carbonyl-oxygen is pointing towards the catalytic amino acids Tyr183 and 7 
Ser170, and forming hydrogen bonds with them. This orientation is essential, since in the 8 
reduction reaction, the hydrogen is transferred from Tyr183 to the substrate [46]. Thus, the 9 
binding orientation of triadimefon allows the reduction reaction to take place. In contrast, 10 
triadimenol has a flipped binding mode compared to triadimefon, suggesting why this compound 11 
LV QRW R[LGL]HG E\ ȕ-HSD1. These findings suggest that after reduction of triadimefon to 12 
triadimenol, the compound rotates away from the catalytic amino acids, thus preventing its 13 
oxidation. However, the fact that triadimenol fits to the binding pocket and forms hydrogen 14 
bonds with the catalytic amino acid Ser170 and the cofactor, could explain the weak inhibitory 15 
activity of this compound. 16 
,QDQDWWHPSWWRHVWLPDWHZKHWKHUH[SRVXUHWRWULDGLPHIRQRUWULDGLPHQROPLJKWDIIHFWȕ-HSD1-17 
dependent glucocorticoid activation, we determined IC50 values of the two fungicides for 18 
cortisone reduction. Regarding the expected exposure levels upon intake of contaminated food or 19 
water or upon occupational exposure of field workers and uptake through skin, it is highly 20 
XQOLNHO\ WKDW FRQFHQWUDWLRQV DV KLJK DV  0 DUH UHDFKHG WR VLJQLILFDQWO\ LQKLELW ȕ-HSD1-21 
dependent cortisone reduction. On the other side, cortisone efficiently inhibited the carbonyl 22 
reduction of triadimefon. Under the conditions applied, an apparent Km of 300-400 nM for 23 
cortisone reduction has been obtained [47]. Thus, the IC50 of about 300 nM obtained in the 24 

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present study suggests that at elevated concentrations of 11-oxoglucocorticoids, i.e. during stress 1 
situations or therapeutic treatment, the carbonyl reduction of triadimefon may be significantly 2 
lowered. The competition of cortisone (or 11-dehydrocorticosterone) and triadimefon for binding 3 
WR ȕ-HSD1 may explain the lower than expected clearance of triadimefon based on the 4 
physiologically-based pharmacokinetic model in the study by Crowell et al. [43]. The observation 5 
suggests that the circadian rhythm of glucocorticoids should be considered for estimation of the 6 
clearance of triadimefon.  7 
In conclusion, the use of recombinant enzymes GHPRQVWUDWHG WKH DELOLW\ RI ȕ-HSD1 to 8 
irreversibly catalyze the carbonyl reduction of triadimefon. Comparison of human, rat and mouse 9 
ȕ-HSD1 revealed at least five times higher catalytic efficiency of the human compared with the 10 
rodent enzymes, which is relevant regarding an improved cross-species extrapolation for risk 11 
assessment. Absence of triadimenol formation upon incubation of microsomes from livers of 12 
ȕ-HSD1-deficient mice and of liver miFURVRPDO SUHSDUDWLRQV ZLWK VHOHFWLYH ȕ-HSD1 13 
LQKLELWRUV LQGLFDWHWKDWȕ-HSD1 is the major if not only enzyme catalyzing the conversion of 14 
triadimefon to triadimenol. Finally, inhibition studies suggest that the carbonyl reduction of 15 
triadimefon is impaired by elevated cortisone levels. 16 
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Figure Legends1 
2 
3 
Fig. 1. Conversion of cortisone to cortisol by liver microsomes. Human liver microsomes (HLM, 4 
black bars, f.c. 0.5 mg/mL), rat liver microsomes (RLM, grey bars, f.c. 0.25 mg/mL) and mouse 5 
liver microsomes (MLM, white bars, f.c. 0.5 mg/mL) were incubated for 15 min at 37°C in the 6 
presence of 1 μM cortisone and 1 mM glucose-6-phosphate, in the absence or presence of 20 μM 7 
of the ȕ-HSD1 inhibitor T0504. The amount of cortisone and cortisol was then quantitated. 8 
Lack of activity of liver microsomes from ȕ-HSD1-deficient mice is indicated by KO. Data 9 
(mean s SD) were obtained from at least three independent experiments using pooled samples.10 
Repeated measures ANOVA found significant species differences in cortisone reduction. Post 11 
hoc analysis by Tukey test was used for multiple comparisons. *** P < 0.001. 12 
13 
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1 
Fig. 2. Conversion of triadimefon to triadimenol by mouse liver microsomes. Microsomes (1 2 
mg/mL), prepared from wild-type (wt) and liver-VSHFLILFȕ-HSD1 knock-out mice (ko), were 3 
incubated for 1 h at 37°C in the presence of 1 μM triadimefon and either 1 mM of NADPH or 14 
mM of glucose-6-phosphate (G6P), in the absence or presence of 20 μM T0504 or glycyrrhetinic 5 
acid (GA). Data represent mean s SD from at least three independent experiments using pooled 6 
samples. Repeated measures ANOVA found significant differences in the groups. Post hoc 7 
analysis by Tukey test was used for multiple comparisons. ** p < 0.01, *** p < 0.001, ns = not 8 
significant.9 
10 

29 
 
1 
Fig. 3. Triadimenol formation in liver microsomes. Human liver microsomes (HLM, black bars, 2 
f.c. 0.2 mg/mL), rat liver microsomes (RLM, grey bars, f.c. 1 mg/mL) and mouse liver 3 
microsomes (MLM, white bars, f.c. 1 mg/mL) were incubated for 1 h at 37°C with 1 μM 4 
triadimefon and 1 mM G6P, in the absence or presence of 20 μM T0504. Lack of activity of 5 
MLM of ȕ-HSD1-deficient mice is indicated by KO. Data (mean s SD) were obtained from at 6 
least three independent experiments using pooled samples. Repeated measures ANOVA found 7 
significant species differences in triadimefon reduction. Post hoc analysis by Tukey test was used 8 
for multiple comparisons. *** P < 0.001. 9 
10 
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1 
Fig. 4. ,QKLELWLRQ RI ȕ-HSD1-dependent cortisone reduction by triadimefon and triadimenol. 2 
,QKLELWLRQ RI WKH ȕ-HSD1-dependent conversion of cortisone to cortisol by various 3 
concentrations of triadimefon and triadimenol was measured in lysates of HEK-293 cells 4 
transfected with the human enzyme as described in Section 2. Lysates were simultaneously 5 
incubated with cortisone (1 μM) and triadimefon or triadimenol for 15 min at 37°C. Data were 6 
normalized to vehicle control (0.05% DMSO) and represent mean s SD from three independent 7 
experiments.8 
9 
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1 
Fig. 5. ,QKLELWLRQRIȕ-HSD1-dependent triadimefon reduction by cortisone. Inhibition of the 2 
ȕ-HSD1-dependent conversion of triadimefon to triadimenol by various concentrations of 3 
cortisone was measured in lysates of HEK-293 cells transfected with the human enzyme as 4 
described in Section 2. Lysates were simultaneously incubated with triadimefon (1 μM) and 5 
cortisone for 60 min at 37°C. Data were normalized to vehicle control (0.05% DMSO) and 6 
represent mean s SD from three independent experiments. 7 
8 
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1 
Fig. 6. 7ULDGLPHQRO LV QRW R[LGL]HG E\ ȕ-+6' DQG ȕ-HSD2. Recombinant human ȕ-2 
HSD1 and ȕ-HSD2 were expressed in HEK-293 cells. Cells were lysed by sonication to obtain 3 
YHVLFOHVZLWKPL[HGRULHQWDWLRQȕ-HSD1 activity was measured by incubation of lysates for 1 4 
h at 37°C with 1 μM triadimefon and 1 mM NADPH or with 1 μM triadimenol and 1 mM 5 
NADP+. ȕ-HSD2 activity was measured in the presence of 1 μM triadimenol and 1 mM NAD+.6 
Data (mean s SD) were obtained from at least three independent experiments. Repeated7 
measures ANOVA found significant differences. Post hoc analysis by Tukey test was used for 8 
multiple comparisons. *** P < 0.001. 9 
10 
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1 
Fig. 7. 7KH ELQGLQJ RULHQWDWLRQV RI WULDGLPHIRQ F\DQ DQG WULDGLPHQRO PDJHQWD LQ WKH ȕ-2 
HSD1 binding site. The carbonyl-oxygen of triadimefon is facing towards catalytic residues, with 3 
a distance of the hydroxyl on Tyr183 to the carbonyl-oxygen of 3.12 Å. Triadimenol is predicted 4 
to have a flipped binding orientation, where the reduced carbonyl-oxygen faces away from the 5 
catalytic residues, with a distance of the hydroxyl on Tyr183 to the carbonyl-oxygen of 6.96 Å.  6 
7 
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1 
Fig. 8. The predicted binding orientations of triadimefon (A and B) and triadimenol (C and D) in 2 
ȕ-HSD1. The ligand-protein interactions are color-coded: hydrogen bond acceptor – red arrow, 3 
hydrophobic – yellow sphere. The ligand binding pocket is colored by aggregated lipophilicity. 4 
The catalytic amino acids are highlighted in ball- and stick style and the cofactor NADPH in stick 5 
style.6 
7 
8 
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Table 11 
2 
Kinetic parameters of ȕ-HSD1-dependent carbonyl reduction of triadimefon. HEK-293 cells 3 
werHWUDQVLHQWO\WUDQVIHFWHGZLWKHLWKHUKXPDQUDWRUPRXVHȕ-HSD1, followed by measuring 4 
the carbonyl reduction of triadimefon and determination of apparent Vmax and apparent KM values 5 
as described in Section 2. The appVmax values are expressed relative to total protein concentration 6 
of the lysates used. Data were calculated by non-linear regression using four parametric logistic 7 
curve fitting (GraphPad Prism) and represent mean s SD of three independent experiments. 8 
One-way ANOVA found significant differences (P < 0.01) in appVmax values, post hoc analysis 9 
by Tukey test was used for multiple comparison. Human appVmax value was significant higher 10 
then rat appVmax (p < 0.01) and mouse appVmax (p < 0.05). Other comparisons were not 11 
significant.12 
13 
ȕ-HSD1 appVmax appKM appVmax/ appKM
Human 0.54 ± 0.060 nmol × mg-1 × h-1 3.5 ± 0.8 μM 154 × 10-6 l × mg-1 × h-1
Rat 0.14 ± 0.031 nmol × mg-1 × h-1 12.8 ± 4.2 μM 11 × 10-6 l × mg-1 × h-1
Mouse 0.31 ± 0.129 nmol × mg-1 × h-1 10.4 ± 6.5 μM 30 × 10-6 l × mg-1 × h-1
14 
15 
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Abstract1 
Bupropion is widely used for treatment of depressions and as smoking cessation drug. Despite of 2 
more than 20 years of therapeutic use, its metabolism is not fully understood. While CYP2B6 has 3 
been shown to form hydroxybupropion, the enzyme(s) generating erythro- and 4 
threohydrobupropion remained unclear. Experiments using the unspecific inhibitor glycyrrhetinic 5 
acid (GA) and human liver and placenta microsomes suggested a role for ȕ-hydroxysteroid 6 
dehydrogenases ȕ-HSDs) in the formation of erythro- and threohydrobupropion. ȕ-HSD2 7 
converts the active glucocorticoids cortisol and prednisolone to the inactive cortisone and 8 
prednisone. ȕ-HSD1 catalyzes the reverse reaction and, in addition, accepts several other 9 
substrates. In the present study, we used human, rat and mouse liver microsomes, recombinant 10 
HQ]\PHVDQGD VHOHFWLYH LQKLELWRU WR DVVHVV WKH UROHRIȕ-HSD1 in the carbonyl reduction of 11 
bupropion and to characterize species-VSHFLILFGLIIHUHQFHV7KHUHVXOWVUHYHDOHGȕ-HSD1 as the 12 
major enzyme converting bupropion to threohydrobupropion. The reaction was irreversible and 13 
stereoselective. Human liver microsomes showed 10 and 80 times higher activity than rat and 14 
mouse liver microsomes. ȕ-HSD1 did not form erythrohydrobupropion, indicating the15 
existence of another carbonyl reductase that generates erythrohydrobupropion. In line with this 16 
observation, erythrohydrobupropion formation was not altered in experiments with microsomes 17 
IURPȕ-HSD1-GHILFLHQWPLFHRUXSRQLQFXEDWLRQZLWKȕ-HSD1 inhibitor. Molecular docking 18 
VXSSRUWHGWKHH[SHULPHQWDOILQGLQJVVXJJHVWLQJWKDWȕ-HSD1 selectively converts R-bupropion 19 
to threohydrobupropion. Enzyme inhibition experiments suggested that exposure to bupropion 20 
XQOLNHO\ LPSDLUV ȕ-HSD1-dependent glucocorticoid activation but that pharmacological21 
administration of cortisone or prednisone inhibits ȕ-HSD1-dependent bupropion metabolism.  22 
23 
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1. Introduction1 
Bupropion (Wellbutrin®) is used since more than 20 years in the treatment of depressions and as 2 
an efficient smoking cessation drug (Zyban®) [1]. Further, it has been proposed for the treatment 3 
of attention-deficit/hyperactivity disorders [2]. According to a recent review, approximately 40 4 
million patients worldwide are treated with bupropion [3]. Despite of its frequent use, the 5 
mechanisms of bupropion metabolism are not fully understood. The identification and 6 
characterization of the enzymes involved may help to optimize the therapeutic use of bupropion 7 
and avoid potential drug-drug interactions.  8 
Bupropion is used as a racemic mixture of R- and S-bupropion (Fig. 1) and acts as a dopamine 9 
and norepinephrine reuptake inhibitor. The first studies with bupropion in humans in the 1980s 10 
led to the identification of the three major metabolites hydroxybupropion, erythrohydrobupropion 11 
and threohydrobupropion [4-7]; however, the enzymes responsible for the metabolism remained 12 
unknown. A decade later, cytochrome P450 2B6 (CYP2B6) was identified as the enzyme 13 
responsible for the formation of hydroxybupropion [8, 9]. Another ten years later, experiments 14 
with KXPDQDQGEDERRQSODFHQWDODQG OLYHUPLFURVRPHVDQG WKHXQVSHFLILFȕ-hydroxysteroid 15 
dehydrogenase (ȕ-HSD LQKLELWRU ȕ-glycyrrhetinic acid (GA) suggested that bupropion is 16 
metabolized by one of the ȕ-HSDs to erythrohydrobupropion and threohydrobupropion [5, 10,17 
11]. Incubations with the unspecific inhibitor GA yielded lower amounts of both 18 
threohydrobupropion and erythrohydrobupropion, suggesting the involvement of ȕ-HSD1 in 19 
the carbonyl reduction of bupropion.  20 
Two distinct ȕ-HSD HQ]\PHVDUHNQRZQȕ-HSD1 is responsible for the conversion of the 21 
inactive 11-ketoglucocorticoids cortisone (humans) and 11-dehydrocorticosterone (rodents) to the 22 
DFWLYHȕ-hydroxygOXFRFRUWLFRLGVFRUWLVROKXPDQVDQGFRUWLFRVWHURQHURGHQWVZKHUHDVȕ-23 
HSD2 catalyzes the reverse reaction [12]. 11ȕ-HSD2 is known to inactivate cortisol by 24 
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conversion to cortisone. It plays a crucial role in protecting mineralocorticoid receptors (MR) 1 
from activation by glucocorticoids [13] $OWKRXJK ȕ-HSD2 is able to act as a reversible 2 
enzyme for some substrates such as dexamethasone/11-ketodexamethasone under in vitro3 
conditions [14] ȕ-HSD2 functions exclusively as a dehydrogenase in vivo and a role in the 4 
reduction of bupropion can be excluded. ȕ-HSD1 is expressed in many metabolically active 5 
tissues such as liver, adipose and skeletal muscle [15]. In addition to the reduction of cortisone, 6 
ȕ-HSD1 essentially converts the pro-drug prednisone to its active form prednisolone [16],7 
thereby enabling binding to and activation of the glucocorticoid receptor (GR) and regulation of 8 
GR-dependent target genes. Due to the adverse metabolic effects of prolonged periods of 9 
exposure to excessive glucocorticoid levels and the observed metabolic disturbances in transgenic 10 
mice RYHUH[SUHVVLQJȕ-HSD1 in adipose tissue [17], there are considerable efforts to develop 11 
inhibitors for therapeutic applications [18, 19]. 1HYHUWKHOHVV ȕ-HSD1 is a multi-functional 12 
carbonyl reductase with broad substrate specificity [20]. It is able to reduce endogenous sterols 13 
such as 7-ketocholesterol [21, 22], the secondary bile acid 7-oxolithocholic acid [23], 7-14 
ketodehydroepiandrosterone [24] and several xenobiotics, including triadimefon [25], 4-15 
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) [26] oracin [27], metyrapone [28] and 16 
ketoprofen [29]. 17 
The evidence from earlier studies using microsomes and the unspecific inhibitor GA suggested a 18 
UROH IRU ȕ-HSD1 in the formation of the two metabolites erythrohydrobupropion and 19 
threohydrobupropion. 6LQFHLWVWLOOUHPDLQHGXQFOHDUZKHWKHULQGHHGȕ-HSD1 is responsible for 20 
the generation of these two metabolites, and whether it has a major or minor contribution, we 21 
XVHGKHSDWLFPLFURVRPHVDVHOHFWLYHȕ-HSD1 inhibitor, and recombinant enzyme to assess the 22 
UROH RI ȕ-HSD1 in bupropion metabolism. Furthermore, we investigated species-specific 23 
differences in the carbonyl reduction of bupropion by human, rat and mouse liver microsomes as 24 
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ZHOO DV WKH FRUUHVSRQGLQJ UHFRPELQDQW HQ]\PHV 7KH FRQWULEXWLRQ RI ȕ-HSD1 was further 1 
assessed using microsomes from liver-VSHFLILF ȕ-HSD1 knockout mice. Finally, the putative 2 
binding of bupropion WR ȕ-HSD1 was investigated by molecular modeling, providing an 3 
explanation for the selective carbonyl reduction of bupropion to threohydrobupropion by human 4 
ȕ-HSD1.5 
6 
2. Materials and Methods7 
2.1. Chemicals and reagents8 
Microsomes from a liver of a 77 year old male Caucasian were purchased from Celsis In Vitro 9 
Inc (Baltimore, MD). Human embryonic kidney (HEK-293) cells from ATCC (No CRL-1573) 10 
were purchased from LGC Standards S.a.r.l. (Molsheim Cedex, France). Cell culture medium 11 
was purchased from Invitrogen (Carlsbad, CA), 5H-1,2,4-triazolo(4,3-a)azepine,6,7,8,9-12 
tetrahydro-3-tricyclo(3·3·1·13·7)dec-1-yl (T0504) from Enamine (Kiev, Ukraine), and steroids 13 
from Steraloids (Newport, RI). The metabolites hydroxybupropion, erythrohydrobupropion and 14 
threohydrobupropion were purchased from Toronto Research Chemicals Inc. (North York, 15 
Canada), and bupropion and all other chemicals from Sigma-Aldrich Chemie GmbH (Buchs, 16 
Switzerland). The solvents were of analytical and high performance liquid chromatography grade 17 
and reagents of the highest grade available.18 
19 
2.2. Cell culture and transfection20 
HEK-293 cells were grown at 37 °C in Dulbecco's modified Eagle medium (DMEM, containing 21 
4.5 g/L glucose, 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/mL streptomycin, 1 × 22 
MEM non-essential amino acids and 10 mM HEPES buffer, pH 7.4). For the experiments with 23 
recombinant ȕ-HSD1, HEK-293 cells were transiently transfected by the calcium phosphate 24 
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transfection method as described earlier [25] with plasmids for human, rat or mouse ȕ-HSD1 1 
[30]. Cells were harvested 48 h post-transfection, centrifuged at 900 × g for 4 min, and cell 2 
pellets were immediately shock frozen and stored at -80°C until further use. Protein concentration 3 
was determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific Inc., Rockford, 4 
IL, USA).5 
6 
2.3. Preparation of liver microsomes7 
Microsomes were prepared as described earlier [25]. Livers were taken from adult male Sprague 8 
Dawley rats, C57BL/6J mice and liver-specific knock-out mice (LKO) generated by crossing 9 
albumin-Cre transgenic mice on a C57BL/6J background with floxed homozygous HSD11B110 
mice on a mixed C57BL/6J/129SvJ background [31]. Liver tissue was homogenized, and 11 
microsomes were obtained after differential centrifugation as described [25]. Microsomes were12 
finally resuspended in a buffer containing 0.15 M potassium chloride, 0.25 M sucrose, and 10 13 
mM Tris-maleate, pH 7.0. Aliquots were stored at -80°C until further use. The microsomal 14 
protein concentration was measured using the Pierce BCA protein assay kit. The quality of the 15 
microsomal preparations was analyzed using the cytochrome C reductase assay kit (Sigma-16 
Aldrich Chemie GmbH) and by assessing the latent activity of the ȕ-HSD1-dependent17 
oxoreduction of cortisone in the presence of glucose-6-phosphate (G6P).18 
19 
2.4. Enzyme activity measurements using liver microsomes20 
The oxoreduction of cortisone by liver microsomes was measured as reported earlier [25]. The 21 
metabolism of bupropion was determined at 37 °C (1 h incubation) in a final reaction volume of 22 
22 μL of TS2 buffer (100 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM MgCl2, 250 mM 23 
sucrose, 20 mM Tris–HCl, pH 7.4) containing 1 μM of bupropion and either human liver 24 
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microsomes (final concentration (f.c.) of 0.4 mg/mL) or rat, mouse or LKO mouse liver1 
microsomes (all at a f.c. of 1 mg/mL), supplemented with either 1 mM G6P or 1 mM NADPH in 2 
the presence or absence of 0RI WKH VHOHFWLYHȕ-HSD1 inhibitor T0504. Reactions were 3 
stopped by adding 200 μL 0.3 M zinc sulfate in a 1:1 (v/v) mixture of water and methanol.4 
Atrazine was added as an internal standard at an f.c. of 50 nM, followed by vortexing for 10 s and 5 
centrifugation for 10 min at 12,000 × g on a table top centrifuge. Samples were further purified 6 
by an ethyl acetate extraction. Supernatants (180 μL) were added to 600 μL ethyl acetate and 7 
incubated for 10 min on a thermomixer at 700 rpm. Following centrifugation for 10 min at 8 
12,000 × g, supernatants (550 μL) were evaporated to dryness, reconstituted in 100 μL methanol 9 
and stored at -20°C until analysis by liquid chromatography–tandem mass spectrometry (LC–10 
MS/MS) (section 2.6).  11 
12 
2.5. Enzyme activity measurements using lysates of transfected HEK-293 cells  13 
Frozen pellets of HEK-293 cells transiently expressing human, rat or mouse ȕ-HSD1 were 14 
resuspended in TS2 buffer and sonicated. Lysates were then incubated for 1 h at 37 °C in the 15 
presence of 1 mM NADPH and different concentrations of bupropion (8 μM, 4 μM, 2 μM, 1 μM, 16 
500 nM, 250 nM and 125 nM) in a final volume of 22 μL to estimate apparent KM and apparent 17 
Vmax values. Substrate conversion was kept below 25% in all experiments. Reactions were 18 
stopped and processed as described in section 2.4. 19 
For measuring the reductase activity of ȕ-HSD1, cell lysates were incubated in the presence of 20 
1 μM cortisone or 1 μM bupropion as substrate and various concentrations of either bupropion or 21 
cortisone and prednisone as the respective inhibitor. IC50 values were calculated by non-linear 22 
regression using four parametric logistic curve fitting (GraphPad Prism software). 23 
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1 
2.6. Liquid chromatography-tandem mass spectrometry measurements2 
An Acquity UPLC BEH C18 column (1.7 μm, 2.1 × 150 mm ID Waters, Milford, MA) and an 3 
Agilent 1290 Infinity Series chromatograph (Agilent Technologies, Basel, Switzerland) were 4 
used for chromatographic separations.  5 
The mobile phase consisted of solvent A (H2O/acetonitrile, 95:5 (v/v), containing 0.1% formic 6 
acid, and solvent B (H2O/acetonitrile, 5:95 (v/v), containing 0.1% formic acid, at a flow rate of 7 
0.5 mL/min. Bupropion, hydroxybupropion, threohydrobupropion and erythrohydrobupropion 8 
were separated using 15% solvent B for 6 min, followed by a linear gradient from 6 to 10 min to 9 
reach 100% solvent B, and then 100% solvent B for 3 min. The column was then re-equilibrated 10 
with 15% solvent B. Cortisone and cortisol were resolved as described earlier [25]. 11 
The UPLC was interfaced to an Agilent 6490 triple quadropole tandem mass spectrometer 12 
(MS/MS). The entire UPLC-MS/MS system was controlled by Mass Hunter workstation software 13 
(version B.01.05). The injection volume of each sample was 5 μL. The mass spectrometer was 14 
operated in electrospray ionization (ESI) positive ionization mode, a source temperature of 15 
350°C, a nebulizer pressure of 20 psi and a capillary voltage of 4000 V.  16 
The compounds were analyzed using multiple-reaction monitoring (MRM) and identified by 17 
comparing their retention time and mass to charge ratio (m/z) with those of authentic standards. 18 
The transitions, collision energy and retention time were m/z 240.1/184.1, 19 V and 4.9 min for 19 
bupropion; m/z 242/168, 20 V and 5.4 min for threohydrobupropion, m/z 242/168, 20 V and 4.8 20 
min for erythrohydrobupropion; m/z 256/238.1, 17 V and 3.0 min for hydroxybupropion and m/z21 
216/174, 16 V and 5 min for the internal standard atrazine.22 
The UPLC-MS/MS method was validated for accuracy, precision, sensitivity, recovery, and 23 
calibration range. Acceptable inter-GD\DVVD\SUHFLVLRQ6.2%) and accuracy (94.1 – 105.0%) 24 
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were achieved over a linear range of 50 to 5000 nM for bupropion, hydroxybupropion, 1 
threohydrobupropion and erythrohydrobupropion. Recovery of bupropion, hydroxybupropion, 2 
threohydrobupropion and erythrohydrobupropion were 96%, 80%, 79% and 82%, respectively in 3 
all extractions. For each experiment a new calibration curve was determined.4 
5 
2.7. Molecular modeling6 
The 2D structures of R- and S-Bupropion were generated  using ChemBioDraw Ultra 12.0 (1986-7 
2010 CambridgeSoft). The 2D-structures were converted into 3D-structures using ChemBio3D 8 
Ultra 12.0 (1986-2010 CambridgeSoft). The docking studies were performed using GOLD [32,9 
33], which uses a genetic algorithm to produce low-energy binding solutions for small molecules 10 
in the ligand binding pocket. The X-ray FU\VWDO VWUXFWXUH RI ȕ-HSD1 was obtained from the 11 
Protein Data Bank (www.pdb.org [34]). Both stereoisomers of bupropion were docked into the 12 
OLJDQGELQGLQJVLWHRIȕ-HSD1 (PDB code 2BEL, Chain A [35]). The binding site was defined 13 
as a 10 Å sphere, centered on the hydroxyl-oxygen of Ser170 (x: 3.84, y: 22.49, and z: 13.34). 14 
The protein side chains were handled as rigid and the ligand conformations as flexible during the 15 
docking run. The program was set to define the atom types of the ligands and the protein 16 
automatically. GoldScore was selected as a scoring function. The program was allowed to 17 
terminate the docking run in cases where three best-ranked solutions were within an RMSD of 18 
1.0 Å from each other. Using these settings, the program successfully reproduced the binding 19 
mode of the cocrystallized ligand carbenoxolone, thus validating the docking settings. 20 
21 
22 
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3. Results1 
3.1. Species-specific differences in the metabolism of bupropion2 
(DUOLHUVWXGLHVXVLQJWKHXQVSHFLILFȕ-HSD inhibitor GA and microsomes prepared from human 3 
placenta [5] and liver [11] or from baboon liver [10] VXJJHVWHGDUROHIRUȕ-HSD enzymes in 4 
WKHPHWDEROLVPRIEXSURSLRQ7RWHVWRXUDVVXPSWLRQWKDWȕ-HSD1 catalyzes the oxoreduction 5 
of bupropion and to study the stereo-selectivity of the reaction, we first measured the metabolism 6 
of bupropion in human liver microsomes that were incubated in the presence of G6P. We recently 7 
reported that intact liver microsomes, where the ER lumen is protected by the microsomal 8 
membrane, contain an endogenous NADPH regenerating system consisting of H6PDH, and that 9 
ȕ-HSD1 reductase activity can be measured by incubation of microsomes with the substrate 10 
and G6P [25]. Upon incubation with G6P and bupropion, human liver microsomes efficiently 11 
formed threohydrobupropion and to a lesser extent (4-5 fold) erythrohydrobupropion (Fig. 2). 12 
6XUSULVLQJO\ WKH VHOHFWLYH ȕ-HSD1 inhibitor T0504 completely blocked the formation of 13 
threohydrobupropion but had no effect on the formation of erythrohydrobupropion. To assess 14 
possible species-specific differences, we compared the activities of human, rat and mouse liver 15 
microsomes. The rat and mouse liver microsomes showed 10- and 80-fold lower activities to 16 
generate threohydrobupropion. Significant changes were identified by multiple measures 17 
ANOVA (p < 0.0001) between threohydrobupropion formation comparing human against rodent 18 
species with Tukey test (*** p < 0.001). It is important to note that under the same conditions rat 19 
liver microsomes showed a two-fold higher activity to reduce the substrate cortisone than human 20 
and mouse liver microsomes, which had comparable activities [25]. Rat liver microsomes formed 21 
equal amounts of threohydrobupropion and erythrohydrobupropion and mouse liver microsomes 22 
about 2-fold more erythrohydrobupropion than threohydrobupropion. As with the human liver 23 
PLFURVRPHVWKHȕ-HSD1 inhibitor T0504 selectively blocked threohydrobupropion, suggesting 24 
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WKDWȕ-HSD1 stereo-selectively reduces bupropion to threohydrobupropion. To further support 1 
D UROH IRU ȕ-HSD1, we used liver microsomes from liver-VSHFLILF ȕ-HSD1 knockout mice 2 
(LKO). Threohydrobupropion formation was completely abolished, while erythrohydrobupropion 3 
formation was comparable to that in wild-type mice, suggesting that another enzyme is 4 
responsible for the formation of erythrohydrobupropion.  5 
6 
3.2. Impact of cofactor on bupropion metabolism 7 
As reported recently, the preparation of rodent microsomes yielded approximately 90% inside-8 
out vesicles (e.g. luminal compartment protected by the vesicle membrane and cytoplasmic side 9 
facing the solution), whereas the commercially available human liver microsomes show 75% 10 
latency [25]. Incubation of human liver microsomes with G6P yielded approximately 8-fold 11 
higher amounts of threohydrobupropion than erythrohydrobupropion, but only minor amounts of 12 
hydroxybupropion (Fig. 3). As expected, incubation of microsomes with NADPH mainly led to 13 
the cytochrome P450-dependent formation of hydroxybupropion. The formation of 14 
threohydrobupropion is probably due to the microsomal fraction with reverse orientation. Similar 15 
observations were made with mouse and rat liver microsomes, and even higher differences 16 
between NADPH- and G6P-dependent formation of hydroxybupropion versus erythro- and 17 
threohydrobupropion, respectively, were measured (data not shown).18 
To compare the relative activities of cytochrome P450-GHSHQGHQWK\GUR[\ODWLRQDQGȕ-HSD1-19 
dependent carbonyl reduction in vitro, human liver microsomes were incubated in the presence of 20 
both NADPH and G6P (Fig. 4). Threohydrobupropion was the major product formed, followed 21 
by hydroxybupropion and erythrohydrobupropion.  22 
23 
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3.3. Carbonyl reduction of bupropion by recombinant human 11ȕ-HSD1 measured in cell 1 
lysates 2 
The lysates of HEK-293 cells transiently transfected with human ȕ-HSD1 efficiently converted 3 
bupropion to threohydrobupropion (Fig. 5). Importantly, no other metabolites were detected and 4 
lysates of untransfected HEK-293 cells did not metabolize bupropion. These incubations were 5 
performed in the presence of NADPH, because the cells were lysed by sonication, which 6 
generates microsomal vesicles with mixed (inside-out and rightside-out) orientation. Therefore,7 
ȕ-HSD1 activity can be easily measured upon incubation with NADPH, which is not the case 8 
if cells are homogenized by a more gentle procedure. An apparent Km of 2.1 ± 0.9 μM and Vmax9 
of 0.22 ± 0.03 nmol/mg/h for the carbonyl reduction of bupropion was obtained for human ȕ-10 
+6'VXJJHVWLQJWKDWEXSURSLRQLVOHVVHIILFLHQWO\UHGXFHGE\ȕ-HSD1 than cortisone.  11 
)XUWKHUPRUHZH DVVHVVHGZKHWKHU ȕ-HSD1 catalyzes the reverse reaction by incubating cell 12 
lysates with threohydrobupropion and NADP+. No bupropion could be detected, indicating that 13 
the reaction is irreversible (data not shown).  14 
15 
3.4. Inhibition of 11ȕ-HSD1-dependent cortisone reduction by bupropion and vice versa16 
To test whether the substrates influence each other, we first assessed the effect of bupropion on 17 
glucocorticoid activation. The reduction of cortisone was inhibited with an IC50 value of 165 ± 51 18 
μM (Fig. 6). Next, we tested the impact of cortisone and the widely used synthetic glucocorticoid 19 
prednisone on the carbonyl reduction of bupropion. The conversion of bupropion to 20 
threohydrobupropion was inhibited by cortisone and prednisone with IC50 of 193 ± 40 nM (Fig. 21 
7A) and 2.9 ± 0.3 μM, respectively (Fig. 7B).  22 
23 
24 
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3.5. Binding mode prediction of bupropion to 11ȕ-HSD1 by molecular docking1 
Both isomers of bupropion geometrically ILW WR WKH ELQGLQJ VLWH RI ȕ-HSD1 and both are2 
predicted to bind next to the catalytic triad Ser170-Tyr183-Lys187 and the cofactor NADPH. 3 
However, the stereochemistry of these two isomers allows only one of them, R-bupropion, to be 4 
PHWDEROL]HGE\ȕ-HSD1. Since the hydrogens in the reduction reaction are transferred to the 5 
substrate via the cofactor and Tyr183 [36, 37], it is essential that the carbonyl-oxygen of 6 
bupropion is located next to these residues. This is the case for R-bupropion (Fig. 8A): the 7 
carbonyl oxygen points towards Tyr183 and the cofactor is at 2.46 Å distance from the carbonyl-8 
carbon. In contrast, S-bupropion is located in the same place, but because of the different 9 
stereochemistry, the tert-butyl-group points towards the cofactor, thus pushing the carbonyl-10 
group further away from the cofactor and Tyr183 (Fig. 8B). Thus, the S-bupropion carbonyl 11 
group is more distant from the catalytic H-donors and has a non-favorable interaction angle with 12 
the Tyr183 hydroxyl group. These docking results support our biological findings that only 13 
WKUHRK\GUREXSURSLRQLVIRUPHGE\ȕ-HSD1. Erythrohydrobupropion is not formed because of 14 
steric hindrance coming from the stereochemistry of S-bupropion. 15 
16 
4. Discussion17 
Based on earlier studies using microsomes from human and baboon liver and placenta together 18 
ZLWK WKH XQVSHFLILF LQKLELWRU*$ LWZDV VXJJHVWHG WKDW ȕ-HSD enzymes are involved in the 19 
formation of both erythrohydrobupropion and threohydrobupropion [5, 10, 11]. However, since 20 
*$ PLJKW LQKLELW RWKHU HQ]\PHV WKH UHODWLYH FRQWULEXWLRQ RI ȕ-HSD enzymes remained 21 
unclear. In the present study, ZH XVHG OLYHU PLFURVRPHV DQG WKH KLJKO\ VHOHFWLYH ȕ-HSD1 22 
inhibitor T0504 (also known as Merck-544, [30, 38] DV ZHOO DV UHFRPELQDQW ȕ-HSD1 to 23 
characterize the carbonyl reduction of bupropion.  24 
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The comparison of human, rat and mouse liver microsomes revealed clearly highest activity of 1 
human liver microsomes to catalyze the carbonyl reduction of  bupropion, and  2 
threohydrobupropion was the preferred metabolite formed (Fig. 2). These findings provide an 3 
explanation for the observations by Welch et al. who found only low levels of these metabolites 4 
in plasma of mice and rats [39]. Furthermore, these authors reported that hydroxybupropion was 5 
a major urinary metabolite in human, mouse and dog, whereas rats predominantly excreted side 6 
chain cleavage products of bupropion such as m-chlorobenzoic acid. It was proposed that the 7 
distinct metabolism of bupropion may account for the species-specific pharmacological response 8 
of bupropion. Thus, our findings further support earlier studies indicating that rodents are not 9 
adequate models for the prediction of bupropion metabolism in humans.  10 
7KHVSHFLILFȕ-HSD1 inhibitor completely abolished the formation of threohydrobupropion by 11 
liver microsomes from all three species, without affecting the formation of 12 
erythrohydrobupropion. Importantly, microsomes from liver-specific knock-out mice were 13 
unable to generate threohydrobupropion but the formation of erythrohydrobupropion was 14 
comparable to that by wild-type mouse liver microsomes. These results indicate that ȕ-HSD1 15 
is the major if not the only enzyme responsible for the formation of threohydrobupropion and 16 
emphasize the existence of another carbonyl reductase responsible for the formation of 17 
erythrohydrobupropion. The fact that erythrohydrobupropion is formed in the presence of G6P 18 
indicates that the unknown enzyme is localized within the ER and is dependent on H6PDH 19 
activity. 20 
8VLQJ WKH UHFRPELQDQW HQ]\PH ZH VKRZHG WKDW KXPDQ ȕ-HSD1 irreversibly catalyzes the 21 
carbonyl reduction of bupropion to threohydrobupropion. Analysis of the binding of bupropion 22 
DQG LWV PHWDEROLWHV WR ȕ-HSD1 by molecular modeling indicates that R-bupropion adopts a 23 
IDYRUDEOHELQGLQJSRVLWLRQ LQ WKH VXEVWUDWHSRFNHWRIȕ-HSD1, allowing the electron transfer 24 

16 
 
from the cofactor to form threohydrobupropion. In contrast, steric hindrance prevents optimal 1 
binding of S-bupropion and erythrohydrobupropion, suggesting that electron transfer cannot 2 
occur.  3 
7R VWDUW WR XQGHUVWDQG ZKHWKHU DGPLQLVWUDWLRQ RI EXSURSLRQ PLJKW LQWHUIHUH ZLWK ȕ-HSD1-4 
dependent glucocorticoid activation, we determined IC50 for cortisone reduction. Regarding the 5 
rapid metabolism of bupropion in vivo [39] and the high IC50 of 165 ± 51 μM, it is unlikely that 6 
exposure to bupropion ZLOO VLJQLILFDQWO\ LQKLELW WKH ȕ-HSD1-dependent conversion of 7 
endogenous cortisone to cortisol. On the other hand, cortisone and prednisone efficiently 8 
inhibited the carbonyl reduction of bupropion. The low IC50 values of cortisone and prednisone to 9 
inhibit bupropion reduction suggest that pharmacological use of these glucocorticoids as well as10 
elevated endogenous cortisone levels during stress may abolish the concomitant carbonyl 11 
reduction of bupropion.  12 
Bupropion and its metabolites show different potency regarding the inhibition of biogenic amine 13 
uptake, different half-life and AUC [4, 6, 40-43]. It has been described earlier that 14 
hydroxybupropion, the metabolite generated by CYP2B6 has the highest potency [6, 7].15 
Pharmacological administration of cortisone and prednisone, high endogenous cortisone during 16 
stress, or the use of ȕ-HSD1 inhibitors (currently in development to treat metabolic disease 17 
[15, 18]) are likely to result in higher hydroxybupropion levels, which will need a readjustment 18 
of the therapeutic dose of bupropion. Subjects receiving hormone replacement therapy, which 19 
leads to inhibition of CYP2B6 had diminished hydroxybupropion levels and increased erythro- 20 
and threohydrobupropion levels [44].  21 
It has been shown that the glucuronides of erythro- and threohydrobupropion account for 13% of 22 
the urinary excretion of bupropion in man after a single 200 mg dose of bupropion [39]. An 23 

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impaired ȕ-HSD1-mediated metabolism of bupropion is expected to result in a delayed 1 
excretion, which may enhance the pharmacological effect of bupropion and hydroxybupropion.  2 
In conclusion, our results demonstrate WKDW ȕ-HSD1 exclusively catalyzes the carbonyl3 
reduction of R-bupropion to threohydrobupropion and that another ER luminal enzyme is 4 
responsible for the formation of erythrohydrobupropion (Fig. 1). Bupropion reduction by human 5 
ȕ-HSD1 is about 10 and 80 times more efficient than that by the rat and mouse enzymes. 6 
:KHUHDV EXSURSLRQ XQOLNHO\ LPSDLUV ȕ-HSD1-dependent glucocorticoid activation, the 7 
metabolism of bupropion is expected to be inhibited by high endogenous cortisone or 8 
pharmacological cortisone or prednisone, and dose adjustments of bupropion might be necessary 9 
to achieve optimal therapeutic effects. Further studies are needed to identify the ER luminal 10 
enzyme responsible for erythrohydrobupropion formation and to examine the consequences of 11 
ȕ-HSD1 inhibition on bupropion metabolism in humans. 12 
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Figure Legends1 
2 
Fig. 1. Structures of bupropion and its major metabolites. 3 
4 

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1 
Fig. 2. Species-specific oxoreduction of bupropion by liver microsomes. Human liver 2 
microsomes (HLM, final concentration (f.c.) 0.4 mg/mL), rat liver microsomes (RLM, f.c. 13 
mg/mL), mouse liver microsomes (MLM, f.c. 1 mg/mL) and microsomes from livers of liver-4 
specific ȕ-HSD1-deficient mice (LKO, f.c. 1 mg/mL) were incubated for 1 h at 37°C with 1 5 
μM bupropion and 1 mM glucose-6-phosphate (G6P), in the absence or presence of 20 μM of the 6 
ȕ-HSD1 inhibitor T0504. Data (mean ± SD) were obtained from at least three independent 7 
experiments using pooled microsomes. *** p < 0.001, multiple measures ANOVA found 8 
significant species differences in bupropion reduction (p < 0.0001), post hoc analysis by Tukey 9 
test was used for multiple comparison. 10 
11 

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1 
Fig. 3. Impact of cofactor on the metabolism of bupropion by human liver microsomes. Human 2 
liver microsomes (f.c. 0.4 mg/mL) were incubated for 1 h at 37°C in the presence of 1 μM 3 
bupropion and either 1 mM NADPH or 1 mM glucose-6-phosphate (G6P). Data represent mean ± 4 
SD from at least three independent experiments using pooled microsomes. ns = not significant, * 5 
p < 0.05, *** p < 0.001, multiple measures ANOVA found significant differences in the groups 6 
(p < 0.0001), post hoc analysis by Tukey test was used for multiple comparison. 7 
8 
9 
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1 
Fig. 4. Bupropion and its major metabolites after incubation of human liver microsomes with 2 
NADPH and G6P. Human liver microsomes (f.c. 0.2 mg/mL) were incubated for 1 h at 37°C in 3 
the presence of 1 μM bupropion, 1 mM NADPH and 1 mM G6P. Data represent mean ± SD from 4 
at least three independent experiments with pooled microsomes.5 
6 

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1 
Fig. 5. Concentration-dependent reduction of bupropion to threohydrobupropion. HEK-293 cells 2 
WUDQVLHQWO\ WUDQVIHFWHG ZLWK SODVPLG IRU KXPDQ ȕ-HSD1 were sonicated to obtain mixed 3 
vesicles, followed by incubation for 1 h at 37°C in the presence of 1 mM NADPH and different 4 
concentrations of bupropion as given in Materials and Methods. Apparent KM (2.1 μM ± 0.9 μM) 5 
and apparent Vmax (0.22 ± 0.03 nmol/mg/h) values were calculated. Data represent mean ± SD 6 
from at least three independent experiments. 7 
8 
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1 
Fig. 6. Inhibition of ȕ-HSD1-dependent reduction of cortisone by bupropion. Lysates of HEK-2 
FHOOV WUDQVLHQWO\WUDQVIHFWHGZLWKKXPDQȕ-HSD1 were incubated with 1 μM cortisone, 1 3 
mM NADPH and different concentrations of bupropion for 15 min at 37°C. Data were 4 
normalized to vehicle control (0.05% DMSO) and represent mean ± SD from three independent 5 
experiments.6 
7 
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1 
Fig. 7. ,QKLELWLRQ RI ȕ-HSD1-dependent threohydrobupropion reduction by cortisone and 2 
prednisone. Lysates of HEK-293 cells WUDQVLHQWO\ WUDQVIHFWHG ZLWK KXPDQ ȕ-HSD1 were 3 
incubated with 1 μM bupropion, 1 mM NADPH and different concentrations of cortisone (A) or 4 
prednisone (B) for 60 min at 37°C. Data were normalized to activity of vehicle control (0.05% 5 
DMSO) and represent mean ± SD from three independent experiments. 6 
7 
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1 
Fig. 8. Proposed binding modes of R-bupropion and S-bupropion in the ligand binding pocket of2 
human ȕ-HSD1. R-bupropion (A) is colored in green and S-bupropion (B) in blue. The 3 
catalytic triad and the cofactor are colored in grey. The distances between the substrate and the 4 
protein are given in Å. 5 
6 
7 
8 

26 
 
References1 
[1] Holm KJ, Spencer CM. Bupropion: A Review of its Use in the Management of Smoking 2 
Cessation. Drugs 2000;59:1007-24. 3 
[2] Jafarinia M, Mohammadi M-R, Modabbernia A, Ashrafi M, Khajavi D, Tabrizi M, et al. 4 
Bupropion versus methylphenidate in the treatment of children with attention-5 
deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharm Clin 6 
2012;27:411-8. 7 
[3] Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical 8 
experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim 9 
Care Companion J Clin Psychiatry 2005;7:106-13. 10 
[4] Laizure SC, DeVane CL, Stewart JT, Dommisse CS, Lai AA. Pharmacokinetics of 11 
bupropion and its major basic metabolites in normal subjects after a single dose. Clin 12 
Pharmacol Ther 1985;38:586-9. 13 
[5] Wang X, Abdelrahman DR, Zharikova OL, Patrikeeva SL, Hankins GDV, Ahmed MS, et 14 
al. Bupropion metabolism by human placenta. Biochem Pharmacol 2010;79:1684-90. 15 
[6] Martin P, Massol J, Colin JN, Lacomblez L, Puech AJ. Antidepressant profile of 16 
bupropion and three metabolites in mice. Pharmacopsychiatry 1990;23:187-94. 17 
[7] Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44:79-81. 18 
[8] Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, et al. Validation 19 
of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 20 
Catalytic Activity. Drug Metab Dispos 2000;28:1222-30. 21 
[9] Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, et al. 22 
CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions 23 
with Other Antidepressants. Drug Metab Dispos 2000;28:1176-83. 24 
[10] Wang X, Abdelrahman DR, Fokina VM, Hankins GD, Ahmed MS, Nanovskaya TN. 25 
Metabolism of bupropion by baboon hepatic and placental microsomes. Biochem 26 
Pharmacol 2011;82:295-303. 27 
[11] Molnari JC, Myers AL. Carbonyl reduction of bupropion in human liver. Xenobiotica 28 
2012;42:550-61. 29 
[12] White PC, 0XQH7$JDUZDO$.ȕ-Hydroxysteroid Dehydrogenase and the Syndrome 30 
of Apparent Mineralocorticoid Excess. Endocr Rev 1997;18:135-56. 31 

27 
 
[13] Odermatt A, Kratschmar DV. Tissue-specific modulation of mineralocorticoid receptor 1 
function by 11beta-hydroxysteroid dehydrogenases: An overview. Mol Cell Endocrinol 2 
2012;350:168-86. 3 
[14] Rebuffat AG, Tam S, Nawrocki AR, Baker ME, Frey BM, Frey FJ, et al. The 11-4 
ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist. Mol Cell 5 
Endocrinol 2004;214:27-37. 6 
[15] Atanasov AG, Odermatt A. Readjusting the glucocorticoid balance: an opportunity for 7 
modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab 8 
Immune Disord Drug Targets 2007;7:125-40. 9 
[16] Hult M, Jornvall H, Oppermann UC. Selective inhibition of human type 1 11beta-10 
hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett 11 
1998;441:25-8. 12 
[17] Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-13 
hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the 14 
treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 15 
2003;3:255-62. 16 
[18] Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 17 
(11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig 18 
Drugs 2008;17:481-96. 19 
[19] Sun D, Wang M, Wang Z. Small molecule 11beta-hydroxysteroid dehydrogenase type 1 20 
inhibitors. Curr Top Med Chem 2011;11:1464-75. 21 
[20] Odermatt A, Nashev LG. The glucocorticoid-activating enzyme 11[beta]-hydroxysteroid 22 
dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological 23 
considerations. J Steroid Biochem Mol Biol 2010;119:1-13. 24 
[21] Hult M, Elleby B, Shafqat N, Svensson S, Rane A, Jornvall H, et al. Human and rodent 25 
type 1 11beta-hydroxysteroid dehydrogenases are 7beta-hydroxycholesterol 26 
dehydrogenases involved in oxysterol metabolism. Cell Mol Life Sci 2004;61:992-9. 27 
[22] Schweizer RA, Zurcher M, Balazs Z, Dick B, Odermatt A. Rapid hepatic metabolism of 28 
7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific 29 
differences between the rat, human, and hamster enzyme. J Biol Chem 2004;279:18415-30 
24.31 

28 
 
[23] Odermatt A, Da Cunha T, Penno CA, Chandsawangbhuwana C, Reichert C, Wolf A, et 1 
al. Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 2 
11beta-hydroxysteroid dehydrogenase 1. Biochem J 2011;436:621-9. 3 
[24] Nashev LG, Chandsawangbhuwana C, Balazs Z, Atanasov AG, Dick B, Frey FJ, et al. 4 
Hexose-6-phosphate dehydrogenase modulates 11beta-hydroxysteroid dehydrogenase 5 
type 1-dependent metabolism of 7-keto- and 7beta-hydroxy-neurosteroids. PLoS One 6 
2007;2:e561. 7 
[25] Meyer A, Vuorinen A, Zielinska AE, Da Cunha T, Strajhar P, Lavery GG, et al. Carbonyl 8 
reduction of triadimefon by human and rodent 11beta-hydroxysteroid dehydrogenase 1. 9 
Biochem Pharmacol 2013. 10 
[26] Maser E, Friebertshauser J, Volker B. Purification, characterization and NNK carbonyl 11 
reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: 12 
enzyme cooperativity and significance in the detoxification of a tobacco-derived 13 
carcinogen. Chem Biol Interact 2003;143-144:435-48. 14 
[27] Wsol V, Szotakova B, Skalova L, Maser E. Stereochemical aspects of carbonyl reduction 15 
of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-16 
hydroxysteroid dehydrogenase type 1. Chem Biol Interact 2003;143-144:459-68. 17 
[28] Maser E, Bannenberg G. 11 beta-hydroxysteroid dehydrogenase mediates reductive 18 
metabolism of xenobiotic carbonyl compounds. Biochem Pharmacol 1994;47:1805-12. 19 
[29] Hult M, Nobel CS, Abrahmsen L, Nicoll-Griffith DA, Jornvall H, Oppermann UC. Novel 20 
enzymological profiles of human 11beta-hydroxysteroid dehydrogenase type 1. Chem 21 
Biol Interact 2001;130-132:805-14. 22 
[30] Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RA, Frey FJ, et al. 23 
Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six 24 
species. J Mol Endocrinol 2005;35:89-101. 25 
[31] Lavery GG, Zielinska AE, Gathercole LL, Hughes B, Semjonous N, Guest P, et al. Lack 26 
of significant metabolic abnormalities in mice with liver-specific disruption of 11beta-27 
hydroxysteroid dehydrogenase type 1. Endocrinology 2012;153:3236-48. 28 
[32] Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand 29 
docking using GOLD. Proteins 2003;52:609-23. 30 

29 
 
[33] Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a 1 
genetic algorithm for flexible docking. J Mol Biol 1997;267:727-48. 2 
[34] Berman HM, Westbrook J, Feng Z, Gililand G, Bhat TN, Weissig H, et al. The Protein 3 
Data Bank. Nucleic Acids Res 2000;28:235-42. 4 
[35] Wu x, et al. The High Resolution Structures of Human, Murine and Guinea Pig 11-Beta-5 
Hydroxysteroid Dehydrogenase Type 1 Reveal Critical Differences in Active Site 6 
Architecture. DOI:102210/pdb2bel/pdb  7 
[36] Oppermann UC, Filling C, Berndt KD, Persson B, Benach J, Ladenstein R, et al. Active 8 
site directed mutagenesis of 3 beta/17 beta-hydroxysteroid dehydrogenase establishes 9 
differential effects on short-chain dehydrogenase/reductase reactions. Biochemistry 10 
1997;36:34-40. 11 
[37] Kavanagh KL, Jornvall H, Persson B, Oppermann U. Medium- and short-chain 12 
dehydrogenase/reductase gene and protein families : the SDR superfamily: functional and 13 
structural diversity within a family of metabolic and regulatory enzymes. Cell Mol Life 14 
Sci 2008;65:3895-906. 15 
[38] Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, et 16 
al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of 17 
atherosclerosis in mice. J Exp Med 2005;202:517-27. 18 
[39] Welch RM, Lai AA, Schroeder DH. Pharmacological significance of the species 19 
differences in bupropion metabolism. Xenobiotica; the fate of foreign compounds in 20 
biological systems 1987;17:287-98. 21 
[40] Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three 22 
atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 23 
1998;51:237-54. 24 
[41] Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: 25 
Pharmacokinetic and formulation considerations. Clin Therapeut 2005;27:1685-95. 26 
[42] Hsyu P-H, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics 27 
of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers. J Clin 28 
Pharmacol 1997;37:737-43. 29 

30 
 
[43] Golden Rn, DeVane C, Laizure S, Rudorfer MV, Sherer MA, Potter WZ. Bupropion in 1 
depression: Ii. the role of metabolites in clinical outcome. Arch Gen Psychiat 2 
1988;45:145-9. 3 
[44] Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome 4 
P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured 5 
by bupropion hydroxylation. Clin Pharmacol Ther 2003;74:326-33. 6 
7 
8 

Chapter 3: Steroid metabolism of zebrafish enzymes

Introduction 
In the course of my PhD thesis several projects focused on enzymes of the zebrafish (danio rerio
(dr)) in order to address species-specific differences. The zebrafish is widely used as an aquatic 
model organism in research.  
We tested inhibitory effects of organotins and of the dithiocarbamate thiram on ]HEUDILVKȕ-
hydroxysteroid dehydrogenase type 2 (ȕ-HSD2). We reported earlier that these compounds 
inhibit the human enzyme [26, 27]. In humans, ȕ-HSD2 is responsible for the conversion of 
FRUWLVROWRFRUWLVRQH)LVKȕ-HSD2 has a dual role by converting cortisol to cortisone and 11ȕ-
hydroxytestosterone to 11-ketotestosterone [28-30], which is the main androgen in fish [31]. 
Thiram is a widely used pesticide and likely to enter the aquatic ecosystem. Organotins, even 
after being banned worldwide, are still found in aquatic ecosystems [32] and are found to 
accumulate in sediments and various species of fish [33, 34]. We investigated the effects of these 
FKHPLFDOV RQ ]HEUDILVK ȕ-HSD2, because inhibition of this enzyme may enhance 
glucocorticoid and diminish androgen effects in fish. The results of this project are included as 
the publication “Species-specific differences in the inhibition of human and zebrafish 11ȕ-
hydroxysteroid dehydrogenase 2 by thiram and organotins” at the end of this chapter. 
Another enzyme involved in sex steURLGPHWDEROLVPLQILVKLVȕ-hydroxysteroid dehydrogenase 
type 3 ȕ-HSD3). The drȕ-HSD3 enzyme is a NADPH-dependent reductive enzyme, 
catalyzing the conversion of ǻ4-androstenedione to testosterone as well as the reaction of 11-
ketoandrostenedione to the main androgen 11-ketotestosterone in fish [35]. It has been described 
earlier that a wide range of UV filters (benzophenone-1 (BP-1), benzophenone-2 (BP-2), 
benzophenone-6 (BP-6), 3-benzylidene camphor (3-BC) and 4-methyl-bezylidene camphor (4-
MBC)) can potently inhibit the hsȕ-HSD3 [36]. Together with the students Dominik Vogt,
Céline Murer and Petra Strajhar I performed several experiments with drȕ-HSD2 and drȕ-
HSD3.
We have successfully shown that the function of drȕ-HSD2 is to inactivate cortisol and that it 
is further responsible for the generation of 11-ketotestosterone. In humans ȕ-HSD1 is known to 
convert cortisone to cortisol. Both enzymes together by interplay offer a sophisticated system to 

control the ratio of active and inactive glucocorticoids. It can be regarded as a recycling system, 
as the amount of active glucocorticoids can be easily and rapidly adapted and de novo synthesis is 
not required for fast acting responses. Interestingly, in teleost species WKH JHQH HQFRGLQJ ȕ-
HSD1 is absent. IWZDV DVVXPHG WKDW DQ DQFHVWRU RI ȕ-HSD1 would take over that function. 
Two ancestors of ȕ-HSD1 have been described in zebrafish, drȕ-hydroxysteroid 
dehydrogenase type 3a (11ȕ-HSD3a) and dr11ȕ-K\GUR[\VWHURLG GHK\GURJHQDVH W\SH E ȕ-
HSD3b), also known as dr11ȕ-HSD1-like-protein-like. It is widely assumed that either dr11ȕ-
HSD3a or dr11ȕ-HSD3b take over the function to reduce cortisone to cortisol [37, 38]. We tested 
if one of the two ancestors is responsible for cortisone reduction. In addition, we incubated 
zebrafish microsomes under several conditions to check for 11-oxosteroid reductase activity. 
More information on this project can be found in the draft paper at the end of this chapter. 

Results & Discussion
With the help of Dominik Vogt and Céline Murer, some UV filters were screened at a 
concentration of 20 μM on zebrafish homogenate and on drȕ-HSD3 expressed in zf4 cells. Fig. 
6 shows the activity of ǻ4-androstenedione (AD) reduction in % compared to the vehicle control. 
Black bars show the % activity upon incubation with UV filters on hsȕ-HSD3 expressed in 
HEK-293 cells as published by Nashev et al. [36]. We incubated the full body homogenate of a 
male zebrafish with UV filters and drȕ-HSD3 transiently transfected in zf4 cells. Important 
species-differences were found for BP-2 and BP-3. These two UV filters seem to have a higher 
inhibition on the zebrafish enzyme compared to the human enzyme. BP-6 shows a comparable 
inhibition, whereas 4-MBC and 3-BC show less inhibition upon incubation with the zebrafish 
enzyme compared to the human enzyme. Incubations with BP-1, BP-2 and BP-3 show less 
inhibition in the homogenate, pointing out that these compounds may be metabolized by full 
body zebrafish homogenate. 
Figure 6: ǻ4-androstenedione (AD) reduction (% of control) of UV filters (benzophenone-1 (BP-1), 
benzophenone-2 (BP-2), benzophenone-3 (BP-3), benzophenone-6 (BP-6), 4-methyl-bezylidene camphor (4-
MBC) and 3-benzylidene camphor (3-BC)) at a concentration of 20 μM, oQKXPDQȕ-hydroxysteroid 
dehydrogenase type 3 (hsȕ-HSD3) (data published by Nashev et al. [36]), zebrafish homogenate (final 
concentration 1.5 mg/ml) and intact zf4 cells transiently transfected with ]HEUDILVKȕ-hydroxysteroid 
dehydrogenase type 3 (drȕ-HSD3). Conversions were kept under 30%, AD (200 nM) NADPH (1 mM).

As BP-1, BP-2 and BP-3 showed a strong inhibition at 20 μM, we decided to determine IC50
values of these three UV-filters on the zebrafish enzyme. These determinations were performed 
by Céline Murer (Fig. 7). 
Figure 7: IC50 curves and table of inhibition of zebrafish 17ȕ-HSD3 by the UV filters (benzophenone-1 (BP-1), 
benzophenone-2 (BP-2), benzophenone-3 (BP-3)). Inhibition of ȕ-HSD3-dependent ǻ4-androstenedione 
(AD) reduction to testosterone by various concentrations of UV filters was measured in intact, transiently 
transfected zf4 cells. Incubation with AD (200 nM) and UV filters for 60 min at 37°C. Data were normalized to 
vehicle control (0.05% DMSO) and represent means SD from three independent experiments.

Moreover, experiments by Petra Strajhar suggested that the UV filters have additive effects and 
that they bioaccumulate in vitro (Fig. 8). These experiments have been performed using the 
human enzyme. 
Figure 8: Additive effects by mixtures (left) and bioaccumulation (right) of UV filters (benzophenone-1 (BP-1), 
benzophenone-2 (BP-2)) on human 17ȕ-hydroxysteroid dehydrogenase (hsȕHSD3) activity. Incubations 
have been performed as described in the Master thesis of Petra Strajhar.
We provide evidence that the UV filters BP-1, BP-2 and BP-3 might have stronger endocrine 
disrupting effects on the zebrafish compared to the human enzyme, because all three UV filters 
potently inhibited the zebrafish enzyme. Moreover, stronger effects can be assumed due to 
bioaccumulation and additive effects of mixtures. 
This project should be continued, as the findings are relevant. To provide further evidence an in
vivo assay should be performed with zebrafish. I would incubate zebrafish over different time 
periods and study exposure to mixtures of the three benzophenones. It would be interesting to 
measure concentrations of steroid hormones in zebrafish plasma by LC-MS/MS in order to detect 
potential changes in steroid hormone concentrations. I hypothesize that the additive effects of 
mixtures and the bioaccumulation effects can be seen in vivo as well.
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Dithiocarbamates  and  organotins  can  inhibit enzymes by interacting  with  functionally  essential
sulfhydryl  groups.  Both  classes  of  chemicals  were  shown  to  inhibit human 11-hydroxysteroid dehy-
drogenase  2 (11-HSD2),  which  converts active cortisol into inactive  cortisone and has  a role in  renal
and  intestinal  electrolyte regulation and  in  the  feto-placental  barrier to  maternal  glucocorticoids.  In
fish,  11-HSD2 has a  dual  role by  inactivating glucocorticoids  and  generating  the major  androgen  11-
ketotestosterone.  Inhibition  of  this  enzyme may enhance glucocorticoid and diminish androgen effects in
fish.  Here, we characterized  11-HSD2  activity  of the  model species  zebrafish.  A  comparison with  human
and  mouse 11-HSD2  revealed  species-specific substrate preference.  Unexpectedly, assessment of  the
effects  of  thiram  and  several organotins  on the  activity  of  zebrafish 11-HSD2  showed weak inhibition
by  thiram  and  no  inhibition  by  any  of the  organotins  tested.  Sequence  comparison revealed  the presence
of  an  alanine at  position 253  on  zebrafish  11-HSD2, corresponding to cysteine-264  in  the substrate-
binding  pocket  of the  human  enzyme. Substitution  of alanine-253 by cysteine  resulted in  a  more than
10-fold  increased  sensitivity  of  zebrafish  11-HSD2 to  thiram. Mutating  cysteine-264  on  human  11-
HSD2  to serine resulted  in 100-fold lower inhibitory activity. Our results  demonstrate  significant species
differences  in  the sensitivity  of  human  and  zebrafish 11-HSD2 to inhibition  by thiram and  organotins.
Site-directed  mutagenesis revealed  a  key role of  cysteine-264  in  the  substrate-binding  pocket  of  human
11-HSD2  for  sensitivity  to  sulfhydryl modifying agents.
© 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
In humans, 11-hydroxysteroid dehydrogenase type 2 (11-
HSD2) essentially catalyzes the conversion of the active gluco-
corticoid cortisol (corticosterone in  rodents) to its  inactive form
cortisone (11-dehydrocorticosterone in rodents), thereby regulat-
ing the access of glucocorticoids to  glucocorticoid receptors (GR)
and mineralocorticoid receptors (MR), and rendering specificity of
MR  for aldosterone (Odermatt and Kratschmar, 2012). The con-
sequences of impaired 11-HSD2 activity on electrolyte balance
and blood pressure are manifested in  patients with genetic defects
and suffering from apparent mineralocorticoid excess, and upon
Abbreviations: 11-HSD2, 11-hydroxysteroid dehydrogenase 2; DBT,
dibutyltin;  DMSO, dimethylsulfoxide; DMT, dimethyltin; DOT, dioctyltin; DPT,
diphenyltin; GR, glucocorticoid receptor; LC–MS, liquid chromatography–mass
spectrometry; MR,  mineralocorticoid receptor; MRM,  multiple-reaction monitor-
ing; NEM, N-ethylmaleimide; TBT, tributyltin; TMT, trimethyltin; TPT, triphenyltin.
∗ Corresponding author. Tel.: +41 61 267 1530; fax: +41 61 267  1515.
E-mail  address: alex.odermatt@unibas.ch (A. Odermatt).
ingestion of large amounts of licorice, which contains the inhibitor
glycyrrhetinic acid (Ferrari, 2010). Moreover, in  the placenta 11-
HSD2 acts as a protective barrier for  the fetus from high maternal
cortisol concentrations, and studies in rodents indicated that 11-
HSD2 inhibition during pregnancy causes irreversible changes in
fetal development that lead to a  higher risk for cardiovascular and
metabolic disease (Murphy et al., 2002; Seckl and Holmes, 2007;
Shams et al., 1998; Welberg et al., 2005). Thus, besides genetic
susceptibility, environmental factors, including the exposure to
xenobiotics, need to be considered (Ma  et al., 2011; Odermatt and
Gumy, 2008; Odermatt et al., 2006).
In contrast to human and other mammalian species, stud-
ies addressing the inhibition of 11-HSD2 by xenobiotics in fish
and other aquatic species are missing. Studies on rainbow trout
(Kusakabe et al., 2003), Japanese eel (Jiang et al., 2003; Miura
et al., 1991) and Nile tilapia (Miura et al., 1991) revealed an impor-
tant role of 11-HSD2 in  the formation of the main fish androgen
11-ketotestosterone from 11-hydroxytestosterone. In fish, 11-
HSD2 is highly expressed in the gonads, supporting its role in
androgen metabolism. Thus, xenobiotics inhibiting 11-HSD2 are
expected to enhance glucocorticoid effects and suppress androgen
action in  fish.
0300-483X/$ – see front matter ©  2012 Elsevier Ireland Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.tox.2012.07.001
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We reported earlier that dithiocarbamates (Atanasov et al.,
2003) and organotins (Atanasov et al., 2005), chemicals known
to interfere with functionally important sulfhydryl groups, inhibit
human 11-HSD2. Several dithiocarbamates inhibit human 11-
HSD2 in the nanomolar range, i.e. thiram, disulfiram and maneb,
and some in the micromolar range, i.e. pyrrolidine dithiocarbamate,
diethyldithiocarbamate and zineb. These chemicals are expected
to exert additive inhibitory effects on 11-HSD2 (Atanasov et al.,
2003).
Dithiocarbamates, including thiram (tetramethylthiuram disul-
fide), are widely used as fungicides on seeds and as foliar fungicides
on turf, vegetables and fruits (Vettorazzi et al., 1995). The pesticides
ferbam and ziram are  environmentally degraded to  thiram. Fur-
thermore, thiram is used as an accelerator and vulcanization agent
in the rubber industry. Gupta et al. have shown that the half-life of
thiram under controlled laboratory conditions is longer than that of
other carbamates and ranges from 5 to  12 days in water, depending
on multiple parameters (Gupta et al., 2012). The extensive use of
thiram, the fact that thiram is a  degradation product of other pes-
ticides, the possible persistence in the environment, and additive
inhibitory effects of mixtures of dithiocarbamates, led us to investi-
gate whether thiram might inhibit 11-HSD2 of the aquatic model
organism zebrafish (danio rerio).
Cadmium, that also may affect the function of sulfhydryl groups
on proteins, has been found to decrease 11-HSD2 activity in cul-
tured primary human trophoblast cells and in  cultured human
choriocarcinoma JEG-3 cells, whereby it  remained unclear whether
the reduced activity was due to  direct inhibition of 11-HSD2 or
reduced expression (Ronco et al., 2010; Yang et al., 2006). A very
high environmental enrichment factor has been reported for cad-
mium (Shi et al., 2012).
Moreover,  we tested whether organotins might inhibit zebrafish
11-HSD2. Organotins are, even after the worldwide ban of TBT,
readily detected in  water ecosystems (Castro et al., 2012). They
accumulate in sediments and show high bioaccumulation in var-
ious aquatic species with concentrations up to 53 g/g in Cobia
(Rachycentron canadum) (Jadhav et al., 2011; Kannan et al., 1995;
Liu et al., 2006). Previously, we found that the organotins dibutyltin
(DBT), tributyltin (TBT), diphenyltin (DPT) and triphenyltin (TPT)
inhibit human 11-HSD2, that they show additive inhibitory
effects, and that mutant C264S was less sensitive to inhibition by
TBT (Atanasov et al., 2005), suggesting reversible sulfhydryl modi-
fication as inhibitory mechanism.
In  the present study, we assessed the effects of organotins, thi-
ram, cadmium and the sulfhydryl modifying reference compound
N-ethylmaleimide (NEM) on zebrafish 11-HSD2 activity and com-
pared the effects with those on the human enzyme. Finally, we
performed site-directed mutagenesis to explain differential effects
on human and zebrafish 11-HSD2 by the xenobiotics investigated.
2. Materials and methods
2.1.  Materials
Cadmium chloride was  purchased from Merck KGaA (Darmstadt, Germany),
[1,2,6,7-3H]-cortisol from Amersham Pharmacia (Piscataway, NJ,  USA), unlabeled
steroids  from Steraloids (Newport, RI),  and all other chemicals and cell culture
medium  from Sigma–Aldrich Chemie GmbH (Buchs, Switzerland). The solvents were
of analytical and high performance liquid chromatography grade and the reagents
of  the highest grade available. Cadmium chloride, thiram and organotins were dis-
solved in dimethyl sulfoxide (DMSO) and stored as 20 mM stock solution at −20 ◦C.
N-ethylmaleimide (NEM) was  dissolved in ethanol and stored as  20 mM stock solu-
tion at −20 ◦C.
2.2.  Construction of expression plasmids and site-directed mutagenesis
Expression plasmids for  human wild-type 11-HSD2 and mutant C264S have
been  described earlier (Atanasov et al., 2005; Odermatt et al., 1999). A  full length
zebrafish  (danio rerio) cDNA clone was purchased from ImaGenes GmbH, RZPD,
Berlin,  Germany. The cDNA was amplified by  PCR using an oligonucleotide at the
start codon to introduce a BamHI endonuclease restriction site and a Kozak consen-
sus sequence (5′-CATAAGCTTCCGCCATGTCTATTTTTGTTGGTGGAGCAG-3′) and an
oligonucleotide at the stop codon either to add an XbaI endonuclease restriction site
(5′-ACCTCGAGCTAATCAATACACTTTGTGAAGTTGC-3′)  or to attach a FLAG-epitope
followed  by  the stop codon and an  XbaI endonuclease restriction site  (5′-
ACCTCGAGTCACTTGTCATCGTCGTCCTTGTAGTCCATAGAACCATCAATACACTTTGTGA-
AGTTGCTG-3′). The PCR product was  inserted into the BamHI–XbaI sites of the
pcDNA3.1  vector. Site-directed mutagenesis to construct mutant A253C was
performed  as  described earlier (Atanasov et al., 2005). The selected clones used
in  this study were sequence verified. Protein expression and enzyme activity
was  assessed in transiently transfected HEK-293 cells. Protein expression of
zebrafish wild-type 11-HSD2 and mutant A253C was verified by Western blotting
(Fig.  S1), as described for  human 11-HSD2 wild-type and mutant C264S (Atanasov
et  al., 2005). Briefly, proteins were separated by sodium dodecyl sulfate gel elec-
trophoresis and transferred on a polyvinyl difluoride membrane. The FLAG-tagged
11-HSD2  was  detected by mouse M2  antibody from Sigma–Aldrich Chemie GmbH.
Actin was detected by rabbit anti-actin IgG from Santa Cruz Biotechnology Inc.
(Santa  Cruz, CA,  USA). Horseradish peroxidase-conjugated secondary antibodies
were  used to visualize the bands with Immobilon Western Chemiluminescent
HRP  substrate from Millipore Corporation (Billerica, MA, USA). Untagged and
C-terminally  FLAG-epitope tagged proteins showed comparable activities as  seen
before for  human 11-HSD2 expression constructs (Odermatt et al., 1999).
2.3. Cell culture
Human embryonic kidney cells (HEK-293) were cultivated in  Dulbecco’s mod-
ified  Eagle’s medium (DMEM) containing 4.5 g/L glucose (D5796 Sigma–Aldrich),
10%  fetal bovine serum, 100 U/mL penicillin, 0.1 mg/mL  streptomycin, 1×  MEM  non-
essential amino acids and 10 mM  HEPES buffer, pH 7.4. Cells were incubated at 37 ◦C
in a humidified 5% CO2 atmosphere.
Zebrafish embryonic fibroblast cells ZF-4 (kindly provided by Dr. Jerzy Adamski,
Helmholtz  Zentrum, Munich, Germany) were cultivated in DMEM:F12 (D8437
Sigma–Aldrich),  supplemented with  10% fetal bovine serum, 100 U/mL penicillin
and  0.1 mg/mL  streptomycin. These cells were maintained at 28 ◦C in a humidified
5%  CO2 atmosphere.
2.4. Transient transfection and harvesting of cells
HEK-293 cells were transiently transfected with  plasmids for human wild-type
11-HSD2  (Odermatt et al., 1999) or mutant C264S (Atanasov et al., 2005) using the
calcium phosphate precipitation method. Transfection efficiency was approximately
20%.  Zebrafish wild-type 11-HSD2 and mutant A253C were transfected into ZF-4
cells using Fugene HD according to the manufacturer’s protocol (Roche Applied Sci-
ence, Rotkreuz, Switzerland). Transfection efficiency was approximately 25%. After
48 h transfected cells were detached, centrifuged and cell pellets (5  pellets/10 cm2
dish) shock frozen on dry ice  and stored at −80 ◦C until further use.
2.5. Determination of  recombinant human, mouse and zebrafish 11ˇ-HSD2
activities by liquid chromatography–tandem mass spectrometry (LC–MS)
Reactions were performed for 10 min at 37 ◦C in a total volume of 500 L con-
taining  lysates of HEK-293 cells expressing human, mouse or  zebrafish 11-HSD2
in  buffer TS2 (100 mM NaCl, 1 mM EGTA, 1  mM EDTA, 1 mM MgCl2, 250 mM sucrose,
20 mM Tris–HCl, pH 7.4), supplemented with 500 M NAD+ and the corresponding
substrate (2  nM–2 M  final concentration). Internal standard (100 nM deuterized
d8-corticosterone) was added, followed by extraction with 1 mL ethyl acetate. The
organic phase was transferred to a new tube, evaporated to dryness and reconsti-
tuted  in 100 L  of methanol containing 0.1%  formic acid.
Steroids were resolved on an Atlantis T3 (3  m, 2.1 mm × 150 mm)  column
(Waters, Milford, MA)  at  30 ◦C using an Agilent model 1200 Infinity Series chro-
matograph  (Agilent Technologies, Basel, Switzerland). The mobile phase consisted
of  water and acetonitrile (95:5) containing 0.1% formic acid (solvent A), and water
and acetonitrile (5:95) containing 0.1% formic acid (solvent B) at a total flow rate
of 0.4 mL/min. A  linear gradient was used starting from 30% solvent B  to 70% sol-
vent B  from 0 to 13  min, followed by 95% solvent B for 2  min, and re-equilibration
with  30% solvent B. A  built-in switching valve was used to direct the LC flow to an
Agilent 6410 triple quadrupole MS  (controlled by  Mass Hunter workstation soft-
ware version B.01.04). The injection volume of each sample was 5  L.  The MS was
operated in atmospheric pressure electrospray positive ionization mode, with neb-
ulizer pressure and nebulizer gas flow rate of 45  psi and 10 L/min, respectively, a
source temperature of  350 ◦C and capillary and cone voltage of 4000 V and 190 V,
respectively.
The six steroids were analyzed using multiple-reaction monitoring (MRM).
Metabolites  were identified by comparing their retention time and  mass to charge
ratio (m/z) with those of authentic standards. The transitions, collision energy
and  retention time were m/z 363/121, 25  V, 11.4 min  for cortisol; m/z 361/163,
20  V, 11.6 min  for cortisone; m/z 347/121, 40 V, 13.4 min  for corticosterone; m/z
355/125,  28 V,  13.4 min  for  d8-corticosterone; m/z 345/121, 40 V, 12.9 min for
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Table 1
Comparison of substrate preference of  human, mouse and zebrafish 11-HSD2
activities.
appKm SEM appVmax SEM Vmax/Km
Human
Cortisol 84 23 4.2 0.8  0.050
Corticosterone 5.7 1.7 1.2 0.3  0.211
11-OH-Testo 37 12 3.8 1 0.103
Mouse
Cortisol 44 4 0.41 0.03  0.0093
Corticosterone 24 3 0.17 0.01  0.0071
11-OH-Testo 33 3 0.19 0.02  0.0058
Zebrafish
Cortisol 72 18 0.040 0.003  0.00056
Corticosterone 147 25 0.17 0.02  0.00116
11-OH-Testo 206 19 0.45 0.02  0.00218
Enzymatic activities of lysates from HEK-293 cells transiently transfected with either
human, mouse or zebrafish 11-HSD2 were determined by measuring the oxidation
of  cortisol, corticosterone or 11-hydroxytestosterone in the presence of NAD+ as
described in Section 2. The appVmax values were expressed relative to total protein
concentration in the lysates and allow comparison within a species but not between
different species. Data represent mean ± SEM of inhibition curves from combined
experiments  calculated by  non-linear regression using four parametric logistic curve
fitting (GraphPad Prism).
11-OH-Testo,  11-hydroxytestosterone.
11-dehydrocorticosterone; m/z 305/121, 20 V,  12.3 min  for 11-
hydroxytestosterone; and m/z 303/121, 24  V, 12.5 min  for 11-ketotestosterone.
2.6.  Determination of inhibition of  human and zebrafish 11ˇ-HSD2
Enzyme activity was measured using cell lysates as  described previously
(Kratschmar et al., 2011). Briefly, cell pellets were resuspended in TS2  buffer and
sonicated using a Branson sonicator (5  pulses, output 2, duty cycles 20, performed at
4 ◦C). Lysates were incubated for 10 min  at 37 ◦C in  a total volume of  22 L  containing
10  nM [1,2,6,7-3H]-cortisol, 40 nM unlabeled cortisol, 500 M NAD+ and either vehi-
cle or inhibitor. To assess the inhibition by  Cd2+, TS2 buffer without EGTA and EDTA
was  applied. Reactions were stopped by adding an excess of cortisone and cortisol
(2  mM)  in methanol. Separation of the steroids was  performed by  thin layer chro-
matography (TLC) and product formation was determined by scintillation counting.
In all experiments conversion of cortisol to cortisone was kept below 30%. IC50 values
were calculated by non-linear regression using four parametric logistic curve fitting
(GraphPad Prism). Data (mean ±  SD) were obtained from at least three independent
experiments.
3. Results
3.1. Substrate preference of human, mouse and zebrafish
11ˇ-HSD2
The  main physiological substrates of human, mouse and
zebrafish 11-HSD2 are cortisol, corticosterone and 11-
hydroxytestosterone, respectively. Therefore, we first compared
11-HSD2-dependent oxidation of these three substrates in  order
to identify species-specific substrate preference (Table 1). Because
radiolabeled 11-hydroxytestosterone was not available, and
to measure activities for the three substrates under comparable
conditions, an LC-MS based method for  quantification of these
steroids was established. Due to higher protein expression of the
human enzyme compared with mouse and zebrafish 11-HSD2,
as determined by immune-detection using antibody against the
C-terminal FLAG-tag (data not shown), an  approximately 10-fold
higher apparent Vmax (activity per total protein in the lysate)
was obtained. Thus, the appVmax values only allow comparisons
within a given species. A  more than 10-fold higher affinity of
human 11-HSD2 for corticosterone compared with cortisol was
obtained, with 3–4 times higher appVmax for the latter. The affinity
for 11-hydroxytestosterone was about two times higher than
that for cortisol with comparable appVmax.  The differences between
cortisol and corticosterone were less pronounced for the mouse
enzyme, despite the fact that mice do not synthesize cortisol.
Fig. 1. Inhibition of human and zebrafish 11-HSD2 activity by thiram. Inhibition of
11-HSD2-dependent conversion of cortisol to cortisone by  various concentrations
of  thiram was measured in lysates of HEK-293 cells  transfected with wild-type and
mutant human or zebrafish enzymes as  described in Section 2. Lysates were simul-
taneously incubated with cortisol (50 nM)  and thiram for 10 min at 37 ◦C.  Data were
normalized to vehicle control (0.05% DMSO) and represent mean ±  SD from  three
independent experiments.
The affinities of zebrafish and human 11-HSD2 for cortisol were
comparable; however, the zebrafish enzyme had a  more than ten
times higher appVmax for 11-hydroxytestosterone compared with
cortisol, in line with a major role in  11-ketotestosterone formation.
3.2. The role of cysteine in the inhibition of human and  zebrafish
11ˇ-HSD2  by thiram
Because  aquatic species may be potentially exposed to the pes-
ticide thiram, we  determined the inhibition of 11-HSD2 from the
model organism zebrafish by thiram and compared its effect with
that on the human enzyme. Whereas human wild-type 11-HSD2
was potently inhibited by thiram (IC50 96 ± 17 nM,  mean ± SD),
zebrafish wild-type 11-HSD2 was relatively resistant toward thi-
ram inhibition with an  IC50 of 18.3 ± 6.0 M  (Fig. 1).
A  sequence comparison of human and zebrafish 11-HSD2
(Fig. S2) revealed important differences in the presence of cysteine
residues. The zebrafish enzyme has an  alanine residue at position
253, which corresponds to cysteine-264 in the human enzyme.
Molecular modeling suggested that cysteine-264 on human 11-
HSD2 has stabilizing interactions with the 3-carbonyl on cortisol
(see Fig. 6  in Furstenberger et al., 2012), which may  explain the
inhibitory effect upon carbamoylation of this residue by dithiocar-
bamates. To investigate the role of this cysteine, we substituted
alanine-253 on  zebrafish 11-HSD2 by  a cysteine. Mutant A253C
was  well expressed and functionally intact despite approximately
twofold lower appVmax than wild-type 11-HSD2. We then com-
pared the thiram-dependent inhibition of 11-HSD2 zebrafish
wild-type and mutant A253C with human wild-type and mutant
C264S. Insertion of the cysteine in the zebrafish enzyme led to a ten
times higher sensitivity toward thiram (IC50 1.3 ± 0.1 M).  In  con-
trast, substitution of cysteine-264 by  serine rendered the human
enzyme relatively resistant to thiram, with an  over 100 times higher
IC50 of 12.6 ± 1.9 M.
3.3.  Confirmation of the role of cysteine-264 by
N-ethylmaleimide inhibition
The  effect of the sulfhydryl modifying agent N-ethylmaleimide
(NEM) on human 11-HSD2 wild-type and mutant C264S was stud-
ied (Fig. 2). Estimated IC50 values of 1 M  and 10 M,  respectively,
were obtained for  the wild-type and mutant enzyme. As observed
for dithiocarbamates (Atanasov et al., 2003), pre-incubation of  11-
HSD2 with NEM enhanced the inhibitory effect (not shown), in line

Author's personal copy
A. Meyer et al.  / Toxicology 301 (2012) 72– 78 75
Fig. 2. Inhibition of human 11-HSD2 wild-type and mutant C264S by N-
ethylmaleimide. Lysates of cells expressing human 11-HSD2 wild-type (black bars)
or mutant C264S (white bars) were simultaneously incubated with cortisol (50 nM)
and N-ethylmaleimide (NEM), followed by  determination of cortisone formation.
Data  were normalized to vehicle control (0.05% DMSO) and represent mean ± SD
from four independent experiments.
with the proposed covalent modification of catalytically relevant
sulfhydryl groups by  this chemical.
3.4. Effect of various organotins on human and zebrafish
11ˇ-HSD2
Organotins can interfere with enzyme function by  reversible
interactions with sulfhydryl groups, and we previously reported the
inhibition of 11-HSD2 by some organotins (Atanasov et al., 2005).
Therefore, we compared the effects of organotins on cortisol oxi-
dation by human and zebrafish 11-HSD2 (Fig. 3). The organotins
DBT, TBT, DPT and TPT completely abolished the activity of human
Fig. 3. Effect of various organotins on human and zebrafish 11-HSD2 activity.
Human  (white bars) and zebrafish 11-HSD2 (black bars) activity was  measured
with  50 nM cortisol as substrate in the presence of vehicle (0.05% DMSO) or  20 M
of the corresponding organotin for 10 min  at  37 ◦C using cell lysates. Data were
normalized  to vehicle control and represent mean ± SD  from  three independent
experiments.
Fig. 4.  Inhibition of human 11-HSD2 wild-type and mutant C264S activity by
TPT.  The concentration-dependent inhibition of human 11-HSD2 wild-type and
mutant C264S was determined in cell lysates that were simultaneously incubated
with  50 nM cortisol and the  concentration of TPT indicated. Data were normalized
to  vehicle control (0.05% DMSO) and represent mean ± SD from  three independent
experiments.
11-HSD2 at 20 M,  in line with our earlier study. While DMT  was
a weak inhibitor with 25% remaining activity at 20 M,  TMT  and
DOT did not affect the activity of human 11-HSD2. Interestingly,
the zebrafish enzyme was not affected by any of the organotins
tested at concentrations up to 20 M,  demonstrating the lower sen-
sitivity of the zebrafish compared with the human enzyme toward
organotins.
In our earlier study, we  observed an  approximately twofold
weaker inhibition by TBT of mutant C264S compared with human
11-HSD2 wild-type enzyme (Atanasov et al., 2005). Here, we
assessed whether other organotins also show this effect. Surpris-
ingly, substitution of C264S did not affect inhibition of human
11-HSD2 by DBT and DPT (not shown). We  observed only
for TPT a  two  times weaker inhibition of the mutant C264S
(IC50 0.95 ± 0.25 M)  compared with the wild-type enzyme (IC50
0.38 ± 0.12 M)  (Fig. 4).
3.5.  Inhibition of human 11ˇ-HSD2 wild-type and mutant C264S
by  cadmium
Recent reports suggested that cadmium might inhibit 11-
HSD2 expression and/or activity (Ronco et al., 2010; Yang et al.,
2006); however, the direct effect of cadmium on 11-HSD2 activity
has not been determined. Here, we  incubated lysates express-
ing human 11-HSD2 wild-type or mutant C264S with increasing
concentrations of cadmium and observed an  almost complete inhi-
bition at 5 M  (Fig. 5). Only weak inhibition was seen at  2  M.
The fraction of bound and unbound cadmium was  not determined
because there was  no obvious difference in the inhibition of wild-
type and mutant enzymes. Cadmium-dependent inhibition was
therefore not further studied.
4.  Discussion
In a previous study, we  reported on the inhibition of human
11-HSD2 by dithiocarbamates, with thiram as the most potent
inhibitor (Atanasov et al., 2003). Because mutation of cysteine-
90 in  the cofactor binding pocket resulted in a complete loss
of enzyme activity, we  postulated that dithiocarbamates might
inhibit 11-HSD2 by carbamoylation of cysteine-90, thereby pre-
venting NAD+ to bind. Zebrafish 11-HSD2 also has a  cysteine at
the analogous position in  the cofactor binding site (cysteine-79,
see Fig. S2); therefore, we  hypothesized that zebrafish 11-HSD2
would exhibit a similarly high sensitivity to inhibition by  dithiocar-
bamates and other chemicals interacting with sulfhydryl groups.
However, as shown in the present study, the dithiocarbamate

Author's personal copy
76 A.  Meyer et al. / Toxicology 301 (2012) 72– 78
Fig. 5. Inhibition of human 11-HSD2 wild-type and mutant C264S activity by cad-
mium. Lysates expressing human 11-HSD2 wild-type and mutant C264S were
simultaneously  incubated for 10 min  at 37 ◦C with 50 nM cortisol and various con-
centrations of cadmium chloride, followed by  determination of  cortisone formation.
Data  were normalized to vehicle control (0.05% DMSO) and represent mean ±  SD
from three independent experiments.
thiram exerts only a weak inhibitory effect on zebrafish 11-HSD2.
Thus, we conclude that the cysteine residue in the cofactor binding
site seems to be essential for proper folding and enzyme activity
but plays a minor role in the sensitivity to sulfhydryl modifying
agents.
The lack of a cysteine in  the substrate binding pocket of zebrafish
11-HSD2, which can form stabilizing interactions with the 3-
carbonyl on the steroid substrate, provides an explanation for the
loss of inhibition by  thiram. The increased sensitivity to  thiram
of the zebrafish mutant A253C emphasizes the importance of a
cysteine residue in the substrate binding pocket of 11-HSD2.
Based on the observed weak inhibition of zebrafish 11-HSD2
by thiram, it is unlikely that impaired glucocorticoid inactiva-
tion or 11-ketotestosterone formation contributes significantly to
thiram-induced disturbances during zebrafish development such
as notochord distortions (Teraoka et al., 2006) or craniofacial abnor-
malities (van Boxtel et al., 2010).
Covalent carbamoylation of cysteine-264 on human 11-HSD2
upon incubation with thiram is expected to  cause steric hindrance
that prevents substrate binding. The dramatic loss of inhibition by
thiram of mutant C264S suggests that cysteine-264 is the major site
on  human 11-HSD2 for inhibition by  dithiocarbamates.
The decreased inhibitory effects on human 11-HSD2 mutant
C264S by the tri-organotins TBT and TPT but not the di-organotins
DMT, DBT and DPT suggest that the sulfhydryl group on cysteine-
264 forms stabilizing interactions with tri- but not di-organotins,
and that cysteine-264 plays a minor role in the inhibition of human
11-HSD2 by di-organotins.
The  major fish androgen 11-ketotestosterone activates andro-
gen receptor transcriptional activity with comparable potency as
testosterone, whereas 11-hydroxytestosterone is far less potent
(Yazawa et al., 2008). Therefore, in fish, inhibition of 11-HSD2 is
expected to show anti-androgenic effects. Our findings that none
of the organotins tested inhibited the zebrafish enzyme are in  line
with reports on the association of the organotins TBT and TPT with
androgenic effects and the cause of imposex in  marine species
(Birchenough et al., 2002; Castro et al., 2012; Matthiessen and
Gibbs, 1998; Stange et al., 2012). TBT- and TPT-induced imposex,
developmental disturbances and impaired cell differentiation may
be caused, at least in  part, by  activation of retinoid X  receptors
(RXR)  and peroxisome-proliferation activated receptors (PPARs)
(Grun and Blumberg, 2006; Grun et al., 2006; Nakanishi et al., 2005;
Stange et al., 2012).
Our  results reveal significant species-specific differences of
11-HSD2 in  the substrate preference and sensitivity to environ-
mental xenobiotics. Whereas the zebrafish enzyme is not inhibited
by organotins and is relatively resistant to sulfhydryl modifying
agents, human 11-HSD2 is inhibited by  several organotins and is
highly sensitive to dithiocarbamates. Thus, 11-HSD2 inhibition by
these chemicals may  be toxicologically relevant for humans but not
fish.
Prenatal and perinatal exposure to elevated glucocorticoid con-
centrations has been associated with reduced birth weights and
an increased susceptibility to metabolic and cardiovascular dis-
eases later in life (Benediktsson et al., 1993; Reinisch et al., 1978;
Seckl and Holmes, 2007). 11-HSD2 is highly expressed in the
syncythiotrophoblast at the site of the maternal-fetal exchange
(Krozowski et al., 1995) and has a  pivotal role throughout preg-
nancy to decrease fetal cortisol exposure (Edwards et al., 1993).
Importantly, prenatal treatment with the 11-HSD2 inhibitor car-
benoxolone resulted in reduced birth weights, increased anxious
behavior and enhanced secretion of corticotrophin-releasing hor-
mone (Welberg et al., 2000). Evidence from 11-HSD2-deficient
mice  indicated an association of reduced placental weight with
a  restricted increase in fetal vessel density in  the final period
of pregnancy (Wyrwoll et al., 2009). The diminished placental
vascularization and the resulting impaired placental transport of
nutrients were proposed to be causal for the observed restricted
fetal growth. Organotins and dithiocarbamates were reported to
efficiently penetrate the fetal-placental barrier (Adeeko et al., 2003;
Cooke et al., 2004; Guven et al., 1998). Importantly, lower birth
weights and edema formation were reported in the litter of preg-
nant rats that were treated with dithiocarbamates (Guven et al.,
1998) and organotins (Adeeko et al., 2003; Cooke et al., 2004; Grote
et al., 2007), suggesting elevated glucocorticoids due to 11-HSD2
inhibition as a  potential mode of action.
Reduced birth weights were also observed in  the off-spring of
pregnant rats treated with cadmium (Ronco et al., 2009). These
rats had reduced serum testosterone levels (Ji  et al., 2011). It was
proposed that high levels of glucocorticoids, as a result of 11-
HSD2 inhibition, lower testosterone levels (Ge  et al., 2005; Ma et al.,
2011). Previous studies in  humans indicated that newborns deliv-
ered from mothers who smoked during pregnancy had reduced
birth weight, which was  highly correlated with placental levels of
cadmium, one of the toxic compounds of tobacco smoke (Ronco
et al., 2005). These observations suggest 11-HSD2 inhibition as a
potential mechanism for the fetal developmental toxicity of dithio-
carbamates, organotins and cadmium.
There is a  lack of studies on concentrations of thiram and other
dithiocarbamate pesticides in a larger human population. Although
environmental concentrations of thiram are lower than the concen-
trations used in the present study, the additive inhibitory effects of
dithiocarbamates and their suicide inhibition of 11-HSD2 need
to be taken into account. Thiram-induced toxicity is especially
relevant for agricultural workers who are exposed to high concen-
trations.
Despite low concentrations of organotins in water, significant
bioaccumulation has been observed in several marine species (Liu
et  al., 2006; López-Serrano Oliver et al., 2011; Wang et al., 2010),
and it was  shown that organotins enter the human food chain
(Rantakokko et al., 2008). In addition to consumption of seafood,
humans can be exposed to organotins from leaching of polyvinyl
chloride water pipes and food packing material (Atanasov et al.,
2005; Okoro et al., 2011; Sadiki and Williams, 1999). In human
and wildlife, organotin concentrations in serum ranging from 10 to
400 nM were measured (Kannan et al., 1999; Nielsen and Strand,
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2002; Takahashi et al., 1999). In lipid-rich tissues even higher con-
centrations may  be reached.
Thus, inhibition of placental 11-HSD2 by the compounds
investigated in the present work should be considered for risk
assessment since several animal studies indicate that 11-HSD2
inhibition during pregnancy causes irreversible changes in  fetal
development that lead to a  higher risk for cardiovascular and
metabolic disease later in life (Murphy et al., 2002; Seckl and
Holmes, 2007; Shams et al., 1998; Welberg et al., 2005). Further
studies in vivo will need to address the impact of sulfhydryl mod-
ifying agents on 11-HSD2 activity, especially under conditions of
oxidative stress and glutathione depletion.
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Abstract1 
2 
The zebrafish is a widely used model organism in various research fields, with increasing use in 3 
the field of endocrinology. In humans, ȕ-K\GUR[\VWHURLG GHK\GURJHQDVH W\SH  ȕ-HSD1) 4 
plays an important role in glucocorticoid activation by converting inactive cortisone to active5 
cortisol and the synthetic prednisone to its active metabolite prednisolone. Activated 6 
glucocorticoids are able to transactivate the glucocorticoid receptor (GR) which results in the 7 
WUDQVFULSWLRQRI*5WDUJHWJHQHVȕ-hydroxysteroid dehydrogenase type ȕ-HSD2) can be 8 
seen as a FRXQWHUSDUW WR ȕ-HSD1 as it inactivates the 11-hydroxylated glucocorticoids and 9 
prevents GR activation. Interestingly, although cortisol is an important stress hormone in 10 
zebrafish, WKH ]HEUDILVK KDV QR JHQH HQFRGLQJ ȕ-HSD1. We have previously shown that 11 
zebrafish ȕ-+6' LV UHVSRQVLEOH IRU WKH FRQYHUVLRQ RI FRUWLVRO WR FRUWLVRQH DQG ȕ-12 
hydroxytestosterone to 11-ketotestosterone, the main androgen in fish. A phylogenetic analysis 13 
LGHQWLILHG WZR SRVVLEOH DQFHVWRUV RI ȕ-+6' LQ ]HEUDILVK ȕ-+6'D DQG ȕ-HSD3b. We 14 
tested whether these two enzymes possess the ability to reduce cortisone to cortisol. Furthermore, 15 
the metabolism of cortisone in zebrafish microsomes was analysed. We found no conversion of 16 
cortisone to cortisol either by WKH WZR SRVVLEOH DQFHVWRUV RI ȕ-HSD1, nor by zebrafish 17 
microsomes. Furthermore, zebrafish microsomes did not reduce 11-ketotestosterone. Our results 18 
suggest the absence of 11-oxosteroid reductase activity in zebrafish, which must be taken into 19 
account when studying the metabolism and/or effects of glucocorticoids and androgens in 20 
zebrafish.  21 
22 

1. Introduction1 
2 
The increasing use of the zebrafish (danio rerio) as a model organism in various applications has 3 
been highlighted in a series of recent reviews [1-8]. The zebrafish is a small tropical fresh water 4 
fish, which is currently, with the help of advanced genetic techniques, being used to establish 5 
new models for neurodegeneration, depression and cancer. Furthermore, it is used to study 6 
embryonic development, angiogenesis, toxicity of nanomaterials, to assess drug-induced toxicity 7 
by high-throughput screening and, as proposed by Dickmeis et al., to screen for compounds that 8 
might impair glucocorticoid stress hormone signaling [1-9]. The advantages of using zebrafish as 9 
an in vivo model include their relatively low maintenance costs, high fecundity, and optical 10 
transparency during the development of the embryo and larvae, which allows unrestricted 11 
visualization of these processes [1]. Furthermore, the zebrafish genome has a high degree of 12 
homology with the human genome, and both species have a similar number of chromosomes13 
[10]. 14 
A plethora of physiological processes are controlled by corticosteroids. Corticosteroids can be 15 
divided into the mineralocorticoids and the glucocorticoids, which are able to transactivate the 16 
mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) respectively, and regulate 17 
their transcriptional activities [11]. It is believed that these receptors evolved from a common 18 
ancestor, the corticosteroid receptor, by a whole genome duplication event in the chondrichthyes. 19 
It is hypothesized that a second whole genome duplication event occurred in the teleost lineage, 20 
resulting in two genes encoding GR and two genes encoding MR, whereby the second gene 21 
coding for the MR was lost in the evolutionary process [12-15]. The fish MR has been shown to 22 
play a role in electrolyte balance [16], and can be activated by cortisol, aldosterone and 23 
deoxycorticosterone [12, 17-19], although aldosterone is absent in teleost fish [14]. It has been 24 

shown that the fish MR, like the human MR, is activated by cortisol at lower concentrations than 1 
needed for GR transactivation [17, 19, 20]. It has been shown that 11ȕ-hydroxysteroid 2 
dehydrogenase type 2 (ȕ-HSD2) is responsible for converting cortisol into cortisone and 3 
therefore prevents MR activation by cortisol [21]. We have shown recently that zebrafish ȕ-4 
HSD2 converts cortisol to cortisone, so it can be assumed that drȕ-HSD2 also protects the MR 5 
from transactivation by cortisol [22] $GGLWLRQDOO\ ȕ-HSD2 in fish is essential for the 6 
conversiRQRIȕ-hydroxytestosterone to 11-ketotestosterone, the main androgen in fish [22-25]. 7 
The zebrafish has been proposed as a good model to study glucocorticoid-mediated endocrine 8 
disorders [7, 8, 26, 27], because the zebrafish has only one GR gene [27] as seen in mammals, 9 
compared to other teleost species where multiple GR genes are found [12-14, 19]. For the 10 
zebrafish as in mammals there are two splice-YDULDQWVGHVFULEHG*5ĮDQG*5ȕ [28]. It has been 11 
shown that the GR together with cortisol regulates a multitude of physiological processes and 12 
plays a key role in the regulation of inflammation, insulin resistance, obesity, hypertension and 13 
hyperglycemia [29]. In fish it has been demonstrated that cortisol is the major stress hormone and 14 
plays a role in the regulation of metabolic processes and inflammation [27, 30] as well as in 15 
circadian cell cycle rhythm [31]. 16 
Crucial for GR DFWLYDWLRQLVȕ-K\GUR[\VWHURLGGHK\GURJHQDVHW\SHȕ-HSD1), an enzyme 17 
converting the inactive glucocorticoid cortisone to the active glucocorticoid cortisol, which binds 18 
to the GR and leads to its translocation into the nucleus and transcription of GR target genes [32,19 
33]. ,Q KXPDQV ȕ-+6' WRJHWKHUZLWK ȕ-HSD2 plays an important role in controlling the 20 
ratio of the inactive cortisone and the active glucocorticoid cortisol)XUWKHUPRUHȕ-HSD1 is 21 
essential for the activation of the synthetic glucocorticoid prednisone to its active metabolite 22 
prednisolone.  23 

It is known that cortisol is the main glucocorticoid acting on teleost fish GR [12, 13, 34]. 1 
Interestingly, the zebrafish has no gene coding for 11ȕ-HSD1, but it is has been speculated 2 
through SK\ORJHQHWLF DQDO\VLV WKDW ȕ-HSD3a LV WKH DQFHVWRU RI ȕ-HSD1 [35, 36] and may 3 
therefore reduce cortisone [36] and consecutively activate the GR and plays a role to maintain the 4 
balance between active and inactive glucocorticoids. On the other hand, it was shown by Huang 5 
et al. WKDW KXPDQ ȕ-HSD3 (SCDR10B) can oxidize cortisol; however, only at very high 6 
substrate concentrations [37]. Recently, D QRYHO LVRIRUP RI ȕ-HSD3a has been identified,7 
FDOOHGȕ-HSD3bDOVRNQRZQDVȕ-HSD1-like-protein-like. It is widely assumed that either 8 
ȕ-+6'DRUȕ-HSD3b could mimic the function RIȕ-HSD1 to reduce cortisone to cortisol9 
[35, 36], although this has never been shown. Nevertheless, based on the results of the 10 
phylogenetic analysis and the observation by Huang et al., it is generally accepted that a cortisone 11 
reductase activity exists in fish [37]. 12 
The increasing use of zebrafish as a model organism for endocrine studies [38] and the lack of 13 
knowledge on cortisone reduction in zebrafish, led us to investigate the role of the two ancestors 14 
RI ȕ-HSD1. Therefore, we tested whether cortisone is reduced to cortisol by drȕ-HSD3a 15 
and/or drȕ-HSD3b. We also employed zebrafish microsomes and homogenates to examine 16 
cortisone metabolism in zebrafish. Furthermore, we tested whether cortisone is activated to 17 
cortisol in vivo with the help of the GRIZLY assay (Glucocorticoid Responsive In vivo Zebrafish 18 
Luciferase activitY) [9]. 19 
20 

2. Results1 
2 
In a first experiment the two proposed ancestors of 11ȕ-HSD1, dr11bHSD3a and dr11bHSD3b 3 
were tested in intact HEK-293 cells at 37°C (data not shown). We could not detect any cortisone 4 
reductase activity and therefore we repeated this experiment at 28°C. We could not detect any 5 
cortisone reductase activity (data not shown) and therefore, dr11bHSD3a and dr11bHSD3b were 6 
transiently transfected in zf4 cells at 28°C. Both enzymes showed no 11-oxosteroid reductase 7 
activity with cortisone. These experiments were performed in both intact cells and cell lysates 8 
(Table 1).  9 
6LQFH ȕ-HSD1 did not show a reductase activity we wanted to test if drȕ-HSD2 had 11-10 
oxosteroid reductase activity in zebrafish. We tested the cell lysates of transiently transfected zf411 
cells, whether dr11ȕ-HSD2 might be responsible for the reduction of cortisone by supplying 12 
NADH as a cofactor (Table 1). We did not observe any reduction of cortisone. 13 
The results led us to investigate whether any 11-oxosteroid reductase activity can be observed in 14 
zebrafish microsomes. We were able to demonstrate that zebrafish microsomes are able to 15 
convert 11ȕ-hydroxytestosterone to 11-ketotestosterone and cortisol to cortisone upon incubation 16 
with the cofactor NAD+ (Table 1). We tested the reverse reaction with NADH and NADPH but 17 
could not observe any reduction of cortisone to cortisol or 11-ketotestosterone WR ȕ-18 
hydroxytestosterone (Table 1). We observed that cortisone is not reduced to cortisol, but to 20ȕ-19 
hydroxycortisone as described recently by Tokarz et al. [39], using NADPH as cofactor (Figure 20 
1). We stimulated the formation of 20ȕ-hydroxycortisone upon incubation with NADPH and the 21 
detergent Brij®58. Additionally, we showed that 20ȕ-hydroxycortisone was formed following 22 
the incubation of microsomes with glucose-6-phosphate (G6P) (Figure 1). 23 

In order to translate our in vitro findings into an in vivo model, we performed the GRIZLY assay1 
in 5 days post fertilization larvae to examine whether cortisone is metabolized to cortisol and can 2 
then activate the GR. Cortisol was able to activate the GR by glucocorticoid response elements 3 
(GRE) driven luciferase expression, whereas cortisone following a 24 h incubation at 4 
concentrations up to 80 μM did not show any effect on the GR-dependent reporter. These results 5 
indicate that 5 days post fertilization zebrafish larvae have no enzyme to reduce cortisone to 6 
cortisol, or any other steroid hormone that can activate the GR [9]. 7 
8 

3. Discussion1 
2 
The zebrafish does not have the gene encoding ȕ-HSD1, and it was assumed that one of the 3 
ancestors RIȕ-HSD1 would mimic its function and reduce cortisone to cortisol [35, 36]. Our 4 
results LQGLFDWHWKDWWKHDQFHVWRUVRIȕ-HSD1 are not able to reduce cortisone. We tested drȕ-5 
HSD3a and drȕ-HSD3b in intact cells and cell lysates and could not detect any conversion of6 
cortisone. Therefore, the role of these enzymes still remains unclear. Additionally, we tested 7 
whether drȕ-HSD2 might reduce cortisone. Similar observations have been made with hsȕ-8 
HSD1, a bidirectional enzyme, able to catalyze the cortisone reduction and cortisol oxidation the 9 
latter only under non-physiological conditions [40]. Our current results show that zebrafish ȕ-10 
HSD2 is not a bidirectional enzyme, comparable to the hsȕ-HSD2, which also does not reduce 11 
cortisone. 12 
Our results in zebrafish microsomes and our in vivo system show an important species-specific13 
difference in cortisone metabolism. Cortisone is not metabolized to cortisol by zebrafish 14 
microsomes. Zebrafish larvae at 5 days post fertilization are not able to metabolize cortisone into15 
cortisol or any other compound with GR activating properties, although it has been shown that 16 
these larvae already possess a functional hypothalamic pituitary adrenal (HPA) axis and respond 17 
to stress by increasing glucocorticoid production [8, 26, 30]. We conclude that there is a 18 
considerable difference between human and zebrafish in the regulation of the balance between 19 
inactive and active glucocorticoids. In humans the balance is controlled tightly by the interplay of20 
ȕ-HSD1 and ȕ-HSD2 [41]. Cortisol can be locally inactivated in both species, but once 21 
cortisol is inactivated it cannot be regenerated in fish as we could not identify any 11-oxosteroid 22 
reductase activity. In contrast, in humans, cortisone can be reactivated E\ȕ-HSD1-dependent 23 

conversion to cortisol. It remains unclear whether the teleost species possess another mechanism 1 
which involves different glucocorticoids and enzymes. Until now it was assumed that fish, like 2 
humans, control the balance of cortisone and cortisol through ȕ-+6' DQG ȕ-HSD2. We 3 
showed that our microsomal incubations ZLWK FRUWLVRQH OHG VROHO\ WR WKH IRUPDWLRQ RI ȕ-4 
hydroxycortisone. This observation is in line with a novel pathway of cortisol catabolism in fish5 
recently proposed by Tokarz et al., suggesting that cortisol is consecutively transformed by 11ȕ-6 
HSD2 and ȕ-hydroxysteroid dehydrogenase type 2 (20ȕ-HSD2) to 20ȕ-hydroxycortisone. The 7 
authors suggest that a) the two enzymes act as a metabolic switch, since 20ȕ-HSD2 irreversibly8 
reduces the amount of available cortisone for the reverse UHDFWLRQWRFRUWLVROE\ȕ-HSD3 and b) 9 
that 20ȕ-hydroxycortisone can be excreted either directly or after glucuronidation or sulfatation 10 
[39]. Our results indicate that 20ȕ-HSD type 2 will not act as a metabolic switch, since the 11 
reduction of cortisone to cortisol does not occur in zebrafish.  12 
We were able to VWLPXODWHWKHIRUPDWLRQRIȕ-hydroxycortisone upon incubation with Brij®58. 13 
Moreover, we observed the conversion of cortisone WRȕ-hydroxycortisone by sole incubation 14 
with G6P. 7KHVH WZR ILQGLQJ VXJJHVW WKDW WKH HQ]\PH UHVSRQVLEOH IRU ȕ-hydroxycortisone 15 
formation might face the lumen of the endoplasmic reticulum (ER). Detergents permeabilize the 16 
ER membrane allowing luminal enzymes greater access to cofactors and therefore enhance the 17 
activity of luminal enzymes. The IRUPDWLRQRIȕ-hydroxycortisone stimulated by G6P suggests 18 
the involvement of hexose-6-phosphate dehydrogenase (H6PDH). H6PDH is an ER luminal 19 
enzyme which converts NADP+ to NADPH by using G6P, and has been described to stimulate 20 
ȕ-HSD1, which is an ER luminal enzyme [42].  21 
Our microsomal incubations show that 11-ketotestosterone, the main androgen in fish, is not 22 
FRQYHUWHG WR ȕ-hydroxytestosterone, however we were able to measure the reaction of ȕ-23 

hydroxytestosterone to 11-ketotestosterone. This provides a possible explanation why 11-1 
oxosteroid reductase activity is absent in zebrafish, because the presence of an enzyme in 2 
zebrafish with 11-oxosteroid reductase activity might convert the main androgen 11-3 
ketotestosterone to its inactivHPHWDEROLWHȕ-hydroxytestosterone.  4 
To our knowledge this is the first study to show, that the ancestors RIȕ-HSD1 in zebrafish, 5 
ȕ-+6'DDQGȕ-HSD3b do not reduce cortisone. We suggest that 11-oxoreductase activity is 6 
absent in teleost fish. We believe that the zebrafish is an interesting model for endocrinology, 7 
especially in glucocorticoid related research topics, because the zebrafish has only one GR gene 8 
[27]. However, it must be taken into account that 11-oxosteroid reductase activity is absent in 9 
zebrafish. There are clearly species-specific differences in cortisol metabolism, and it remains to 10 
be shown whether the zebrafish possesses a system to enzymatically modify the ratio of inactive 11 
to active glucocorticoids. Our results would suggest the absence of such a system. These findings 12 
must be taken into account when designing experiments and evaluating data obtained related to 13 
glucocorticoid research with the model organism zebrafish. 14 
15 

4. Materials and Methods1 
4.1. Materials 2 
3 
Steroids were purchased from Steraloids (Newport, RI), all other chemicals and cell culture 4 
medium from Sigma–Aldrich Chemie GmbH (Buchs, Switzerland). The solvents were of 5 
analytical and high performance liquid chromatography grade and the reagents of the highest 6 
grade available. Substrates were dissolved in methanol and stored as 10 mM stock solution at7 
í20°C. 8 
9 
4.2. Construction of expression plasmids 10 
11 
7KH H[SUHVVLRQ SODVPLG IRU ]HEUDILVK ȕ-HSD3a was constructed by A. Odermatt and A. 12 
Dzyakonchuk and was described in the PhD thesis of A. Dzyakonchuk. For the construction of 13 
the zebrafish ȕ-HSD3b expression plasmid, mRNA was isolated from a male whole zebrafish. 14 
The mRNA was transcribed to DNA using SuperScript® II from Invitrogen (Carlsbad, CA) 15 
according to the manufacturer’s manual. The cDNA was amplified by PCR using an 16 
oligonucleotide at the start codon to introduce a BamHI endonuclease restriction site and a Kozak 17 
consensus sequence (5’ - ATA GGA TCC GCC ATG AAG GTG CTT TTC GGG GTG-3’) and 18 
an oligonucleotide at the stop codon either to add an XbaI endonuclease restriction site (5’- GAA 19 
TCT AGA TTA CGG CCC AGA CGA CAG TTT GC - 3’) or to attach a FLAG-epitope 20 
followed by the stop codon and an XbaI endonuclease restriction site (5’ - GAA TCT AGA TTA 21 
CTT GTC ATC GTC GTC CTT GTA GTC CAT AGA ACC CGG CCC AGA CGA CAG TTT 22 

GC - 3’). The PCR product was inserted into the BamHI–XbaI sites of the pcDNA3.1 vector. The 1 
selected clones used in this study were sequence verified.2 
3 
4.3. Cell culture, transfection and expression analysis4 
5 
Human embryonic kidney cells (HEK-293) were cultivated in Dulbecco's modified Eagle 6 
medium (DMEM) containing 4.5 g/L glucose (D5796 Sigma-Aldrich), 10% fetal bovine serum, 7 
100 U/ml penicillin, 0.1 mg/ml streptomycin, 1 × MEM non-essential amino acids and 10 mM 8 
HEPES buffer, pH 7.4. Cells were incubated at 37°C in a humidified 5% CO2 atmosphere.9 
Zebrafish embryonic fibroblast cells zf4 (kindly provided by Dr. Jerzy Adamski, Helmholtz 10 
Zentrum, Munich, Germany) were cultivated in DMEM:F12 (D8437 Sigma–Aldrich), 11 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 0.1 mg/mL streptomycin.12 
These cells were maintained at 28°C in a humidified 5% CO2 atmosphere.13 
Cells were transiently transfected with drȕ-HSD3a, drȕ-HSD3b, hsȕ-HSD1 [43] and 14 
drȕ-HSD2 [22]. HEK-293 cells were transfected using the calcium phosphate transfection 15 
method [44], transfection efficiency was approximately 20%. Zf4 cells were transfected using 16 
Fugene HD according to the manufacturer’s protocol (Roche Applied Science, Rotkreuz, 17 
Switzerland). Transfection efficiency was approximately 25%.18 
Cells were trypsinized 48 h post transfection, and 5 pellets per 10 cm2 dish were obtained after 4 19 
min centrifugation at 900 g, the pellets were immediately shock frozen on dry ice and stored at -20 
80°C. The protein concentration was measured with the Pierce BCA protein assay kit (Thermo 21 
Fisher Scientific Inc., Rockford, IL, USA) according to the manufacturer’s manual. Protein 22 
expression was verified by western blot, loading 20 μg of the FLAG-tagged enzymes as 23 
described for drȕ-HSD2 enzyme [22], using mouse M2 antibody from Sigma-Aldrich Chemie 24 

GmbH (Buchs, Switzerland). Actin was detected by rabbit anti-actin IgG from Santa Cruz 1 
Biotechnology Inc. (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated secondary 2 
antibodies were used to visualize the bands with Immobilon Western Chemiluminescent HRP 3 
substrate from Millipore Corporation (Billerica, MA, USA). 4 
5 
4.4. Cell incubations6 
7 
HEK-293 cells transiently transfected with drȕ-HSD3a, dr1ȕ-HSD3b and with hsȕ-HSD18 
as a positive control, as well as zf4 cells transiently transfected with drȕ-HSD3a, drȕ-9 
HSD3b and dr1ȕ-HSD2 were incubated as described previously [45]. Briefly, 20’000 of the 10 
transfected cells were seeded on a 96 well plate. The medium was changed to charcoal-treated 11 
serum-free DMEM, followed by 24 h incubation with 1 μM cortisone or 1 μM cortisol at both 12 
28°C and 37°C. The assay with cell lysates was performed as described previously [22]. Briefly, 13 
lysates were incubated at 28°C or 37°C in TS2 buffer (100 mM NaCl, 1 mM EGTA, 1 mM 14 
EDTA, 1 mM MgCl2, 250 mM sucrose, 20 mM Tris–HCl, pH 7.4) with 1) 1 μM cortisone 15 
supplemented with either 500 μM NADPH or NADH or with 2) 1 μM cortisol supplemented 16 
with 500 μM NAD+ or NADP+. Cell lysates transfected with dr11ȕ-HSD2 were incubated with 1) 17 
1 μM cortisone supplemented with 500 μM NADH or with 2) 1 μM cortisol supplemented with 18 
500 μM NAD+.19 
Upon termination of the reactions the internal standard (100 nM deuterized d4-cortisol) was 20 
added, followed by extraction with 1 mL ethyl acetate. The organic phase was transferred to a 21 
new tube, evaporated to dryness and reconstituted in 100 μL methanol and stored at -20°C until 22 
analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (section 4.6). 23 
24 

4.5. Determination of microsomal activities 1 
2 
Zebrafish microsomes were prepared by ultracentrifugation as described previously [44]. Briefly, 3 
zebrafishes were homogenized using 2 ml of solution A (10 mM imidazole, 0.3 M sucrose, pH 4 
7.0) per 100 mg, using 10 – 12 strokes with a Potter-Elvehjem with PTFE pestle while rotating5 
(220 rpm). Debris and nuclei were removed by two centrifugation steps for 10 min at 1000 x g, 6 
the supernatant was centrifuged twice for 10 min at 12’000 x g to remove mitochondria, followed 7 
by ultracentrifugation for 1 h at 100’000 x g to obtain microsomes. The pellet was washed with 8 
500 μL per 100 mg solution B (20 mM tris-maleate, 0.6 M potassium chloride, 0.3 M sucrose, pH 9 
7.0) and the ultracentrifugation step was repeated. Afterwards, the pellet was resuspended in 200 10 
μL per 100 mg solution C (10 mM tris-maleate, 0.15 M potassium chloride, 0.25 M sucrose, pH 11 
7.0). The microsomes were then aliquoted and shock frozen on dry ice and stored at -80°C until 12 
further use. The concentration of the microsomes was measured with the Pierce BCA protein 13 
assay kit (Thermo Fisher Scientific Inc., Rockford, IL, USA) according to the manufacturer’s 14 
manual.15 
To determine microsomal metabolism, the zebrafish microsomes (f.c. 1.5 mg/ml) were incubated 16 
for 1 h at 28°C in TS2 buffer with 1 μM cortisone or 1 μM 11-ketotestosterone in the presence of 17 
1) 500 μM NADH, 2) 500 μM NADPH, 3) 500 μM NADPH and 0.05 % Brij®58, 4) 1 mM 18 
glucose-6-phosphate (G6P). Under the same experimental conditions, 1 μM cortisol or 1 μM19 
ȕ-hydroxytestosterone was incubated in the presence of 500 μM NAD+. 20 
Upon termination of the reactions the internal standard (100 nM deuterized d4-cortisol for 21 
cortisone and cortisol, 100 nM deuterized d2-testosterone for ȕ-hydroxytestosterone and 11-22 
ketotestosterone) was added, followed by extraction with 1 mL ethyl acetate. The organic phase 23 

was transferred to a new tube, evaporated to dryness and reconstituted in 100 μL methanol and 1 
stored at -20°C until analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS)2 
(section 4.6). 3 
4 
4.6. Liquid chromatography-tandem mass spectrometry settings5 
6 
An Atlantis T3 column (3 μm, 2.1 × 150 mm, Waters) and an Agilent 1200 Infinity Series 7 
chromatograph (Agilent Technologies, Basel, Switzerland) were used for chromatographic 8 
separations (HPLC).  9 
The mobile phase consisted of solvent A (95:5, H2O:ACN (v/v), containing 0.1% formic acid) 10 
and solvent B (5:95, H2O:ACN (v/v), containing 0.1% formic acid), at a total flow rate of 0.4 11 
P/PLQȕ-hydroxytestosterone, 11-ketotestosterone and d2-testosterone were separated using 12 
25% solvent B for 4 min, followed by a linear gradient from 4 to 6 min to reach 100% solvent B, 13 
and then 100% solvent B for 2 min. The column was then re-equilibrated with 25% solvent B.  14 
ȕ-hydroxycortisone, cortisone, cortisol and d4-cortisol were separated using 30% solvent B for 15 
4 min, followed by a linear gradient from 4 to 7 min to reach 40% solvent B, and then 100% 16 
solvent B from 7 to 7.5 min. The column was then re-equilibrated with 30% solvent B. 17 
The LC was interfaced to an Agilent 6490 triple quadropole tandem mass spectrometer (MS/MS). 18 
The LC-MS/MS system was controlled by Mass Hunter workstation software (version B.01.05). 19 
The injection volume of each sample was 10 μL. The mass spectrometer was operated in 20 
electrospray ionization (ESI) positive ionization mode, with the source temperature of 350°C, 21 
with nebulizer pressure of 20 psi. The capillary voltage was set at 4000 V.  22 

The compounds were analyzed using multiple-reaction monitoring (MRM) and identified by 1 
comparing their retention time and mass to charge ratio (m/z) with those of authentic standards. 2 
The transitions, collision energy and retention time were m/z 9PLQIRUȕ-3 
hydroxytestosterone; m/z 303.1/121, 24 V, 3.3 min for 11-ketotestosterone; and m/z 291.3/99, 28 4 
V, 5.6 min for the internal standard d2-testosterone; m/z 363/121, 25 V, 3.35 min for ȕ-5 
hydroxycortisone; m/z 361/163, 25 V, 4.9 min for cortisone, m/z 363/121, 25 V, 4.6 min for 6 
cortisol; and m/z 367/121, 25 V, 4.6 min for the internal standard d4-cortisol.7 
8 
4.7. GRIZLY assay 9 
10 
The GRIZLY assay was performed by Weger et al. as described previously [9]. 11 
12 
13 
14 
15 
16 
17 
18 
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Figure Legends1 
cortisone to 
cortisol
cortisol to cortisone 11-KT to 
ȕ-OHT
ȕ-OHT to 11-KT
Zebrafish
microsomes
No activity Conversion, qualitative 
measurement
No activity Conversion, qualitative 
measurement
drȕ-HSD3a in 
zf4 at 28°C 
No activity No activity ND ND
drȕ-HSD3b in 
zf4 at 28°C 
No activity No activity ND ND
drȕ-HSD2 in zf4
at 28°C 
No activity 0.12 ± 0.023 nmol/mg/h ND Conversion described 
in HEK-293 [22] 
ND: not determined2 
Table 1: Overview of incubations. Incubations were performed as outlined in the Materials and 3 
Methods section. Briefly, zebrafish microsomes (f.c. 1.5 mg/ml) were incubated for 1 h at 28°C 4 
in TS2 buffer with 1 μM cortisone or 1 μM 11-ketotestosterone (11-KT) in the presence of 1) 500 5 
μM NADH, 2) 500 μM NADPH, 3) 500 μM NADPH and 0.05 % Brij®58, 4) 1 mM glucose-6-6 
phosphate (G6P). Under the same experimental conditions, 1 μM cortisol or 1 μ0 ȕ-7 
hydroxytestosterone (ȕ-OHT) was incubated in the presence of 500 μM NAD+.8 
Cell lysates transiently transfected with drȕ-HSD3a or drȕ-HSD3b were incubated at 28°C 9 
in TS2 buffer with 1) 1 μM cortisone supplemented with either 500 μM NADH or NADPH or 10 
with 2) 1 μM cortisol supplemented with 500 μM NAD+ or NADP+.11 
Cell lysates transfected with drȕ-HSD2 were incubated with 1) 1 μM cortisone supplemented 12 
with 500 μM NADH or with 2) 1 μM cortisol supplemented with 500 μM NAD+.13 

1 
2 
Figure 1: % conversion of 1 μM cortisone (E) in zebrafish microsomes (final concentration 1.5 3 
mg/ml) to ȕ-hydroxycortisone ȕ-OH-E) (black bars) and cortisol (F) (white bars). 4 
Microsomes were incubated for 1 h at 28°C in the presence of 500 μM NADPH with or without 5 
0.05% Brij®58 or 1 mM glucose-6-phosphate (G6P). Data (mean ± SD) were obtained from 6 
three independent experiments using pooled samples. 7 

1 
Figure 2: Measuring glucocorticoid signaling activity in a living animal via glucocorticoid 2 
response elements (GRE) driven luciferase expression in a transgenic zebrafish line (GRE:Luc). 3 
Bioluminescence from individual 5 days post fertilization transgenic larvae in 96-well microtiter 4 
plates was monitored on a luminescence plate reader. GRE:Luc larvae responded to a treatment 5 
with hydrocortisone with an increase in relative luciferase activity. No increase in relative 6 
luciferase activity was observed after treatment with cortisone.7 
8 

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Chapter 4: 17ȕ-HSD2 inhibitor testing

Introduction 
The inhibition of ȕ-K\GUR[\VWHURLG GHK\GURJHQDVH W\SH  ȕ-HSD2) has recently been 
suggested to be a potential drug target to treat osteoporosis [39]. We currently collaborate with 
two research groups aiming at the development of selective ȕ-HSD2 inhibitors. ȕ-HSD2 
belongs to the SDR superfamily and has been shown to play an important role in estradiol 
metabolism. It can deactivate active estradiol into inactive estrone, but also testosterone and Į-
dihydrotestosterone (DHT) into their inactive forms ǻ-androstenedione DQG Į- 
androstanedione [40]. Active androgens and estrogens are described to play an important role in 
bone formation and resorption, therefore a local LQKLELWLRQ RI ȕ-HSD2 in bones might be a 
potential mechanism to treat osteoporosis [39, 41, 42]. ȕ-HSD2 inhibitors have been proposed 
as a treatment for osteoporosis, a disease that is often caused by estrogen-deficiency, especially in
post-menopausal women. 
The group of Prof. Hartmann (Saarland University, Germany) has constructed SRWHQWȕ-HSD2 
inhibitors. I tested their structurally optimized 2,5-thiophene amides for selectivity on hsȕ-
HSD1 and hsȕ-HSD2. The publication can be found at the end of this chapter.
The group of Prof. Schuster (University Innsbruck, Austria) DSSURDFKHGWKHVHDUFKIRUQHZȕ-
HSD2 inhibitors by employing ligand-based pharmacophore modeling and virtual screening. 
Published ȕ-HSD2 inhibitors were identified from the literature, and pharmacophore models 
representing the common chemical and steric features of these inhibitors were constructed. These 
models were then employed to virtual screening of the commercial database SPECS. The hitlists 
of the models were compared with each other and 29 compounds were purchased for biological 
evaluation according to their drug-likeness, pharmacophore fit score, novelty, and availability.  
With the same pharmacophore model the complete Sigma® catalogue was screened. Over 120 
FRPSRXQGVZHUHLGHQWLILHGWRSRWHQWLDOO\LQKLELWȕ-HSD2. Based on possible exposure, 16 of 
these chemicals are now being tested on hsȕ-HSD2 by Fabio Bachmann. 

Results & Discussion
Anna Vuorinen (University Innsbruck, Austria) performed the biological evaluation of selected 
compounds from her in silico screening and found that seven of these compounds inhibited at 
least 70% of the enzyme activity at concentration of 20 μM and that they showed acceptable 
selectivity over the other related SDR enzymes tested. These results validated their 
SKDUPDFRSKRUH PRGHOV DQG WKH QHZO\ GLVFRYHUHG ȕ-HSD2 inhibitors are suitable lead 
structures for further drug development. 
The obtained results were then used to search for similar compounds to get further structure-
activity relationship (SAR) information. The selection of these hits was not guided by the model.
These compounds were then tested by Fabio Bachmann for inhibition of ȕ-HSD2 and for 
selectivity toward ȕ-+6'DQGȕ-HSD3. Only one compound showed strong inhibition at 
20 μM. This compound is currently being analyzed further. The fact that the selected compounds 
are less active gives Anna Vuorinen valuable information for the model refinement and help also 
to understand how the binding pocket is built. 
From the 16 chemicals tested of the virtual Sigma® catalogue library only two substances 
showed strong inhibition at 20 μM. These two compounds will be further analyzed by Fabio 
Bachmann.  
In my opinion, screening with pharmacophore models is a very fast and low-cost approach to 
screen a huge quantity of compounds. But the data obtained must be carefully analyzed and it 
does not replace the biological evaluation. Another pitfall might be false-negative results. It is not 
known how many chemicals are missed by this approach.

Paper: Structural optimization of 2,5-thiophene amides as highly potent and 
VHOHFWLYHȕ-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of 
osteoporosis

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*S Supporting Information
ABSTRACT: Inhibition of 17β-HSD2 is an attractive
mechanism for the treatment of osteoporosis. We report
here the optimization of human 17β-HSD2 inhibitors in the
2,5-thiophene amide class by varying the size of the linker (n
equals 0 and 2) between the amide moiety and the phenyl
group. While none of the phenethylamides (n = 2) were active,
most of the anilides (n = 0) turned out to moderately or
strongly inhibit 17β-HSD2. The four most active compounds
showed an IC50 of around 60 nM and a very good selectivity
toward 17β-HSD1, 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-
HSD2 and the estrogen receptors α and β. The investigated
compounds inhibited monkey 17β-HSD2 moderately, and one
of them showed good inhibitory activity on mouse 17β-HSD2. SAR studies allowed a first characterization of the human 17β-
HSD2 active site, which is predicted to be considerably larger than that of 17β-HSD1.
■ INTRODUCTION
17β-Hydroxysteroid dehydrogenase type 21 (17β-HSD2)
catalyzes the conversion of the highly active 17β-hydroxyste-
roids into the inactive 17-ketosteroids, i.e., the estrogen
estradiol (E2), as well as the androgens testosterone (T) and
5α-dihydrotestosterone (DHT) into their inactive forms
estrone (E1), Δ4-androstene-3,17-dione (Δ4-AD), and 5α-
androstanedione, respectively (Chart 1). In addition, it has
been described to exhibit a 20α-dehydrogenase activity,1
transforming 20α-dihydroprogesterone in progesterone, and a
3β-dehydrogenase activity,2 converting pregnenolone into
progesterone and dehydroepiandrosterone (DHEA) in Δ4-AD.
E2 is known to play an important role in the growth,
development, and maintenance of a diverse range of tissues
(e.g., reproductive tissues, brain). It is also involved in the
maintenance of bone balance, inducing bone formation and
repressing bone resorption by action on the osteoblasts.3 There
is also evidence that T has beneficial effects on bone
formation.4,5
Osteoporosis6 is a systemic disease where rigidity and
mechanical stability of the bone decline. Balance between bone
formation and bone resorption is disrupted, leading to an
increased risk of fractures. High incidence of this disease is
observed in women after menopause when the E2 levels drop
or following treatment with aromatase inhibitors,7 which block
estrogen biosynthesis. Nowadays two first-line therapies are
administered to osteoporotic patients: (1) Bisphosphonates
(alendronate) are effective in both postmenopausal women8
and men;9,10 however, they lead to reduction of only 50% of
fracture risk and are often associated to osteonecrosis of the
jaw. (2) Selective estrogen receptor modulators,11 also called
SERMs (raloxifene), are efficient too but are often associated
with an increased risk of venous thromboembolism. As the
reduction of circulating estrogens induces accelerated bone loss,
estrogen replacement therapy (ERT) was given to postmeno-
pausal osteoporosis patients.12,13 It reduced the risk of fractures
but increased the incidence of cardiovascular diseases and
breast cancer, which prevented the further use of this
therapy.13−15 All therapies currently available for the treatment
of osteoporosis have limitations, and none of them offers a
complete cure for the condition. Osteoporosis is an age-
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dependent disease, and because of the increasing life expect-
ancy and aging population in the industrialized countries, there
is a need for development of improved drugs to combat this
disease. As 17β-HSD2 is expressed in osteoblastic cells,16−18
inhibition of 17β-HSD2, which will lead to an increase in E2
and T levels locally in the bones, therefore offers the potential
as a novel therapy for osteoporosis.
Ideally, 17β-HSD2 inhibitors should be highly potent and
selective. They should not exhibit inhibitory activities on
functionally related 17β-HSD subtypes like types 1, 3, 4, 5
(Chart 1). Inhibition of 17β-HSD type 4, which catalyzes the
same reaction as type 2, is not desirable because it is
ubiquitously expressed and its dysfunction leads to severe
human disorders,19 e.g., Zellweger syndrome like D-bifunc-
tional protein deficiency. Activity suppression of 17β-HSD1, -3,
or -5, which catalyze the reverse reaction (reduction of
estrogens or androgens) will thus be counterproductive because
it would decrease E2 and T levels in bone and might lead to
systemic side effects.
17β-HSD2 inhibitors should not bind to the estrogen
receptors (ER) α and β, as it is expected that the E2 effects
are ER mediated. In addition, activation upon binding to these
receptors might lead to proliferative or antiproliferative effects
in steroidogenic tissues, which should be avoided.
Although 17β-HSD2 was already revealed in 1985 by
Blomquist20 and characterized by Wu in 1993,1 very few 17β-
Chart 1. 17β-HSD1, -2, -3, -4, and -5 in Sex Steroid Metabolism
Chart 2. Structures of Known 17β-HSD2 Inhibitors
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HSD2 inhibitor classes have been reported to date. Among the
steroidal inhibitors, Poirier and colleagues described a series of
steroidal spirolactone derivatives;21−24 the most potent
compound is the C17-spiro-δ-lactone 1 (Chart 2, IC50 = 34
nM 22). Wood et al.25−27 reported about a novel class of cis-
pyrrolidinones as active and selective nonsteroidal 17β-HSD2
inhibitors, with 2 (Chart 2) being one of the most potent
compound (IC50 = 50 nM in a cell-free assay). Three further
classes of nonsteroidal potent and selective 17β-HSD2
inhibitors were recently published by our group (Chart 2):
the hydroxyphenylnaphth-1-ol 3a and 3b,28,29 the hydroxyphe-
nylmethanones30 derived from the triazole 4,31 and the amides
5a, 6b, 6c, and 7.32 These amide derivatives are all substituted
by a benzyl group that is linked to a biphenylamide 5a or a
phenylthiophene 6b, 6c, 7 moiety.
At the time we started this work, a proof of concept for
therapeutic efficacy of 17β-HSD2 inhibition had been described
using compound 2 in vivo in a monkey model,33 showing a
decrease of bone resorption and maintenance of bone
formation. Despite high variations and the moderate effects
observed, this in vivo experiment validates this approach and
underlines the need for new optimized 17β-HSD2 inhibitors.
In the current report, we describe the optimization of 17β-
HSD2 inhibitors in the biphenylamide and phenylthiophene
amide classes focusing on the suppression of the methylene
from the benzyl group (anilide derivatives) or its replacement
by an ethylene linker (phenethylamide derivatives). The
synthesis of a small library of achiral derivatives, the biological
evaluation, and the structure−activity relationship (SAR) of the
new 17β-HSD2 inhibitors will be presented and compared to
the benzyl analogues.32 The selectivity toward further HSD
enzymes and the cytotoxicity profile of the best candidates were
investigated. Selectivity toward 17β-HSD1 was achieved based
on the expertise from the group developing potent and selective
inhibitors of 17β-HSD1.34−45 In order to identify which species
could be more suitable to perform a proof of concept in a
preclinical model, the most potent and selective compounds (at
the human enzymes) identified in this study were further tested
for their ability to inhibit 17β-HSD2 from different species
(rodents and monkey).
■ DESIGN
In a previous study, it was shown that, starting from the weakly
active disubstituted triazole 4,31 opening of the triazole central
moiety32 led to the discovery of a new class of biphenylamide
5a and phenylthiophene amides 6b, 6c, and 7 as 17β-HSD2
inhibitors (Chart 2). All the compounds discovered in this class
share a methylated amide and two hydroxy/methoxyphenyl
moieties differentiated in this study as rings A and C (Chart 2).
In addition ring C is attached to the nitrogen of the amide via a
methylene linker (n = 1, benzyl group). The compounds differ
in their central ring B, which is either a 1,4-phenyl, 1,3-phenyl,
or 2,5-thiophene group. Moderately active compounds were
identified in the class of the 1,3-phenyl derivatives 5a, showing
an IC50 of around 500 nM. Moderate to good active molecules
were discovered in the 2,5-thiophene class 6b and 6c, with IC50
of around 380 nM with the exception of 7, the most active and
promising 17β-HSD2 inhibitor (IC50 = 61 nM and selectivity
factor of 73 toward 17β-HSD1).
With the hypothesis that the central core B and the hydroxy/
methoxyphenyl A ring bind at the same position in the enzyme,
variation of the linker size n (n = 0, 1, and 2) will bring ring C
into different areas of the binding cavity as seen in Figure 1.
Variation of the size of the linker will help the mapping of the
enzyme’s active site, which is unknown, providing information
on the space available there and the global size of the inhibitor
accepted by the enzyme as well as on inhibitor rigidity (n = 0)/
flexibility (n = 2) tolerated by the enzyme.
In order to investigate more deeply the enzyme’s active site
and in an attempt to optimize this class of compounds, a small
library of 17β-HSD2 inhibitors was synthesized keeping the
phenyl C unchanged and varying the size of the linker (n = 0
and n = 2, to be compared with n = 1 previously described32) as
well as the substituents at ring A in both biphenyl and
phenylthiophene amides classes (Chart 3, compounds 8−41).
■ RESULTS
Chemistry. The synthesis of the 1,3-phenyl derivatives 8−
11, depicted in Scheme 1, and the synthesis of the 2,5-
thiophene derivatives 12−41, depicted in Scheme 2, were
performed following a two- to three-step reaction pathway.
First, amidation was carried out by reaction of the commercially
Figure 1. Superimposition of the designed compounds with n = 0
(gray), 1 (green), and 2 (violet). The picture was generated using Moe
2010.10.
Chart 3. Designed Structures
Scheme 1. Synthesis of 1,3-Phenyl Derivatives 8−11a
aReagents and conditions: (i) NEt3, CH2Cl2, 0 °C, 3 h, method A; (ii)
DME/H2O (1/1), Na2CO3, Pd(PPh3)4, 80 °C, 4−14 h, method B;
(iii) BF3·S(Me)2, CH2Cl2, rt, 6−14 h, method C.
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available 5-bromothiophene 12c or the 3(4)-bromobenzoyl
chloride 8c with substituted anilines 8d or with the 2-(3-
methoxyphenyl)-N-methylethanamine 27c under standard
conditions (method A consisting of triethylamine, dichloro-
methane at 0 °C for 3 h) providing the brominated
intermediates 8b, 12b, 16b, 22b, 24b−27b, 33b−36b in
isolated yields between 57% and 99%. Subsequently, Suzuki
coupling using tetrakis(triphenylphosphine)palladium and
sodium carbonate in a mixture DME/water, 1:1 (method B),
afforded the biphenylamides 8a−11a or the phenylthiophene
amides derivatives 12, 13a−16a, 16, 17, 18a, 19−21, 22a, 23−
26, 27a−29a, 30−41 with good yields. Methoxy compounds
were submitted to ether cleavage using boron trifluoride−
dimethyl sulfide complex and yielded the hydroxy molecules
8−11, 13−16, 18, 22, 27−29.
Biological Results. 1. Inhibition of Human 17β-HSD2 in
Cell-Free Assay and Cellular Assay. 17β-HSD2 inhibitory
activities of the synthesized compounds were first evaluated in a
cell-free assay. Human placental enzyme was obtained and used
according to described methods.23,46,47 Briefly, incubations
were run with the enzyme microsomal fraction, tritiated E2,
cofactor, and inhibitor. The separation of substrate and product
was accomplished by HPLC. The percent inhibition values of
compounds 8−41 are shown in Tables 1−3. The IC50 values
determined for selected compounds are reported in Table 4.
Compounds showing less than 10% inhibition when tested at 1
μM were considered to be inactive. The spiro-δ-lactone 1,
Scheme 2. Synthesis of 2,5-Thiophene Derivatives 12−41a
aReagents and conditions: (i) NEt3, CH2Cl2, 0 °C, 3 h, method A; (ii) DME/H2O (1/1), Na2CO3, Pd(PPh3)4, 80 °C, 4−14 h, method B; (iii)
BF3·S(Me)2, CH2Cl2, rt, 6−14 h, method C.
Table 1. Inhibition of Human 17β-HSD2 and 17β-HSD1 by Diphenylamide Derivatives 8−11 in Cell-Free System
n = 0 n = 1
% inhibition at 1 μMa,d % inhibition at 1 μMa,d
R1 R2 compd 17β-HSD2
b 17β-HSD1c compd 17β-HSD2b 17β-HSD1c
4-OH OH 8 28 ni 5a 70 31
4-OMe OMe 8a 53 ni 5b 13 ni
3-OH OH 9 35 13 5c 60 10
3-OMe OMe 9a 64 ni 5d 11 ni
2-OH OH 10 18 ni
2-OMe OMe 10a 40 ni
H OH 11 28 ni
H OMe 11a 37 ni
aMean value of three determinations, standard deviation less than 10%. bHuman placental, microsomal fraction, substrate E2, 500 nM, cofactor
NAD+, 1500 μM. cHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 μM. dni: no inhibition (inhibition of <10%).
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described by Poirier et al.,22 was taken as external reference
(68% at 1 μM in our test; 62−66% at 1 μM in their assay).
In the 1,3-phenyl class (Table 1), comparison of the
biological results indicates that the best 17β-HSD2 inhibitory
activities are obtained either when n is 0 and the substituents
R1 and R2 are methoxy groups (compounds 8a, 9a, 10a) or
when n is 1 and R1 and R2 are hydroxy moieties (compounds
5a and 5c). Taking away R2 (R2 = H; 11 and 11a) is
detrimental for the activity, independent of the nature of R1. It
indicates that R2 is important for the stabilization of the
molecule in the active site. R1 and R2 therefore interact with
amino acids from the binding cavity and behave as H-bond
acceptors when n is 0 or H-bond donors when n is 1.
In the 2,5-thiophene class (Table 2), the highest inhibition
data are observed with the compounds having the linker n = 0
and the substitutents R1 and R2 being methoxy (13a) or when
the linker n is 1 and R1 and R2 are hydroxy (6e) as observed in
the 1,3-phenyl class. The compounds with the linker n = 2 are
either inactive (28, 29a) or weakly active (27a, 27),
independent of the substituents at rings A and C. With the
ethylene linker the compounds might be too long and/or too
flexible to fit in the enzyme active site. They were not further
investigated.
Focusing on compounds with n = 0, the influence of the
central core can also be evaluated. By comparison of the 1,3-
phenyl to the 2,5-thiophene derivatives (for 9a compared to
13a, 64% and 90% inh at 1 μM, respectively; for 10a compared
to 14a, 40% and 66% inh at 1 μM, respectively; for 11a
compared to 15a, 37% and 82% inh at 1 μM, respectively), it is
obvious that the 2,5-thiophene is better than the 1,3-phenyl
moiety. This preference is difficult to explain, as both aromatic
moieties can establish a π-stacking interaction with aromatic
amino acids from the active site. However the overall electronic
density and the molecular electrostatic potential (MEP) differ
depending on the nature of the central scaffold. It is likely that
the MEP induced by the 2,5-thiophene leads to a better
recognition with the corresponding region in the binding cavity.
This property has already been evidence in the discovery of
17β-HSD1 inhibitors.39,48 Thus, the 2,5-thiophene class only
was further investigated in the rest of the study.
Furthermore, the influence of the A and C ring substituents
on the activity can be deduced in the 2,5-thiophene class with
the linker n = 0. Taking away the methoxy group on the A ring
(R2 = H 15a/R2 = OMe 13a, 82%/90% inh at 1 μM,
respectively) does not influence the potency of the compound,
indicating that this group does not play a critical role in the
stabilization of the inhibitor in the active site. Deleting the same
group on the C ring (R1 = H 16a/R1 = OMe 13a, 67%/90%
inh at 1 μM, respectively) leads to a more consistent decrease
in activity, suggesting that this methoxy is involved in specific
interactions that stabilize the inhibitor in the binding cavity or
Table 2. Inhibition of Human 17β-HSD2 and 17β-HSD1 by Phenylthiophene Amide Derivatives Monosubstituted on the A-
Ring 12−29 in Cell-Free System
n = 0 n = 1 n = 2
% inhibition at 1 μMa,d % inhibition at 1 μMa,d % inhibition at 1 μMa,d
R1 R2 compd 17β-HSD2
b 17β-HSD1c compd 17β-HSD2b 17β-HSD1c compd 17β-HSD2b 17β-HSD1c
4-OMe 3-OMe 12 89 15 6a 61 ni
3-OMe 3-OMe 13a 90 11 6b 63 ni 27a 31 ni
3-OH 3-OH 13 34 33 6c 70 21 27 37 23
2-OMe 3-OMe 14a 66 ni 6d 48 ni
2-OH 3-OH 14 69 47 6e 83 16
H 3-OMe 15a 82 24 6f 49 ni 28a 18 11
H 3-OH 15 60 50 6g 81 15 28 11 ni
3-OMe H 16a 67 ni 6h 68 ni
3-OH H 16 31 12 6i 42 ni
H H 17 48 14
4-CN 3-OMe 18a 48 ni 6j ni ni
4-CN 3-OH 18 28 ni 6k 54 7
3-Me 3-OMe 19 95 26
3-N(Me)2 3-OMe 20 82 11
3-SMe 3-OMe 21 88 28
3-OMe 3-Me 22a 87 ni
3-OH 3-Me 22 71 24
3-F 3-OMe 23 67 23 29a ni ni
3-F 3-OH 6l 71 20 29 17 12
3-OMe 3-CF3 24 75 13
3-Me 2-F 25 68 ni
3-OMe 3-Ph 26 83 50
aMean value of three determinations, standard deviation less than 10%. bHuman placental, microsomal fraction, substrate E2, 500 nM, cofactor
NAD+, 1500 μM. cHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 μM. dni: no inhibition (inhibition of <10%).
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that it affects the electrostatic potential of the C ring which
again favors the binding.
The importance of electronic effects is also indicated by the
fact that replacement of the methoxy moiety at the A ring (13a,
90% inh at 1 μM) by other electron donating groups (3-Me 19,
3-NMe2 20, and 3-SMe 21 giving 95%, 82%, and 88% inh at 1
μM, respectively) is well accepted, whereas replacement by
electron withdrawing groups (4-CN 18a and 3-F 23 giving 48%
and 67% inh at 1 μM, respectively) leads to a decrease in
activity. The same is also valid for the C ring, where exchange
of the methoxy moiety 13a (90% inh at 1 μM) by electron
withdrawing groups like 3-CF3 24 (75% inh at 1 μM) or 2-F 25
(68% at 1 μM) slightly reduces the 17β-HSD2 inhibitory
activity, while in the presence of the electron donating 3-Me
22a the percentage inhibition does not change. Introduction of
the large 3-Ph 26 (83% inh at 1 μM) is also well tolerated by
the enzyme, indicating that there is space in the area of the
binding site for introduction of bulky substituents.
A fluorine has been introduced at the 3-methoxyphenyl A
ring as second substituent in this ring (compounds 30−32, 36−
39, Table 3) in the 2,5-thiophene class with the linker n = 0.
Introduction at the 2 position led to 31 and 32 (93% and 85%
inh at 1 μM, respectively), which have similar activity as the
corresponding compounds 13a and 22a. This substituent does
not achieve any specific interaction with the active site but is
also not disturbing the stabilization. Addition of the fluorine at
position 4 induces a slight loss in activity, 39 (66% inh at 1
μM). This decrease in activity is consistent with the electronic
effect described previously (replacement of a methoxy for an
electron withdrawing group, compounds 18a and 23).
Addition of a third substituent on the A ring, a 6-F (37 94%
inh at 1 μM), does not increase the potency of 31.
Compound 31 (93% inh at 1 μM), differing from 35 (49%
inh at 1 μM) in the displacement of the methoxy group on the
C ring from the 3 to the 4 position, leads to a decrease in
activity and reveals the importance of the interaction achieved
by this group, which must have the right orientation.
It was then investigated if the methyl group on the amide
function of 31 is necessary for activity: exchange with a
hydrogen 33 or a phenyl 34 led to two inactive compounds.
The methyl group might be located in a small lipophilic cavity
and participate actively in the stabilization of the compound.
Loss of this group prevents this interaction, and the phenyl
group might be too big to fit into this lipophilic cavity.
For the most active compounds showing more than 70%
inhibition at 1 μM, IC50 values were determined in the cell-free
assay and are shown in Table 4. Four highly active compounds
with the linker n = 0 (13a, 19, 31, and 32) were identified
displaying IC50 values of around 60 nM. They are equipotent to
the previously described 7 carrying a methylene linker. Five
other interesting compounds (12, 20, 26, 36, and 37) were
discovered with IC50 between 100 and 200 nM.
The inhibitory activity of the most potent compounds on
17β-HSD2 was also evaluated in a cellular model system, using
the MDA-MB-231 cell line. The compounds’ efficiency is
expressed as IC50 for the most potent compounds or as
percentage of inhibition for the others (Table 4). The data
obtained lie in the same range as the cell-free inhibition data,
with IC50 values around 100 nM or below. The results indicate
that the compounds can permeate the cell membrane, are stable
in the cell, and are not quickly metabolized.
2. Selectivity Aspect. As 17β-HSD1 catalyzes the reduction
of E1 to E2, the reversed 17β-HSD2 reaction, it should not be
affected by 17β-HSD2 inhibitors. In the 1,3-phenyl class
(compounds 8a−11), the selectivity observed toward this
enzyme (Table 1) is very good: no or a very weak inhibition of
the 17β-HSD1 enzyme was measured at 1 μM. In the series of
the 2,5-thiophenes, independent of the linker size (n = 0, 1, or
2; compounds 12−29), the same results were observed except
for the middle active 17β-HSD2 inhibitors 14, 15, and 30
(69%, 60%, and 67% 17β-HSD2 inh at 1 μM, respectively),
which showed around 50% 17β-HSD1 inhibition at 1 μM. For
the most potent 17β-HSD2 inhibitors (Table 4), the selectivity
was expressed as selectivity factor (SF) calculated as the ratio of
IC50 (17β-HSD2) over IC50 (17β-HSD1). For the compounds
with an IC50 (17β-HSD2) below 200 nM, the SF varied
between 26 and above 800 except for 26 with a SF of 8. The
selectivity toward 17β-HSD1 is good to very good for most of
the new 17β-HSD2 inhibitors described. It is even better for
the compounds without linker (SF of 112, 116, above 800, and
132 for 13a, 19, 31, and 32) compared to the one with a
methylene linker (SF of 73 for 7).
Inhibitors of 17β-HSD2 should have no affinity for the
estrogen receptors (ER) α and β, as it is expected that most E2
effects are ER mediated. All the compounds with an IC50 (17β-
HSD2, cell-free assay) below 500 nM were evaluated for their
relative binding affinity (RBA) to the ERα and ERβ in a
competitive assay using a previously described assay47,49 and
taking E2 as internal reference. All of the tested compounds
showed a RBA below 0.1%, compared to the affinity of E2,
which was arbitrarily set to 100%.
17β-HSD4 catalyzes the oxidation of E2 into E1 as 17β-
HSD2 (Chart 1) and is ubiquitously expressed. 17β-HSD5 is a
Table 3. Inhibition of Human 17β-HSD2 and 17β-HSD1 by
Phenylthiophene Amide Derivatives Di- or Trisubstituted on
the A-Ring 30−41 in Cell-Free System
% inhibition at 1 μMa,d
compd n R1 R2 R3
17β-
HSD2b
17β-
HSD1c
7 1 2-F,3-OMe 3-OH Me 89 ni
30 0 2-F,3-OMe 3-OH Me 76 33
31 0 2-F,3-OMe 3-OMe Me 93 17
32 0 2-F,3-OMe 3-Me Me 85 20
33 0 2-F,3-OMe 3-OMe H ni ni
34 0 2-F,3-OMe 3-OMe Ph ni 13
35 0 2-F,3-OMe 4-OMe Me 49 18
36 0 2-F,3-Me 3-OMe Me 77 ni
37 0 2-F,6-F,3-OMe 3-OMe Me 94 28
38 0 3-F,4-OMe 3-OMe Me 72 15
39 0 3-OMe,4-F 3-OMe Me 66 17
40 0 3-F,4-F 3-OMe Me 50 ni
41 0 2-OMe,4-OMe 3-OMe Me 77 30
aMean value of three determinations, standard deviation less than 8%
except for 27 in HSD1, 23%. bHuman placental, microsomal fraction,
substrate E2, 500 nM, cofactor NAD+, 1500 μM. cHuman placental,
cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 μM.
dni: no inhibition (inhibition of <10%).
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reductive enzyme; it converts the inactive DHEA and 4-
androstene-3,17-dione into the potent 5-androstene-3β,17β-
diol and testosterone, respectively (Chart 1). In order to avoid
systemic side effects and not to counteract the effect of 17β-
HSD2 inhibition, inhibition of these enzymes should be
avoided.
The five most potent compounds 7, 13a, 19, 31, and 32 were
evaluated for their ability to inhibit these two enzymes, using
recombinant human 17β-HSD4 and 17β-HSD5 expressed in E.
coli following the described procedure.50,51 The compounds did
not show any inhibition of 17β-HSD4 when tested at 1 μM and
inhibited 17β-HSD5 only weakly (inhibition between 17% and
33% at 1 μM, Table 5).
11β-HSDs are involved in the glucocorticoid biosynthesis.
11β-HSD1 catalyzes the transformation of the inactive
cortisone into the potent cortisol, and 11β-HSD2 catalyzes
the reverse reaction. Some inhibitors of 11β-HSD152 have a
close structural analogy to the amides identified in this study. In
addition, 17β-HSD2 has a relatively high sequence identity with
11β-HSD2 (45%).53 Therefore, the selectivity profile of the five
structurally most relevant compounds 7, 13a, 19, 31, and 32
was thus extended to these two enzymes using the recombinant
enzymes 11β-HSD1 and 11β-HSD2 stably transfected in HEK-
293 cells following the described procedure.54 Absence or very
low 11β-HSD1 and 11β-HSD2 inhibition was observed at 2
μM except for 7, which showed an IC50 of 1 μM for 11β-HSD1.
This activity is not negligible, but compared to the IC50 of 61
nM for 17β-HSD2, a selectivity factor of around 16 might be
acceptable, especially regarding the fact that 11β-HSD1
activates glucocorticoids and elevated glucocorticoids have
been associated with osteoporosis.55
3. Further Tests. The lipophilicity profiles of 7, 13a, 19, 31,
and 32 were evaluated by calculation of log P (Table 4). For
most of the compounds it is between 4 and 5 or slightly above
Table 4. IC50 Values (17β-HSD2 and 17β-HSD1) and Selectivity Factor for Selected Compounds
cell-free assay
IC50 (nM)
a
compd n R1 R2 17β-HSD2
b 17β-HSD1c selectivity factord
cell testi
IC50 (nM)
g HSD2e cLogP f
5a 1 3-OH OH 482 3801 8 nd 4.04
6c 1 3-OH OH 394 5449 14 nd 4.08
7 1 2-F,3-OMe OH 61 4452 73 78 4.50
12 0 4-OMe OMe 148 6217 42 81%h 4.54
13a 0 3-OMe OMe 68 7593 112 119 4.54
15a 0 H OMe 207 4337 21 nd 4.66
19 0 3-Me OMe 58 6752 116 73 5.15
20 0 3-N(Me)2 OMe 169 10573 63 71%
h 4.95
21 0 3-SMe OMe 242 5306 22 nd 5.10
22a 0 3-OMe Me 207 11454 55 nd 5.15
22 0 3-OH Me 645 6800 11 nd 4.89
24 0 3-OMe CF3 721 12259 17 nd 5.58
26 0 3-OMe Ph 137 1109 8 nd 6.34
31 0 2-F,3-OMe OMe 62 >50000 >800 105 4.69
32 0 2-F,3-OMe Me 62 8209 132 80%h 5.31
36 0 2-F,3-Me OMe 130 5426 42 83%h 5.79
37 0 2-F,6-F,3-OMe OMe 184 4812 26 83%h 4.85
38 0 3-F,4-OMe OMe 242 >40000 >165 nd 4.69
41 0 2-OMe,4-OMe OMe 313 1927 6 nd 4.41
aMean value of three determinations, standard deviation less than 15%. bHuman placental, microsomal fraction, substrate E2, 500 nM, cofactor
NAD+, 1500 μM. cHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 μM. dIC50(17β-HSD1)/IC50(17β-HSD2).
eMDA-MB-231 cell line, substrate E2, 200 nM. fCalculated data. gMean value of two determinations, standard deviation less than 15%. hInhibition
measured at an inhibitor concentration of 1 μM. ind: not determined.
Table 5. Selectivity toward 17β-HSD4, 17β-HSD5, 11β-
HSD1, and 11β-HSD2 for Selected Compounds
compd
inhibition of
17β-HSD4,
% at 1 μMa,b,f
inhibition of
17β-HSD5,
% at 1 μMa,c
inhibition of
11β-HSD1, % at
2 μM (IC50)
a,d,f
inhibition of
11β-HSD2,
% at 2 μMa,d,f
7 ni 33 68 (1 μM) 10
13a ni 17 ni ni
19 ni 20 23 14
31 ni 26 9 8
32 ni 29 ni ni
2−9e ni 88 nd nd
aMean value of three determinations, standard deviation less than 19%
for 17β-HSD5 and less than 9% for 17β-HSD4. bEnzyme expressed in
bacteria (bacterial suspension), substrate [3H]E2, 21 nM, cofactor
NAD+, 750 μM. cEnzyme expressed in bacteria (bacterial lysate),
substrate [3H]A-dione, 21 nM, cofactor NADPH, 600 μM.
dDetermined in lysate of HEK-293 cells expressing recombinant
human enzymes. eExternal reference: compounds 2−9 described by
Schuster et al.50 fni = no inhibition. nd = not determined.
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5, which is still in a good range according to the Lipinski rule of
five56 and which should be correlated to a good permeability.
The cytotoxicity of 7, 13a, 19, 31, and 32 was evaluated in
the MDA-MB-231 cell line based on MTT conversion
following the procedure described by Denisot et al.57 at three
different concentrations: 2.5, 10, and 50 μM. No cytotoxicity
could be observed even at the highest concentration after 3 h of
incubation (data not shown).
In order to identify the appropriate species for demonstration
of in vivo efficacy in a disease-oriented model, the five most
potent compounds 7, 13a, 19, 31, and 32 were tested for their
ability to inhibit the enzyme responsible for E2 into E1
transformation from three different animals: rat, mouse, and
monkey Callithrix jacchus. The compounds were evaluated in a
cell-free assay using the microsomal fraction of liver preparation
from rat and mouse. In the case of the monkey, the microsomal
enzyme was gained from placenta. The compounds showed
middle activity on the monkey enzyme, between 45% and 53%
inh at 1 μM (Table 6). They were inactive to very low active in
the rat, the best one being 7 with 25% inh at 1 μM. In mouse
compounds 13a, 19, and 31 were also barely active (between
26% and 30% inh at 1 μM) except for 32 and 7 which were
middle to good active with 45% and 65% inh at 1 μM,
respectively. It is striking that such a difference in activity is
observed between the rat (Rattus norvegicus) and the mouse
(Mus musculus) 17β-HSD2 inhibition data, as the protein
sequence of both species is highly similar. However from this
study, compound 7, identified as a highly active and selective
17β-HSD2 inhibitor at the human enzyme, exhibits the highest
17β-HSD2 inhibition on the mouse enzyme. This result
suggests that the mouse might be a promising species to
perform an in vivo experiment using compound 7 and to verify
that 17β-HSD2 inhibitors could be effective for the treatment
of osteoporosis.
■ DISCUSSION
The aim of this study was the optimization of 17β-HSD2
inhibitors from the amide class by variation of the size of the
linker (n) located between the amide function and the C ring.
Introduction of an ethylene linker (n = 2) is detrimental for the
activity, independent of the central moiety 1,3-phenyl or 2,5-
thiophene. The compounds might be too long or too flexible.
Taking out these two carbons linker (n = 0) led to the
identification of four promising compounds 13a, 19, 31, and 32
with IC50 values of around 60 nM. Interestingly these
compounds all bear a methoxy function on the C ring while
the equally active 7 with a methylene linker (n = 1) is
hydroxylated on this ring. High activity is only achieved when n
= 1 and the C ring is hydroxylated (7) or n = 0 and the C ring
is methoxylated (13a, 19, 31, and 32). It is striking that there is
no difference in activity between these two series of
compounds. These requirements to achieve high activity are
also intriguing. These data suggest that these two series of
compounds may not interact with the same amino acids in the
binding site. Thus, a different binding mode could be expected
for these two groups of inhibitors.
From this study it is clear that the 2,5-thiophene central core
is superior to the 1,3-phenyl independent of the size of the
linker n = 0 or 1. This result was already observed developing
17β-HSD1 inhibitors. The molecular electrostatic potential
Table 6. Inhibition of E1 Formation by Rat, Mouse, and
Monkey Enzymes Compared to Human Enzyme for Selected
Compounds
compd
human
17β-HSD2a
inh (%) at
1 μM
rat
E1 formationb
inh (%) at
1 μM
mouse
E1 formationc
inh (%) at
1 μM
monkey
E1 formationd
inh (%) at
1 μM
7 89 25 65 47
13a 90 14 29 45
19 95 ni 30 53
31 93 ni 26 45
32 85 ni 45 49
aHuman placenta, microsomal fraction, substrate [3H]E2 + E2 [500
nM], NAD+ [1500 μM], mean value of three determinations, relative
standard deviation of <10%. bRat liver, microsomal fraction, substrate
[3H]E2 + E2 [500 nM], NAD+ [1500 μM], mean value of three
determinations, relative standard deviation of <10%. ni: no inhibition.
cMouse liver, microsomal fraction, substrate [3H]E2 + E2 [500 nM],
NAD+ [1500 μM], mean value of three determinations, relative
standard deviation of <10%. dMonkey placenta, microsomal fraction,
substrate [3H]E2 + E2 [500 nM], NAD+ [1500 μM], mean value of
three determinations, relative standard deviation of <10%.
Figure 2. Mapping of 17β-HSD2 active site: (A) 3D-structure of 2; (B) 3D-structure of 7; (C) 3D-structure of 31; (D) superimposition of 2 to 7 (n
= 1); (E) superimposition of 2 to 31 (n = 0). 2 is colored gray, and 7 and 31 are green. The picture was generated using Moe 2010.10.
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induced by the thiophene on the whole molecule might lead to
better interactions with the enzyme active site. Further, the
thiophene differs from the phenyl ring in the presence of d-
orbitals on the sulfur. They might allow the thiophene
derivatives to undergo specific interactions compared to the
phenyl one.
The human 17β-HSD2 accepts ligands with a high structural
diversity: steroidal substrates E2, T, 20α-dihydroprogesterone,
pregnenolone, and DHEA, steroidal inhibitor spirolactone 1,
nonsteroidal inhibitors cis-pyrrolidinone 2, and amides 7 and
31. These ligands differ in their shape and volume, but they are
all very large. In order to map the enzyme active site, which is
unknown, and having the hypothesis that all these compound
bind in the enzyme active site, we compared the new
nonsteroidal 17β-HSD2 inhibitors with two different linker
sizes (31 for n = 0 and 7 for n = 1) with the equipotent cis-
pyrrolidinone 2 described by Wood et al.25−27 Visualization of
the 3D-structure of these three compounds, after energy
minimization, highlights the folded shape of compound 2 with
the thiophene ring almost parallel to the pyrrolidinone moiety
(Figure 2). Thereby the two aromatic groups, phenyl and
pyridine, are directed in opposite direction while for 7 and 31
they assume an elongated shape. Superimposition of 7 and 31
to 2 (Figure 2) may indicate that the area occupied by the
different compounds varies and sustains the hypothesis that
compound 2 may fit into the enzyme’s active site with another
binding mode compared to 7 and 31. In addition, the fact that
compound 2 does not require any hydroxy or methoxy groups
to achieve high activity in contrast to 7 or 31 also suggests a
different positioning of these compounds in the binding site. It
could therefore be deduced that the 17β-HSD2 active site may
be very large. This space could easily be used to achieve
selectivity toward other enzymes by introduction of appropriate
substituents. It is striking that compounds with a linker n = 2
were inactive, although they were expected to fit from the steric
hindrance point of view. It might indicate that the flexibility
induced by the ethylene linker is not appropriate.
The selectivity profile of the 17β-HSD2 inhibitor is an
important issue. Not to counteract the therapeutic concept, the
functionally related enzymes like 17β-HSD1, -4, -5 should not
be inhibited and no binding affinity to the ERs should be
identified. The most potent 17β-HSD2 inhibitors identified in
this study, 13a, 19, 31, 32, 1, 2, and 7, are all selective toward
17β-HSD1 and do not bind to the estrogen receptors. It might
indicate that the 17β-HSD2 active site is larger than that of
17β-HSD1 and the binding domains of the ERs. The size
difference of the binding sites of these proteins is an interesting
property, as it could facilitate the gain in selectivity of the 17β-
HSD2 inhibitor toward 17β-HSD1 and ERs. In addition it is
notable that the most active compounds with a linker n = 0, i.e.,
13a, 19, 31, and 32, have a much higher selectivity factor than
the one compound with n = 1, i.e., compound 7. In the case of
n = 0, the C ring seems to adopt a conformation of higher steric
hindrance in the 17β-HSD1 active site than in the case of n = 1.
11β-HSD1 and 11β-HSD2 catalyze the oxidoreduction at
position 11 of cortisone in cortisol. These two enzymes have an
important function in the glucocorticoid biosynthesis and
should not be inhibited. On the basis of structural similarities
identified between 11β-HSD1 inhibitors and our amides
derivatives, it is also important to verify the selectivity of our
inhibitors toward these enzymes. None of the new amides
discovered in this study inhibit 11β-HSD1 or 11β-HSD2 to an
appreciable extend except for compound 7 which shows an IC50
of 1 μM for 11β-HSD1 and an IC50 of 61 nM for 17β-HSD2,
the ratio resulting in a selectivity factor (SF) of 16. On the basis
of the fact that elevated glucocorticoids levels have been
associated with osteoporosis, moderate 11β-HSD1 inhibition
might be still of advantage for the therapeutic concept.
Inhibition of 17β-HSD2 is a completely new approach for
the treatment of osteoporosis compared to the existing
treatments. A therapeutic effect similar to the one observed
with estrogen replacement therapy (ERT), which has already
been proven to be efficient in the treatment of osteoporosis, is
expected after treatment with 17β-HSD2 inhibitors. ERT is not
recommended because of severe side effects caused by the
systemic increase in E2 at the necessary high doses. Inhibition
of 17β-HSD2 will allow an increase in E2 in lower doses and
only in targeted organs where the enzyme is present, i.e., in
organs like placenta, brain, bone, breast, and ovaries. In
addition after menopause, the ovaries do not function anymore
and there is atrophy of the breast and of the uterus connected
to a reduction of the metabolism/catabolism of the tissues. The
levels in androstenedione and estrone in these organs may be
reduced and therefore the amount of E2 and testosterone as
well. Consequently treatment with 17β-HSD2 inhibitors may
be less susceptible to induce breast cancer compared to ERT.
17β-HSD2 inhibition is thus not expected to induce severe
adverse effects. A targeted effect in the bones should result in a
superior drug compared to SERMs or bisphosphonates.
The five most potent compounds 7, 13a, 19, 31, and 32 were
investigated regarding their ability to inhibit 17β-HSD2 from
other species in order to identify an appropriate species for
conducting in vivo experiments. The compounds were tested
on the rat, mouse, and monkey 17β-HSD2. Only inhibitor 7
showed a good inhibition on the mouse enzyme. At this stage,
the mouse can be considered as potential species to perform
the in vivo proof of concept. It has the advantage that it is easily
accessible and is well described, as it is often used for the study
of bone diseases.58,59 Metabolic stability and the pharmacoki-
netic profile of compound 7 have to be evaluated in the mouse
to validate this species as adequate model.
In this study, we described the optimization of 17β-HSD2
inhibitors in the 2,5-thiophene and 1,3-phenylamide class by
variation of the linker size between the C ring and the amide
moiety. It led to the discovery of four new highly active
compounds with the C ring directly attached to the amides 13a,
19, 31, and 32 with an IC50 of around 60 nM in a cell-free
assay, a very good cellular activity in the same range as in the
cell-free assay, and a very high selectivity factor toward 17β-
HSD1 above 100 and even higher than 800 for 31. Compounds
13a, 19, 31, and 32 are equipotent to the compound with the
methylene linker 7 but show higher selectivity toward 17β-
HSD1. SAR studies allowed a first characterization of the 17β-
HSD2 active site which must be quite large and certainly larger
than the one of 17β-HSD1. The mouse was identified as a
potential animal in order to perform an in vivo proof of concept
for the demonstration of the efficacy of 17β-HSD2 inhibitors in
osteoporosis.
■ EXPERIMENTAL SECTION
1. Chemical Methods. Chemical names follow IUPAC
nomenclature.
Starting materials were purchased from Aldrich, Acros, Lancaster,
Roth, Merck, Combi-Blocks, or Fluka and were used without
purification.
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Flash column chromatography (FC) was performed on silica gel
(70−200 μm), and reaction progress was monitored by TLC on
Alugram SIL G/UV254 (Macherey-Nagel). Visualization was accom-
plished with UV light.
1H NMR and 13C NMR spectra were measured on a Bruker AM500
spectrometer (at 500 and 125 MHz, respectively) at 300 K in
CD3COCD3. Chemical shifts are reported in δ (parts per million,
ppm) by reference to the hydrogenated residues of deuterated solvent
as internal standard: 2.05 ppm (1H NMR) and 30.8 and 206.3 ppm
(13C NMR). Signals are described as br (broad), s (singlet), d
(doublet), t (triplet), dd (doublet of doublets), ddd (doublet of
doublet of doublets), dt (doublet of triplets), or m (multiplet). All
coupling constants (J) are given in hertz (Hz).
MS measurements were executed using a TSQ Quantum equipped
with an electrospray interface (ESI) or an atmospheric pressure
chemical ionization source (APCI) (Thermo Fischer, Dreieich,
Germany) instrument. GC/MS spectra were measured on a GCD
series G1800A (Hewlett-Packard) instrument with an Optima-5-MS
(0.25 μM, 30 m) column (Macherey Nagel).
IR spectra were recorded on a Spectrum 100 FT-IR spectrometer
(PerkinElmer) as neat sample.
Melting points were measured in open capillaries on a Stuart
Scientific SMP3 apparatus and are uncorrected.
The purity of the compounds was evaluated by LC/MS. The
Surveyor-LC-system consisted of a pump, an autosampler, and a PDA
detector. Mass spectrometry was performed on a TSQ Quantum
(ThermoFisher, Dreieich, Germany). The triple quadrupole mass
spectrometer was equipped with an electrospray interface (ESI) or an
atmospheric pressure chemical ionization (APCI). The system was
operated by the standard software Xcalibur. A RP C18 Nucleodur 100-
5 (3 mm) column (Macherey-Nagel GmbH, Dühren, Germany) was
used as stationary phase. All solvents were HPLC grade. In a gradient
run, the percentage of acetonitrile (containing 0.1% trifluoroacetic
acid) in 0.1% trifluoroacetic acid was increased from an initial
concentration of 0% at 0 min to 100% at 15 min and kept at 100% for
5 min. The injection volume was 15 μL, and flow rate was set to 800
μL/min. MS analysis was carried out at a needle voltage of 3000 V and
a capillary temperature of 350 °C. Mass spectra were acquired in
positive mode from 100 to 1000 m/z, and UV spectra were recorded
at a wavelength of 254 nm and in some cases at 360 nm. All tested
compounds have ≥95% chemical purity except compounds 15a and
21, which have a purity of 94% and 90%, respectively.
Compounds 4,31 5a−d,32 6a−l,32 and 732 were prepared according
to previously described procedures.
General Procedure for Amidation. Method A. At 0 °C, a
solution of 3(4)-bromobenzoyl chloride or 5-bromothiophene-2-
carbonyl chloride (1 equiv) in CH2Cl2 (2 mL/equiv) was added
dropwise to a solution of the corresponding amine (1 equiv) and
triethylamine (1.15 equiv) in solution in CH2Cl2 (2 mL/equiv). The
mixture was kept stirred at 0 °C for 3 h and evaporated under reduced
pressure. The residue was purified by FC with n-hexane/ethyl acetate
or dichloromethane as eluant.
General Procedure for Suzuki Coupling. Method B. A mixture
of aryl bromide (1 equiv), substituted phenylboronic acid (1.2 equiv),
sodium carbonate (2 equiv), and tetrakis(triphenylphosphine)-
palladium (0.1 equiv) in an oxygen free DME/water (1:1) solution
was stirred at 80 °C for 4−14 h under nitrogen. The reaction mixture
was cooled to room temperature. The aqueous layer was extracted
with dichloromethane. The combined organic layers were washed with
brine, dried over sodium sulfate, filtered, and concentrated to dryness.
The product was purified by FC with n-hexane/ethyl acetate,
dichloromethane, or dichloromethane/methanol as eluant.
General Procedure for Ether Cleavage. Method C. To a
solution of methoxyphenyl compounds (1 equiv) in dry dichloro-
methane (5 mL/mmol of reactant), boron trifluoride−dimethyl sulfide
complex (6 equiv/methoxy function) was added dropwise at 0 °C and
stirred for 6−14 h. After the reaction was finished, the reaction mixture
was diluted with dichloromethane and 5% aqueous NaHCO3 was
added until neutral pH was obtained. The aqueous layer was extracted
with dichloromethane. The combined organic layers were washed with
brine, dried over sodium sulfate, evaporated to dryness under reduced
pressure. The product was purified by FC, with dichloromethane/
methanol as eluant.
Detailed Synthesis Procedures of the Most Interesting
Compounds. N-(3-Methoxyphenyl)-5-(4-methoxyphenyl)-N-
methylthiophene-2-carboxamide (12). The title compound was
prepared by reaction of 5-bromo-N-(3-methoxyphenyl)-N-methylthio-
phene-2-carboxamide 12b (40 mg, 0.12 mmol) and 4-methoxyphe-
nylboronic acid (22 mg, 0.14 mmol) with tetrakis(triphenylphosphine)
palladium (14 mg, 0.012 mmol) according to method B for 6 h.
Purification by FC (CH2Cl2/CH3OH, 200:1) afforded the desired
compound as a brown solid (40 mg, yield 92%). C20H19NO3S; MW
353; mp 119−120 °C; MS (ESI) 354 (M + H)+; 1H NMR
(CD3COCD3) 3.37 (s, 3H), 3.81 (s, 3H), 3.82 (s, 3H), 6.55 (d, J = 4.1
Hz, 1H), 6.92−6.96 (m, 3H), 6.97−7.01 (m, 2H), 7.02 (d, J = 4.1 Hz,
1H), 7.37 (td, J = 7.9, 0.6 Hz, 1H), 7.51 (d, J = 9.1 Hz, 2H).
N,5-Bis(3-methoxyphenyl)-N-methylthiophene-2-carboxa-
mide (13a). The title compound was prepared by reaction of 5-
bromo-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide 12b
(75 mg, 0.23 mmol) and 3-methoxyphenylboronic acid (41 mg, 0.27
mmol) with tetrakis(triphenylphosphine)palladium (27 mg, 0.023
mmol) according to method B for 5 h. Purification by FC (CH2Cl2)
afforded the desired compound as a yellow solid (80 mg, yield 98%).
C20H19NO3S; MW 353; mp 116−117 °C; MS (ESI) 354 (M + H)+;
1H NMR (CD3COCD3) 3.38 (s, 3H), 3.82 (s, 3H), 3.83 (s, 3H), 6.58
(d, J = 4.1 Hz, 1H), 6.90 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 6.94 (ddd, J =
7.6, 1.6, 0.9 Hz, 1H), 6.98−7.01 (m, 2H), 7.12 (t, J = 2.0 Hz, 1H), 7.15
(ddd, J = 7.6, 1.6, 0.9 Hz, 1H), 7.15 (d, J = 4.1 Hz, 1H), 7.30 (t, J = 8.0
Hz, 1H), 7.38 (td, J = 8.0, 0.9 Hz, 1H).
N-(3-Methoxyphenyl)-N-methyl-5-phenylthiophene-2-car-
boxamide (15a). The title compound was prepared by reaction of 5-
bromo-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide 12b
(75 mg, 0.23 mmol) and phenylboronic acid (33 mg, 0.27 mmol) with
tetrakis(triphenylphosphine)palladium (27 mg, 0.023 mmol) accord-
ing to method B for 4 h. Purification by FC (n-hexane/ethyl acetate,
10:1 → 6:1) afforded the desired compound as a beige solid (70 mg,
yield 94%). C19H17NO2S; MW 323; mp 126−127 °C; MS (ESI) 324
(M + H)+; 1H NMR (CD3COCD3) 3.38 (s, 3H), 3.82 (s, 3H), 6.60
(d, J = 4.0 Hz, 1H), 6.94 (ddd, J = 8.0, 2.1, 0.9 Hz, 1H), 6.99−7.01 (m,
2H), 7.16 (d, J = 4.0 Hz, 1H), 7.32 (ddt, J = 8.0, 6.3, 1.2 Hz, 1H),
7.36−7.41 (m, 3H), 7.59 (d, J = 8.0 Hz, 2H).
N-(3-Methoxyphenyl)-N-methyl-5-m-tolylthiophene-2-car-
boxamide (19). The title compound was prepared by reaction of 5-
bromo-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide 12b
(33 mg, 0.1 mmol) and 3-methylphenylboronic acid (19 mg, 0.14
mmol) with tetrakis(triphenylphosphine)palladium (12 mg, 0.01
mmol) according to method B for 8 h. Purification by FC (n-
hexane/ethyl acetate, 10:1→ 6:1) afforded the desired compound as a
beige solid (26 mg, yield 77%). C20H19NO2S; MW 337; mp 128−129
°C; MS (ESI) 338 (M + H)+; 1H NMR (CD3COCD3) 2.34 (s, 3H),
3.38 (s, 3H), 3.81 (s, 3H), 6.57 (d, J = 4.0 Hz, 1H), 6.94 (ddd, J = 7.9,
2.2, 0.9 Hz, 1H), 6.98−7.01 (m, 2H), 7.13 (d, J = 4.0 Hz, 1H), 7.14−
7.16 (m, 1H), 7.27 (t, J = 7.9 Hz, 1H), 7.36−7.39 (m, 2H), 7.41−7.42
(m, 1H).
5-(3-(Dimethylamino)phenyl)-N-(3-methoxyphenyl)-N-
methylthiophene-2-carboxamide (20). The title compound was
prepared by reaction of 5-bromo-N-(3-methoxyphenyl)-N-methylthio-
phene-2-carboxamide 12b (49 mg, 0.15 mmol) and 3-
(dimethylamino)phenylboronic acid (30 mg, 0.18 mmol) with
tetrakis(triphenylphosphine)palladium (17 mg, 0.015 mmol) accord-
ing to method B for 14 h. Purification by FC (n-hexane/ethyl acetate,
10:1 → 6:1) afforded the desired compound as an orange solid (26
mg, yield 47%). C21H22N2O2S; MW 366; mp 121−122 °C; MS (ESI)
367 (M + H)+; 1H NMR (CD3COCD3) 2.96 (s, 6H), 3.38 (s, 3H),
3.82 (s, 3H), 6.56 (d, J = 4.0 Hz, 1H), 6.72 (dd, J = 8.2, 2.4 Hz, 1H),
6.86 (d, J = 7.6 Hz, 1H), 6.89 (t, J = 2.0 Hz, 1H), 6.94 (d, J = 7.6 Hz,
1H), 6.98−7.01 (m, 2H), 7.10 (d, J = 4.0 Hz, 1H), 7.19 (t, J = 7.9 Hz,
1H), 7.37 (t, J = 7.9 Hz, 1H).
N-(3-Methoxyphenyl)-N-methyl-5-(3-(methylthio)phenyl)-
thiophene-2-carboxamide (21). The title compound was prepared
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm3014053 | J. Med. Chem. 2013, 56, 167−181176

by reaction of 5-bromo-N-(3-methoxyphenyl)-N-methylthiophene-2-
carboxamide 12b (33 mg, 0.1 mmol) and 3-(methylthio)-
phenylboronic acid (23 mg, 0.14 mmol) with tetrakis-
(triphenylphosphine)palladium (12 mg, 0.01 mmol) according to
method B for 8 h. Purification by FC (n-hexane/ethyl acetate, 10:1 →
7:1) afforded the desired compound as a yellowish solid (22 mg, yield
59%). C20H19NO2S2; MW 369; mp 109−110 °C; MS (ESI) 370 (M +
H)+; 1H NMR (CD3COCD3) 2.52 (s, 3H), 3.38 (s, 3H), 3.82 (s, 3H),
6.59 (d, J = 4.0 Hz, 1H), 6.94 (ddd, J = 8.0, 1.9, 0.9 Hz, 1H), 6.98−
7.02 (m, 2H), 7.18 (d, J = 4.0 Hz, 1H), 7.23 (dt, J = 6.9, 1.9 Hz, 1H),
7.30−7.35 (m, 2H), 7.38 (td, J = 8.0, 0.9 Hz, 1H), 7.44−7.45 (m, 1H).
5-(2-Fluoro-3-methoxyphenyl)-N-(3-methoxyphenyl)-N-
methylthiophene-2-carboxamide (31). The title compound was
prepared by reaction of 5-bromo-N-(3-methoxyphenyl)-N-methylthio-
phene-2-carboxamide 12b (40 mg, 0.12 mmol) and 2-fluoro-3-
methoxyphenylboronic acid (25 mg, 0.14 mmol) with tetrakis-
(triphenylphosphine)palladium (14 mg, 0.012 mmol) according to
method B for 14 h. Purification by FC (n-hexane/ethyl acetate, 10:1→
6:1) afforded the desired compound as a brown solid (30 mg, yield
66%). C20H18FNO3S; MW 371; mp 159−160 °C; MS (ESI) 372 (M +
H)+; 1H NMR (CD3COCD3) 3.38 (s, 3H), 3.82 (s, 3H), 3.90 (s, 3H),
6.65 (dd, J = 4.0, 1.0 Hz, 1H), 6.95 (ddd, J = 7.6, 1.8, 1.0 Hz, 1H),
6.99−7.01 (m, 2H), 7.09−7.20 (m, 3H), 7.23 (dd, J = 4.0, 1.0 Hz,
1H), 7.37 (dd, J = 9.1, 7.9 Hz, 1H).
5-(2-Fluoro-3-methylphenyl)-N-(3-methoxyphenyl)-N-meth-
ylthiophene-2-carboxamide (36). The title compound was
prepared by reaction of 5-bromo-N-(3-methoxyphenyl)-N-methylthio-
phene-2-carboxamide 12b (49 mg, 0.15 mmol) and 2-fluoro-3-
methylphenylboronic acid (28 mg, 0.18 mmol) with tetrakis-
(triphenylphosphine)palladium (17 mg, 0.015 mmol) according to
method B for 14 h. Purification by FC (n-hexane/ethyl acetate, 10:1)
afforded the desired compound as a colorless solid (50 mg, yield 94%).
C20H18FNO2S; MW 355; mp 142−143 °C; MS (APCI) 356 (M +
H)+; 1H NMR (CD3COCD3) 2.29 (d, J = 2.5 Hz, 3H), 3.39 (s, 3H),
3.81 (s, 3H), 6.63 (dd, J = 4.1, 0.9 Hz, 1H), 6.94 (ddd, J = 7.9, 1.9, 0.9
Hz, 1H), 6.98−7.01 (m, 2H), 7.11 (t, J = 7.9 Hz, 1H), 7.22 (dd, J =
4.1, 0.9 Hz, 1H), 7.23−7.25 (m, 1H), 7.36−7.39 (m, 1H), 7.45−7.48
(m, 1H).
5-(2,6-Difluoro-3-methoxyphenyl)-N-(3-methoxyphenyl)-N-
methylthiophene-2-carboxamide (37). The title compound was
prepared by reaction of 5-bromo-N-(3-methoxyphenyl)-N-methylthio-
phene-2-carboxamide 12b (33 mg, 0.1 mmol) and 2,6-difluoro-3-
methoxyphenylboronic acid (26 mg, 0.14 mmol) with tetrakis-
(triphenylphosphine)palladium (12 mg, 0.01 mmol) according to
method B for 14 h. Purification by FC (n-hexane/ethyl acetate, 10:1)
afforded the desired compound as an orange solid (10 mg, yield 26%).
C20H17F2NO3S; MW 389; mp 147−148 °C; MS (ESI) 390 (M + H)+;
1H NMR (CD3COCD3) 3.40 (s, 3H), 3.82 (s, 3H), 3.90 (s, 3H), 6,71
(dt, J = 4.1, 0.9 Hz, 1H), 6.95 (ddd, J = 7.6, 1.9, 0.9 Hz, 1H), 6.99−
7.01 (m, 2H), 7.05 (ddd, J = 11.4, 9.1, 2.2 Hz, 1H), 7.16 (td, J = 9.1,
5.0 Hz, 1H), 7.23 (dt, J = 4.1, 1.1 Hz, 1H), 7.36−7.39 (m, 1H).
5-(3-Fluoro-4-methoxyphenyl)-N-(3-methoxyphenyl)-N-
methylthiophene-2-carboxamide (38). The title compound was
prepared by reaction of 5-bromo-N-(3-methoxyphenyl)-N-methylthio-
phene-2-carboxamide 12b (40 mg, 0.12 mmol) and 3-fluoro-4-
methoxyphenylboronic acid (25 mg, 0.14 mmol) with tetrakis-
(triphenylphosphine)palladium (14 mg, 0.015 mmol) according to
method B for 6 h. Purification by FC (n-hexane/ethyl acetate, 10:1 →
6:1) afforded the desired compound as a yellow solid (40 mg, yield
72%). C20H18FNO3S; MW 371; mp 157−158 °C; MS (ESI) 372 (M +
H)+; 1H NMR (CD3COCD3) 3.38 (s, 3H), 3.82 (s, 3H), 3.91 (s, 3H),
6.55 (d, J = 4.0 Hz, 1H), 6.94 (ddd, J = 7.9, 1.9, 0.9 Hz, 1H), 6.99−
7.01 (m, 2H), 7.08 (d, J = 4.0 Hz, 1H), 7.15 (t, J = 8.5 Hz, 1H), 7.33−
7.39 (m, 3H).
5-(2,4-Dimethoxyphenyl)-N-(3-methoxyphenyl)-N-methyl-
thiophene-2-carboxamide (41). The title compound was prepared
by reaction of 5-bromo-N-(3-methoxyphenyl)-N-methylthiophene-2-
carboxamide 12b (40 mg, 0.12 mmol) and 2,4-dimethoxyphenylbor-
onic acid (27 mg, 0.14 mmol) with tetrakis(triphenylphosphine)
palladium (14 mg, 0.012 mmol) according to method B for 14 h.
Purification by FC (n-hexane/ethyl acetate, 10:1 → 6:1) afforded the
desired compound as a colorless solid (35 mg, yield 74%).
C21H21NO4S; MW 383; mp 117−118 °C; MS (ESI) 384 (M +
H)+; 1H NMR (CD3COCD3) 3.37 (s, 3H), 3.82 (s, 3H), 3.83 (s, 3H),
3.89 (s, 3H), 6.57 (ddd, J = 8.5, 2.4, 0.9 Hz, 1H), 6.63−6.64 (m, 2H),
6.92 (ddd, J = 7.9, 2.1, 0.9 Hz, 1H), 6.97 (t, J = 2.1 Hz, 1H), 7.00 (ddd,
J = 8.2, 2.7, 0.9 Hz, 1H), 7.15 (d, J = 4.3 Hz, 1H), 7.37 (t, J = 8.1 Hz,
1H), 7.55 (d, J = 8.5 Hz, 1H).
5-(3-Methoxyphenyl)-N-methyl-N-m-tolylthiophene-2-car-
boxamide (22a). The title compound was prepared by reaction of 5-
bromo-N-methyl-N-m-tolylthiophene-2-carboxamide 22b (78 mg, 0.25
mmol) and 3-methoxyphenylboronic acid (45 mg, 0.3 mmol) with
tetrakis(triphenylphosphine)palladium (29 mg, 0.025 mmol) accord-
ing to method B for 4 h. Purification by FC (n-hexane/ethyl acetate,
25:1 → 10:1) afforded the desired compound as a colorless solid (65
mg, yield 77%). C20H19NO2S; MW 337; mp 97−98 °C; MS (ESI) 338
(M + H)+; 1H NMR (CD3COCD3) 2.36 (s, 3H), 3.37 (s, 3H), 3.83 (s,
3H), 6.51 (d, J = 4.1 Hz, 1H), 6.90 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H),
7.10−7.11 (m, 1H), 7.13−7.17 (m, 3H), 7.23 (s, 1H), 7.26 (d, J = 7.6
Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H).
5-(3-Hydroxyphenyl)-N-methyl-N-m-tolylthiophene-2-car-
boxamide (22). The title compound was prepared by reaction of 5-
(3-methoxyphenyl)-N-methyl-N-m-tolylthiophene-2-carboxamide 22a
(40 mg, 0.12 mmol) with boron trifluoride−dimethyl sulfide complex
(0.08 mL, 0.72 mmol) according to method C for 14 h. Purification by
FC (CH2Cl2/CH3OH, 100:1 → 50:1) afforded the title compound as
a beige solid (30 mg, yield 79%). C19H17NO2S; MW 323; mp 157−
158 °C; MS (ESI) 324 (M + H)+; 1H NMR (CD3COCD3) 2.36 (s,
3H), 3.37 (s, 3H), 6.52 (d, J = 4.1 Hz, 1H), 6.81 (ddd, J = 8.0, 2.5, 0.9
Hz, 1H), 7.03−7.06 (m, 2H), 7.08 (d, J = 4.1 Hz, 1H), 7.16 (d, J = 8.0
Hz, 1H), 7.20 (d, J = 7.6 Hz, 1H), 7.22 (s, 1H), 7.26 (d, J = 7.6 Hz,
1H), 7.36 (t, J = 8.0 Hz, 1H), 8.51 (s, 1H).
5-(2-Fluoro-3-methoxyphenyl)-N-methyl-N-(m-tolylthio-
phene)-2-carboxamide (32). The title compound was prepared by
reaction of 5-bromo-N-methyl-N-m-tolylthiophene-2-carboxamide 22b
(46 mg, 0.15 mmol) and 2-fluoro-3-methoxyphenylboronic acid (31
mg, 0.18 mmol) with tetrakis(triphenylphosphine)palladium (17 mg,
0.015 mmol) according to method B for 14 h. Purification by FC (n-
hexane/ethyl acetate, 10:1) afforded the desired compound as a
colorless solid (45 mg, yield 85%). C20H18FNO2S; MW 355; mp 120−
121 °C; MS (ESI) 356 (M + H)+; 1H NMR (CD3COCD3) 2.36 (s,
3H), 3.38 (s, 3H), 3.90 (s, 3H), 6.58 (dd, J = 4.0, 1.0 Hz, 1H), 7.08−
7.19 (m, 4H), 7.21 (dd, J = 4.1, 1.0 Hz, 1H), 7.23−7.27 (m, 2H), 7.36
(t, J = 7.7 Hz, 1H).
5-(3-Methoxyphenyl)-N-methyl-N-(3-(trifluoromethyl)-
phenyl)thiophene-2-carboxamide (24). The title compound was
prepared by reaction of 5-bromo-N-methyl-N-(3-(trifluoromethyl)-
phenyl)thiophene-2-carboxamide 24b (36 mg, 0.1 mmol) and 3-
methoxyphenylboronic acid (20 mg, 0.13 mmol) with tetrakis-
(triphenylphosphine)palladium (12 mg, 0.01 mmol) according to
method B for 6 h. Purification by FC (n-hexane/ethyl acetate, 10:1 →
5:1) afforded the desired compound as a yellow solid (35 mg, yield
90%). C20H16F3NO2S; MW 391; mp 97−98 °C; MS (ESI) 392 (M +
H)+; 1H NMR (CD3COCD3) 3.47 (s, 3H), 3.83 (s, 3H), 6.57 (d, J =
4.1 Hz, 1H), 6.91 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 7.11 (t, J = 2.2 Hz,
1H), 7.14 (ddd, J = 7.6, 1.6, 0.9 Hz, 1H), 7.19 (d, J = 4.1 Hz, 1H), 7.31
(t, J = 8.2 Hz, 1H), 7.69−7.78 (m, 3H), 7.81−7.82 (m, 1H); 13C NMR
(CD3COCD3) 39.0, 55.6, 112.0, 115.0, 119.0, 124.1, 125.3, 125.4,
125.8, 125.9, 131.1, 131.7, 132.2, 132.5, 133.0, 133.5, 135.5, 138.2,
146.3, 149.2, 161.2, 162.6; IR (cm−1) 3046, 2963, 1608, 1438, 1330,
1117, 707 .
N-(Biphenyl-3-yl)-5-(3-methoxyphenyl)-N-methylthiophene-
2-carboxamide (26). The title compound was prepared by reaction
of N-(biphenyl-3-yl)-5-bromo-N-methylthiophene-2-carboxamide 26b
(37 mg, 0.1 mmol) and 3-methoxyphenylboronic acid (18 mg, 0.12
mmol) with tetrakis(triphenylphosphine)palladium (12 mg, 0.01
mmol) according to method B for 14 h. Purification by FC (n-
hexane/ethyl acetate 8:1) afforded the desired compound as a yellow
solid (38 mg, yield 95%). C25H21NO2S; MW 399; mp 108−109 °C;
MS (ESI) 400 (M + H)+; 1H NMR (CD3COCD3) 3.46 (s, 3H), 3.81
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(s, 3H), 6.65 (d, J = 4.0 Hz, 1H), 6.89 (dd, J = 8.0, 2.1 Hz, 1H), 7.09
(s, 1H), 7.12 (d, J = 7.6 Hz, 1H), 7.15 (d, J = 4.0 Hz, 1H), 7.28 (t, J =
8.0 Hz, 1H), 7.36−7.39 (m, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.57 (t, J =
7.8 Hz, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.71−7.74 (m, 2H).
log P Determination. The log P values were calculated from
CambridgeSoft Chem & Bio Draw 11.0 using the ChemDrawPro 11.0
program.
2. Biological Methods. [2,4,6,7-3H]E2, [6,7-3H]E2,
[2,4,6,7-3H]E1, and [1,2,6,7-3H]A-dione were bought from Perkin-
Elmer, Boston, MA. Quickszint Flow 302 scintillator fluid was bought
from Zinsser Analytic, Frankfurt, Germany. ReadyFlow III scintillation
fluid was from Beckman. Other chemicals were purchased from Sigma,
Serva, Roth, or Merck.
Cytosolic (17β-HSD1) and microsomal (17β-HSD2) fractions were
obtained from human and Callithrix jacchus placenta according to
previously described procedures46,47,60 and from mouse liver tissues.61
Fresh tissue was homogenized and centrifuged. The pellet fraction
contains the microsomal 17β-HSD2 and was used for the
determination of E1 formation, while 17β-HSD1 was obtained after
precipitation with ammonium sulfate from the cytosolic fraction for
use of testing of E2 formation.
Human 17β-HSD4 and 17β-HSD5 were cloned into the modified
pGEX-2T vector.50 For the multidomain enzyme 17β-HSD4, only the
steroid converting SDR domain was subcloned.50 The human 11β-
HSD1 and 11β-HSD2 were stably transfected in HEK cells as
described earlier by Odermatt.62
Inhibition of 17β-HSD2/E1 Formation in Cell-Free Assay.
Inhibitory activities were evaluated by an established method with
minor modifications.23,63,64 Briefly, the enzyme preparation was
incubated with NAD+ [1500 μM] in the presence of potential
inhibitors at 37 °C in a phosphate buffer (50 mM) supplemented with
20% of glycerol and EDTA, 1 mM. Inhibitor stock solutions were
prepared in DMSO. Final concentration of DMSO was adjusted to 1%
in all samples. The enzymatic reaction was started by addition of a
mixture of unlabeled E2 and [3H]E2 (final concentration of 500 nM,
0.11 μCi). After 20 min, the incubation was stopped with HgCl2 and
the mixture was extracted with ether. After evaporation, the steroids
were dissolved in acetonitrile/water (45:55). E1 and E2 were
separated using acetonitrile/water (45:55) as mobile phase in a C18
RP chromatography column (Nucleodur C18, 3 μm, Macherey-Nagel,
Düren, Germany) connected to a HPLC system (Agilent 1100 series,
Agilent Technologies, Waldbronn, Germany). Detection and
quantification of the steroids were performed using a radioflow
detector (Berthold Technologies, Bad Wildbad, Germany). The
conversion rate was calculated according to the following equation:
% conversion = [(% E1)/(% E1 + % E2)] × 100. Each value was
calculated from at least three independent experiments.
Inhibition of 17β-HSD1/E2 Formation in Cell-Free Assay. The
17β-HSD1 inhibition assay was performed similarly to the 17β-HSD2
test. The microsomal fraction was incubated with NADH (500 μM),
test compound, and a mixture of unlabeled E1 and [3H]E1 (final
concentration of 500 nM, 0.15 μCi) for 10 min at 37 °C. Further
treatment of the samples and HPLC separation were carried out as
mentioned above for 17β-HSD2.
Inhibition of Human 17β-HSD4 and 17β-HSD5. Inhibitory
activity was assessed as described earlier.50,51 Briefly, for 17β-HSD4
inhibition, an appropriate amount of bacteria containing recombi-
nantly expressed human 17β-HSD4 (SDR domain)50 was resuspended
in 100 mM sodium phosphate buffer, pH 7.7. Substrate [6,7-3H]E2
and inhibitor (dissolved in DMSO) were added in final concentrations
of 21 nM and 1 μM (1% (v/v) DMSO), respectively. Controls
contained 1% DMSO without inhibitor. The enzymatic reaction was
started with the addition of NAD+ (750 μM final).
For 17β-HSD5 inhibition, an appropriate amount of bacterial lysate
containing recombinantly expressed human 17β-HSD556 was
dissolved in 100 mM sodium phosphate buffer, pH 6.6. Substrate
[1,2,6,7-3H]A-dione and inhibitor (dissolved in DMSO) were added in
final concentrations of 21 nM and 1 μM (1% (v/v) DMSO),
respectively. Controls contained 1% DMSO without inhibitor. The
enzymatic reaction was started with the addition of NADPH (600 μM
final). The incubation at 37 °C was stopped with 0.21 M ascorbic acid
in methanol/acetic acid (99:1) after the time needed to convert
approximately 30% of the substrate in a control assay without
inhibitor. Steroids were extracted from the assay mixture by SPE using
Strata C18-E columns (Phenomenex), eluted with methanol, and
separated by RP-HPLC (column Luna, 5 μm C18(2), 150 mm;
Phenomenex) at a flow rate of 1 mL/min acetonitrile/water (43:57).
Radioactivity was detected by online scintillation counting with a
Berthold LB506D detector (Berthold Technologies, Bad Wildbad,
Germany) after mixing with ReadyFlow III (Beckman). Conversion
was calculated from integration of substrate and product peaks. For
calculation of inhibitory potential, conversion of the control assays
(assays without inhibitor) was set to 0% inhibition. Assays were run in
triplicate.
Inhibition of 11β-HSD1 and 11β-HSD2 Using Cell Lysates.
HEK-293 cells stably transfected with 11β-HSD1 or 11β-HSD2 were
cultured in Dulbecco’s modified Eagle medium (DMEM) containing
4.5 g/L glucose, supplemented with 10% fetal bovine serum, MEM
nonessential amino acids, 100 U/mL penicillin, 0.1 mg/mL
streptomycin, and 10 mM HEPES, pH 7.4. Cells were grown to
90% confluence, washed with PBS, suspended, and centrifuged for 4
min at 150g. Cell pellets were frozen and stored at −80 °C.
Inhibitors were dissolved in DMSO to obtain stock solutions of 10
mM and stored as 100 μL aliquots at −20 °C. [1,2-3H]Cortisone was
purchased from American Radiolabeled Chemicals (St. Louis, MO,
U.S.), and [1,2,6,7-3H]cortisol was from Amersham Pharmacia
(Piscataway, NJ, U.S.). All other chemicals were obtained from
Sigma-Aldrich Chemie GmbH (Buchs, Switzerland) of the highest
grade available.
Activity assays were performed as described by Kratschmar et al.54
Briefly, cell lysates were incubated for 10 min at 37 °C in TS2 buffer
(100 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM MgCl2, 250 mM
sucrose, 20 mM Tris-HCl, pH 7.4) in a final volume of 22 μL,
containing either vehicle (0.2% DMSO) or the corresponding
inhibitor at 2 and 20 μM. To measure 11β-HSD1 activity, the
reaction mixture contained 380 nM unlabeled cortisone, 20 nM
[1,2-3H]cortisone, and 500 μM NADPH. 11β-HSD2 activity was
determined in a reaction mixture containing 80 nM unlabeled cortisol,
20 nM [1,2,6,7-3H]cortisol, and 500 μM NAD+. Reactions were
stopped after 10 min by the addition of an excess of unlabeled
cortisone and cortisol (2 mM, in methanol). Steroids were separated
by TLC, followed by scintillation counting and calculation of substrate
conversion. Data were obtained from three independent experiments.
Inhibition of 17β-HSD2 in a Cellular Assay. Cellular 17β-HSD2
activity is measured using the breast cancer cell-line MDA-MB-23165
(17β-HSD1 activity negligible). [3H]E2 (200 nM) is taken as substrate
and is incubated with the inhibitor for 6 h at 37 °C. After ether
extraction, substrate and product are separated by HPLC and detected
with a radioflow detector. Potency is evaluated as percentage of
inhibition (inhibitor concentration of 1 μM) and as IC50 values.
ER Affinity in a Cellular Free Assay. The binding affinity of
selected compounds to the ERα and ERβ was determined according to
Zimmermann et al.49 using recombinant human proteins. Briefly, 0.25
pmol of ERα or ERβ was incubated with [3H]E2 (10 nM) and test
compound for 1 h at room temperature. The potential inhibitor was
dissolved in DMSO (5% final concentration). Nonspecific binding was
performed with diethylstilbestrol (10 μM). After incubation, ligand−
receptor complexes were selectively bound to hydroxyapatite (5 g/60
mL of TE buffer). The formed complex was separated, washed, and
resuspended in ethanol. For radiodetection, scintillator cocktail
(Quickszint 212, Zinsser Analytic, Frankfurt, Germany) was added
and samples were measured in a liquid scintillation counter (Rack Beta
Primo 1209, Wallac, Turku, Finland). For determination of the relative
binding affinity (RBA), inhibitor and E2 concentrations required to
displace 50% of the receptor bound labeled E2 were determined:
RBA (%) = IC50(E2)/IC50(compound) × 100. The RBA value for E2
was arbitrarily set at 100%.
Cytotoxicity. For evaluation of cytotoxicity, conversion of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is
determined according to Denizot and Lang with minor modifica-
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tions.57 Experiments were performed in 96-well cell culture plates in
DMEM supplemented with 10% FCS. MDA-MB-231 cells are
incubated with the compounds for 3 h at 37 °C in 5% CO2
humidified atmosphere. After an MTT incubation of another 3 h
the cleavage of MTT to a blue formazane by mitochondrial succinate
dehydrogenase was stopped and cell lysis was carried out by addition
of sodium dodecyl sulfate (SDS) in 0.01 N HCl (10%). The produced
blue formazane was quantified spectrophotometrically at 590 nm.
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Zanchetta, J. R.; Stakkestad, J.; Glüer, C. C.; Krueger, K.; Cohen, F. J.;
Eckert, S.; Ensrud, K. E.; Avioli, L. V.; Lips, P.; Cummings, S. R.
Reduction of vertebral fracture risk in postmenopausal women with
osteoporosis treated with raloxifene: results from a 3-year randomized
clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE)
Investigators. JAMA, J. Am. Med. Assoc. 1999, 282, 637−645.
(12) Felson, D. T.; Zhang, Y.; Hannan, M. T.; Kiel, D. P.; Wilson, P.
W.; Anderson, J. J. The effect of postmenopausal estrogen therapy on
bone density in elderly women. N. Engl. J. Med. 1993, 329, 1141−
1146.
(13) Chen, C.-L.; Weiss, N. S.; Newcomb, P.; Barlow, W.; White, E.
Hormone replacement therapy in relation to breast cancer. JAMA, J.
Am. Med. Assoc. 2002, 287, 734−741.
(14) Beresford, S. A.; Weiss, N. S.; Voigt, L. F.; McKnight, B. Risk of
endometrial cancer in relation to use of oestrogen combined with
cyclic progestagen therapy in postmenopausal women. Lancet 1997,
349, 458−61.
(15) Grady, D.; Gebretsadik, T.; Kerlikowske, K.; Ernster, V.; Petitti,
D. Hormone replacement therapy and endometrial cancer risk: a meta-
analysis. Obstet. Gynecol. 1995, 85, 304−313.
(16) Dong, Y.; Qiu, Q. Q.; Debear, J.; Lathrop, W. F.; Bertolini, D.
R.; Tamburini, P. P. 17Beta-hydroxysteroid dehydrogenases in human
bone cells. J. Bone Miner. Res. 1998, 13, 1539−1546.
(17) Feix, M.; Wolf, L.; Schweikert, H. U. Distribution of 17beta-
hydroxysteroid dehydrogenases in human osteoblast-like cells. Mol.
Cell. Endocrinol. 2001, 171, 163−164.
(18) Eyre, L. J.; Bland, R.; Bujalska, I. J.; Sheppard, M. C.; Stewart, P.
M.; Hewison, M. Characterization of aromatase and 17 beta-
hydroxysteroid dehydrogenase expression in rat osteoblastic cells. J.
Bone Miner. Res. 1998, 13, 996−1004.
(19) van Grunsven, E G; van Berkel, E.; Ijlst, L.; Vreken, P.; de Klerk,
J. B.; Adamski, J.; Lemonde, H.; Clayton, P. T.; Cuebas, D. A.;
Wanders, R. J. Peroxisomal D-hydroxyacyl-CoA dehydrogenase
deficiency: resolution of the enzyme defect and its molecular basis
in bifunctional protein deficiency. Proc. Natl. Acad. Sci. U.S.A. 1998, 95,
2128−2133.
(20) Blomquist, C. H.; Lindemann, N. J.; Hakanson, E. Y. 17 beta-
Hydroxysteroid and 20 alpha-hydroxysteroid dehydrogenase activities
of human placental microsomes: kinetic evidence for two enzymes
differing in substrate specificity. Arch. Biochem. Biophys. 1985, 239,
206−215.
(21) Bydal, P.; Auger, S.; Poirier, D. Inhibition of type 2 17β-
hydroxysteroid dehydrogenase by estradiol derivatives bearing a
lactone on the D-ring: structure−activity relationships. Steroids 2004,
69, 325−342.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm3014053 | J. Med. Chem. 2013, 56, 167−181179

(22) Poirier, D.; Bydal, P.; Tremblay, M. R.; Sam, K. M.; Luu-The, V.
Inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Mol. Cell.
Endocrinol. 2001, 171, 119−128.
(23) Sam, K. M.; Auger, S.; Luu-The, V.; Poirier, D. Steroidal spiro-
gamma-lactones that inhibit 17 beta-hydroxysteroid dehydrogenase
activity in human placental microsomes. J. Med. Chem. 1995, 38,
4518−4528.
(24) Tremblay, M. R.; Luu-The, V.; Leblanc, G.; Noel̈, P.; Breton, E.;
Labrie, F.; Poirier, D. Spironolactone-related inhibitors of type II
17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor
binding affinities, and proliferative/antiproliferative activities. Bioorg.
Med. Chem. 1999, 7, 1013−1023.
(25) Cook, J. H.; Barzya, J.; Brennan, C.; Lowe, D.; Wang, Y.;
Redman, A.; Scott, W. J.; Wood, J. E. 4,5-Disubstituted cis-
pyrrolidinones as inhibitors of 17β-hydroxysteroid dehydrogenase II.
Part 1: Synthetic approach. Tetrahedron Lett. 2005, 46, 1525−1528.
(26) Gunn, D.; Akuche, C.; Baryza, J.; Blue, M.-L.; Brennan, C.;
Campbell, A.-M.; Choi, S.; Cook, J.; Conrad, P.; Dixon, B.; Dumas, J.;
Ehrlich, P.; Gane, T.; Joe, T.; Johnson, J.; Jordan, J.; Kramss, R.; Liu,
P.; Levy, J.; Lowe, D.; McAlexander, I.; Natero, R.; Redman, A. M.;
Scott, W.; Seng, T.; Sibley, R.; Wang, M.; Wang, Y.; Wood, J.; Zhang,
Z. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-
hydroxysteroid dehydrogenase. Part 2. SAR. Bioorg. Med. Chem. Lett.
2005, 15, 3053−3057.
(27) Wood, J.; Bagi, C. M.; Akuche, C.; Bacchiocchi, A.; Baryza, J.;
Blue, M.-L.; Brennan, C.; Campbell, A.-M.; Choi, S.; Cook, J. H.;
Conrad, P.; Dixon, B. R.; Ehrlich, P. P.; Gane, T.; Gunn, D.; Joe, T.;
Johnson, J. S.; Jordan, J.; Kramss, R.; Liu, P.; Levy, J.; Lowe, D. B.;
McAlexander, I.; Natero, R.; Redman, A. M.; Scott, W. J.; Town, C.;
Wang, M.; Wang, Y.; Zhang, Z. 4,5-Disubstituted cis-pyrrolidinones as
inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3.
Identification of lead candidate. Bioorg. Med. Chem. Lett. 2006, 16,
4965−4968.
(28) Wetzel, M.; Marchais-Oberwinkler, S.; Hartmann, R. W. 17β-
HSD2 inhibitors for the treatment of osteoporosis: identification of a
promising scaffold. Bioorg. Med. Chem. 2011, 19, 807−815.
(29) Wetzel, M.; Marchais-Oberwinkler, S.; Perspicace, E.; Möller,
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Appendix

Protocol: Preparation of intact liver microsomes & cytochrome C reductase assay
IMPORTANT: Work always on ice! 
Solution A: 10 mM imidazole, 0.3 M sucrose, pH 7.0 
Solution B: 20 mM tris-maleate, 0.6 M KCl, 0.3 M sucrose, pH 7.0 
Solution C: 10 mM tris-maleate, 0.15 M KCl, 0.25 M sucrose, pH 7.0 
Per 100 mg tissue use 2 mL sol. A, 0.5 mL sol. B and 0.2 mL sol. C. All solutions are 
supplemented with 1 % protease inhibitor (7x stock of complete®, Mini Protease Inhibitor 
Cocktail, Roche) 
1. Use 100 mg fresh or frozen liver tissue and 2 mL solution A, homogenize with a Potter-
Elvehjem PTFE pestle and glass tube applying approximately 10 - 12 strokes with 
rotations (220 rpm) with the polytron, transfer homogenate to a plastic tube 
2. centrifuge at Û& PLQ ¶u g, transfer supernatant into new plastic tube, repeat 
centrifugation transfer supernatant into new plastic tube 
3. centrifuge at Û&PLQ¶u g, transfer supernatant into ultracentrifugation tube 
(Microfuge Tube Polyallomer® from Beckman in lab 5007) 
4. centrifuge at Û&PLQ¶u g with ultracentrifuge (BZ 5th floor)
5. resuspend pellet in 0.5 mL of solution B (will be difficult to resuspend) 
6. centrifuge at Û&PLQ¶u g with ultracentrifuge (BZ 5th floor)
7. resuspend pellet in 0.2 mL of solution C (that will yield approx. 2 mg/mL) 
8. spin 5 sec, at Û& PD[LPDO VSHHG table top centrifuge, remove white chunks, transfer 
supernatant to new tube, make aliquots and freeze at – 80 °C.  
9. Characterize microsomes by total protein assay (BCA) and test for activity with 
cytochrome C reductase assay kit.
Cytochrome C reductase assay kit from Sigma in 96-well plate (Sigma CY0100) 
1. 95 μL working solution (0.9 mg cytochrome C + 2 ml assay buffer) 
2. 5 μL of enzyme (approx. 10 μg, dilute as needed with dilution buffer)
3. 10 μL NADPH (0.85 mg/mL) (22 μL of NADPH aliquot + 1 mL H2O)
4. Positive control - Dilute an aliquot of the cytochrome c reductase (NADPH) (Catalog 
Number C9363) 10-fold with the enzyme dilution buffer just before assaying
5. Set the spectrophotometer to 550 nm and run the kinetic program at 25°C: 
a. Initial delay = 5 seconds 
b. interval= 10 seconds 
c. readings = 7
Calculate activity (Units/mL   ǻ$550/min * dilution factor * 0.11) / (21.1 * volume of the 
enzyme sample (mL))
Should be over 3 Units/mL for microsomes.

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